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IL-17A is a well-characterised pro-inflammatory cytokine, which has been implicated 
in the immunopathology of inflammatory arthritis. IL-17F is less well-studied. This 
thesis describes investigations into the phenotype of IL-17F+ CD4+ T cells, what 
drives IL-17F expression in CD4+ T cells and how IL-17F may contribute to 
inflammation. 
 
Healthy donor CD4+ T cells were cultured with IL-1β, IL-23, anti-CD3 mAb and anti-
CD28 mAb, and cytokine expression was analysed by flow cytometry. In comparison 
to IL-17A+ IL-17F- CD4+ T cells, IL-17F+IL-17A- and IL-17A+IL-17F+ CD4+ T 
cells contained lower proportions of cells co-expressing IL-10 and higher proportions 
of cells co-expressing IFNγ. Titration of anti-CD28 mAb into healthy donor CD4+ T 
cell cultures revealed that strong co-stimulation increased the frequency of IL-17F+IL-
17A- and IL-17A+IL-17F+ CD4+ T cells, whereas IL-17A+IL-17F- CD4+ T cell 
frequencies decreased. This was shown to be via an IL-2 dependent mechanism. To 
allow for the further characterisation of different IL-17A+ and IL-17F+ CD4+ T cell 
populations an IL-17A and IL-17F capture assay was developed in this thesis. 
  
Addition of human recombinant IL-17A, IL-17F and TNFα to synovial fibroblasts 
from patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA) resulted in 
significant production of IL-6. Combined blockade of IL-17A and IL-17F reduced IL-
6 production to a larger extent than blockade of IL-17A alone, indicating IL-17F can 
contribute to inflammation. While IL-17A protein and IL-17A+ T cells were detected 
at increased levels in the inflamed joint of RA and PsA patients, little IL-17F protein 
and few IL-17F+ T cells were detected. 
 
Collectively, data presented in this thesis indicate that IL-17A and IL-17F are 
differentially regulated and that strong T cell stimulation induces IL-17F. 
Additionally, data suggests IL-17A+IL-17F-, IL-17F+IL-17A- and IL-17A+ IL-17F+ 
CD4+ T cells are functionally distinct. Finally, it is shown that in an environment 
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where IL-17A and IL-17F are present dual blockade of IL-17A and IL-17F is more 
effective at reducing inflammation. 
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The term ‘cytokines’ defines a broad group of proteins that are secreted by cells and 
elicit diverse and overlapping effects on target cells. Essentially, they act as a vital 
communication network between cells. Cytokines affect a plethora of biological 
processes including embryonic development, cognitive function and the immune 
response. They can regulate non-specific response to infection, specific response to 
antigen and disease pathogenesis 1. The cytokine families include interleukins (IL), 
interferons (IFN), tumour necrosis factors (TNF), chemokines and haemopoietic 
colony-stimulating factor (CSF). Cytokines can act on nearby cells (paracrine action), 
distant cells (endocrine action) or the cytokine secreting cell itself (autocrine action). 
Two or more cytokines targeting the same cell can act synergistically or 
antagonistically. Finally, cytokines can be pleotropic or redundant. Pleotropic refers 
to the ability of cytokines to act on multiple cell types, whereas redundant refers to 
different cytokines inducing similar signals 2,3. Pleiotropic actions can be attributed to 
the presence of a cytokine receptor on multiple cell lineages and redundancies can in 
part be attributed to similar cellular distributions of receptors for different cytokines, 
which share the same signalling pathway. Prior to discussing the IL-17 cytokine 
family, I will provide an overview of all cytokine families and the function of other 
cytokines which are important in this project. 
 
1.1.1 Interleukins 
The ILs are a diverse group of cytokines, which were originally identified to be 
secreted by leukocytes (T cells, monocytes and macrophages) and act upon 
leukocytes. However, research has since shown other cell subsets including 
endothelial cells and fibroblasts can be cellular sources and targets of ILs 4. ILs can be 
classified into sub-groups based on sequence homology, signalling receptors or 
functional properties. The IL sub-families include the common γ-chain, IL-1, IL-6, IL-
10 and IL-17 sub-families. These families and their members are displayed in table 
1.1. Members of the common-γ chain cytokine family signal through a receptor 
complex sharing a γ-chain subunit. This family plays a crucial role in regulating the 
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proliferation, differentiation and survival of immune cells 5. IL-2 is a pleotropic 
cytokine, which is predominantly produced by activated CD4+ T cells. It plays a 
critical role in the development and function of T regulatory cells (Tregs) 6. 
Accordingly, IL2R knock-out mice develop systemic autoimmune disease 
characteristic of reduced Treg cell numbers 7. With its pleotropic ability, IL-2 can also 
induce the expansion of CD4+ and CD8+ T cells 8, promote the proliferation of B cells 
9 and augment cytokine production and cytotoxic activity of natural killer (NK) cells 
10. Moreover, IL-2 can prevent over-stimulation of T cells by inducing Fas-mediated 
apoptosis in CD4+ T cells 11.  
 
Of the IL-1 family members, IL-1α and IL-1β are the two major agonistic molecules. 
Studies have shown that IL-1α and IL-1β display differences in their expression and 
roles. The IL-1α precursor is constitutively expressed in epithelial cells. It is released 
upon cell death by necrosis, which occurs in ischemic conditions such as stroke. 
Subsequently, the IL-1α pre-cursor becomes active and acts as an ‘alarmin’ rapidly 
initiating a cascade of inflammatory cytokines and chemokines 12,13.  As such, IL-1α 
is important in mediating the early phases of sterile inflammation. In contrast, IL-1β 
is produced by cells of the innate immune system, including monocytes and 
macrophages. It is rapidly induced upon activation of pattern recognition receptors 
(PRRs) such as toll-like receptors (TLRs) by pathogen products or factors released by 
damaged cells 14. IL-1β is first produced as an inactive pre-cursor, which is activated 
and released into the extracellular space upon cleavage by caspase-1. Caspase-1 is 
abundant in hematopoietic cells, however the pro-enzyme (pro-caspase-1) first 
requires cleavage by the inflammasome. The protein-nucleotide-binding domain and 
leucine-rich repeat pyrin containing protein-3 (NLRP3) (also known as cryoprin) is a 
key component of this macromolecular complex 13. Other enzymes such as elastase, 
cathepsin G and proteinase-3 also have the ability to generate active IL-1β 15,16. 
Functionally, IL-1β has been shown to elicit a wide-range of responses from T cells, 
in particular findings have identified a key role for IL-1β in the differentiation of T 
helper (Th17 cells) 17,18. IL-1β stimulates T cell proliferation by up-regulating IL-2R 
expression and activating signalling pathways such as the NFκB pathway that can have 
anti-apoptotic effects 19. In addition, IL-1β enables effector T cells to proliferate even 





Members Common Feature 
Common-γ chain cytokines 
 
IL-2, IL-4, IL-7, IL-9, IL-15, 
IL-21 
Signal through type I receptors 
that contain the γ-chain 5 
 
Common-β chain cytokines 
 
IL-3, IL-5, GM-CSF Signal through type I receptors 




IL-1α, IL-1β, IL-1 receptor 
agonist (Ra), IL-18, IL-33, IL-
36α, IL-36β, IL-36γ, IL-36Ra, 
IL-37 and IL-1Hy2 
 
Signal via the IL-1 receptor 
family 12 
IL-6 IL-6, IL-11, ciliary 
neutrophilic factor (CNTF), 
leukemia inhibitory factor 
(LIF), oncostatin M (OSM), 
cardiotropin 1 (CT-1), 
cardiotrophin-like cytokine 
(CTL) and IL-27 
 
Receptors contain signal-
transducing component gp130 
1 
IL-10 IL-10, IL-19, IL-20, IL-22, IL-
24, IL-26, IL-28, IL-29 
 
Similarities with structure and 
location of encoding genes, 
protein structures and receptor 
complexes 27 
IL-12 IL-12, IL-23, IL-27, IL-35 
 
Heterodimeric cytokines 1 
IL-17 IL-17A, IL-17B, IL-17C, IL-
17D, IL-17E, IL-17F 
Share a conserved cysteine 
motif  31 
 
Table 1.1 The interleukin sub-families 
The members and common features and interleukin sub-families.  
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The IL-6 family is highly pleiotropic. The IL-6 cytokine itself is strongly linked to the 
acute-phase response, which is a complex early-defence system triggered by different 
stimuli including trauma, infection, stress, neoplasia and inflammation. The aim of 
this response is to re-establish homeostasis and promote healing  21. IL-6 has been 
shown to rapidly induce a wide range of acute phase proteins from hepatocytes, 
including C-reactive protein (CRP), serum amyloid A, fibrinogen and haptoglobin 22. 
In combination with transforming growth factor (TGF)-β, IL-6 plays an important role 
in promoting differentiation of murine naïve CD4+ T cells into Th17 cells 23. 
However, IL-6 also has the ability to suppress TGF-β-induced Treg differentiation 24. 
Studies have revealed that IL-6 has the ability to induce the differentiation of activated 
B cells into antibody-producing plasma cells 25. IL-6 also plays a role in leukocyte 
recruitment in vivo. A study by Romano et al. revealed that IL6 knock-out mice have 
impaired leukocyte accumulation in subcutaneous air pouches, associated with a 
reduction in chemokine production. Subsequently, it was shown IL-6 and its soluble 
receptor sIL-6Rα can act on endothelial cells inducing the secretion of the chemokines 
IL-8 and monocyte chemoattractant protein (MCP)-1 26.  
 
In contrast to IL-6, the IL-10 sub-family is anti-inflammatory. The main sources of 
IL-10 are T cells, monocytes and macrophages. IL-10 signals through the IL-10 
receptor (a class II cytokine receptor family composed of IL-10R1 and IL-10R2) and 
activates the JAK/STAT pathway in target cells 27. IL-10 is a potent anti-inflammatory 
cytokine, which plays an important role in regulating the immune response. The 
importance of IL-10 in regulating the immune response is evidenced by the IL10 
knock-out mouse phenotype, which displays dysregulated inflammatory responses 28. 
One of the mechanisms by which IL-10 exerts anti-inflammatory effects is by potently 
inhibiting monocyte/macrophage activation. Addition of IL-10 to J744 mouse 
macrophage cells in the presence of LPS, inhibited macrophage activation by LPS 29. 
IL-10 potently inhibits monocyte and macrophage production of TNFα and CC and 
CXC chemokines, therefore reducing chemokine-driven recruitment of neutrophils 
and other immune cells to sites of inflammation 30. 
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The IL-17 family, IL-17A, IL-17B, IL-17C, IL-17D and IL-17E are grouped together 
as they share a conserved cysteine motif 31. IL-17A is the best characterised IL-17 
family member which displays pro-inflammatory characteristics. The cellular sources, 
receptors and functions of the IL-17 members are extensively discussed later. 
 
1.1.2 Interferons 
The IFN family are important for fighting viral infections and regulation of the 
immune system. They can bind to surface receptors on infected and neighbouring cells 
triggering a cascade of events, which results in the rapid transcription of several host 
proteins (including oligoadenylate synthetase) that can suppress viral infection 32. 
Three classes of IFNs exist: Type I IFN, Type II IFN and Type III IFN. Type I IFN 
includes IFNα and IFNβ, which are secreted by innate immune cells such as 
macrophages and dendritic cells 33. As well as their anti-viral properties, these 
cytokines can activate CD8+ T cells and NK cells that kill infected targets 34. The type 
II includes IFNγ, which is secreted by T cells, NK cells, monocytes, macrophages and 
dendritic cells 35. IFNγ has been shown to induce a T helper (Th) 1 immune response 
and activate macrophages and NK cells. Furthermore, it has the ability to up-regulate 
class II major-histocompatibility complex (MHC), which in turn promotes peptide-
specific activation of CD4+ T cells 35. Finally, Type III comprises of IFNλ1, IFNλ2 
and IFNλ3, which can be produced by plasmocytoid dendritic cells 36. Studies have 
also shown that the type III IFNs have the ability to increase MHC I and MHC II 
expression on DCs 36.  
 
1.1.3 Tumour necrosis factor (TNF) family 
Early studies demonstrated that tumours contaminated by a bacterial infection could 
regress and disappear 37. At this point, it was hypothesised that bacteria were releasing 
a factor which induced the necrosis of specific tumours, this factor was termed tumour 
necrosis factor (TNF). Later studies revealed that antigens, such as lipopolysaccharide 
(LPS), present in the outer membrane of gram-negative bacteria elicited the production 
of TNF from immune cells 38. Since then the TNF family has expanded to comprise 
19 members, including TNFα (also referred to as TNF), TNFβ (lymphotoxin-α) and 
other ligands such as receptor activator of nuclear factor kappa-B ligand (RANKL) 
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and TNF-related apoptosis-inducing ligand (TRAIL). TNFα is mainly produced by 
activated macrophages and monocytes. It is expressed as a transmembrane protein that 
can be cleaved by the metalloprotease TNFα converting enzyme (TACE) to release a 
soluble TNFα form 39. Through the activation of the NFκB pathway, TNFα has a 
powerful pro-inflammatory capacity. TNFα can promote monocyte/macrophage 
differentiation 40, enhance activated B cell proliferation 41 and promote the 
proliferation of fibroblasts 42. Depending on the target cell, TNFα is a potent inducer 
of IL-6 43 and the further production of TNFα itself 44. In concordance, a report 
demonstrated that in healthy humans infused with recombinant TNFα,circulating IL-
6 is significantly elevated 45. TNFα alongside other TNF family members (TRAIL) 
demonstrate a potent apoptotic ability. LPS has been shown to induce apoptosis in 
macrophages via the autocrine production of TNFα 46. 
 
1.1.4 Chemokines 
Chemokines are characterised by the presence of three to four conserved cysteine 
residues and can be sub-divided based on the positioning of the N-terminal cysteine 
residues. The majority of known chemokines are from the C-X-C or C-C subfamily. 
The C-X-C subfamily is characterised by a variable amino acid separating the first two 
cysteines, while the cysteine residues are adjacent to one another in the C-C family 47. 
Chemokines are essential for the directional migration of leukocytes during normal 
and inflammatory processes. Once the chemokine is induced, the directed migration 
of cells expressing the appropriate chemokine receptors occurs along a chemical 
ligand gradient known as the chemokine gradient. Subsequently, cells move towards 
an environment of high local concentrations of chemokines. The best studied members 
of the C-X-C and C-C chemokine subfamilies are CXCL8 (also known as IL-8) and 
MCP-1 (also known as CCL2), respectively 48,49. IL-8 is a critical inflammatory 
mediator, which is predominantly known for its ability to recruit neutrophils to sites 
of inflammation. However, it has also been identified in the chemoattraction of 
monocytes, lymphocytes, basophils and eosinophils 50. MCP-1 was initially reported 
to recruit monocytes. In an in vitro chemotaxis assay, approximately 30% of input 
monocytes responded and migrated towards MCP-1 51. However, further studies have 
suggested MCP-1 also plays an important role in the migration, generation and 
survival of memory CD8+ T cells 52. 
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1.1.5 Colony stimulating factors 
Granulocytes and macrophages play an important role in the innate immune system, 
protecting the body against bacterial, viral and fungal infections. The colony-
stimulating factors are master regulators of granulocyte and macrophage populations. 
Multiple tissue types produce them locally at the site of inflammation or systemically. 
The distinct types of CSF include granulocyte-macrophage colony stimulating factor 
(GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-
stimulating factor (M-CSF) and multipotential colony-stimulating factor (commonly 
referred to as IL-3) 53. A common set of pluripotent stem cells, residing mostly in the 
bone marrow, give rise to large numbers of neutrophils, basophils, eosinophils, 
monocytes and lymphocytes circulating in the periphery. As many of these cells are 
short-lived they must be continually replenished. In health, numbers of these cells are 
constant, however during infection the production of granulocytes and macrophages 
can be greatly and rapidly increased. CSFs are crucial for co-ordinating and controlling 
this cell production. G-CSF and M-CSF support the growth and proliferation of 
neutrophils and macrophages, respectively. Whereas, GM-CSF supports the growth of 
neutrophils, macrophages, eosinophils and other cell types 53,54.  
 
Collectively, a plethora of evidence demonstrates the diverse functions of cytokines 
mediated via a variety of different receptors, signalling pathways and molecules. 
Cytokines are interlinked and play a crucial role in regulating the immune and 
inflammatory response.  
 
1.2 Cytokine signalling 
1.2.1 The cytokine receptor families 
Receptors for cytokines are structurally diverse. However, the majority of cytokines 
signal through one of five families of receptor proteins – type I or type II cytokine 
receptor family, tumour necrosis factor receptor (TNFR) family, IL-1 receptor family 
or the chemokine receptor family. A significant number of cytokines signal through 
the type I cytokine receptor family (hematopoietin receptor subfamily) which includes 
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homodimeric and heterodimeric receptors. Heterodimeric receptors are subdivided 
based on the presence of receptor signalling components (β-chain, γ-chain and gp130). 
The conserved extracellular domain of type I cytokine receptors contains four 
conserved cysteine residues in the amino-terminal region and a conserved Trp-Ser-X-
Trp-Ser (WSXWS) motif located proximal to the transmembrane domain 55. Type II 
cytokine receptors are similar to type I receptors but lack the conserved motif. They 
are multimeric receptors composed of heterologous subunits. Type II cytokine 
receptors are predominantly receptors for IFNs and the IL-10 family 56. Type I and II 
cytokine receptors signal through the Janus tyrosine kinase (JAK)/ signal transducer 
and activator of transcription (STAT) pathway.  
 
The IL-1 receptor family is characterised by extracellular immunoglobulin (Ig)-like 
domains and Toll-IL-1-receptor (TIR) domains. Each IL-1 ligand (IL-1α, IL-1β etc.) 
binds specifically to an extracellular ligand binding chain containing three Ig-like 
regions. In the case of IL-1α, IL-1β this is type I IL-1 receptor (IL-1RI). A second 
accessory chain is recruited, forming a heterotrimeric complex with the ligand binding 
chain and ligand. This initiates signal transduction. The accessory chain is not present 
upon binding of the IL-1 and IL-36 receptor agonists. Each ligand binding or accessory 
chain bears a TIR domain. This domain is also shared by the Toll-like receptors (TLR), 
which bind a broad spectrum of microbial products 57. Signal transduction rapidly 
assembles two signalling proteins, myeloid differentiation primary response gene88 
(MyD88) and interleukin-1 receptor-activated protein kinase (IRAK)4. 
Autophosphorylation of IRAK4 leads to the phosphorylation of IRAK1 and IRAK2 
which subsequently elicits the recruitment and oligomerization of tumour necrosis-
associated factor (TRAF)6. TRAF6 subsequently induces NF-κB-induced 
transcription of inflammatory genes 58. 
 
The tumour necrosis factor receptor (TNFR) family bears a repeated cysteine rich 
extracellular sequence homology. To date, there are at least 27 members of the TNFR 
family including LT receptor, Fas, CD40, TRAIL receptors, RANK and death or 
decoy receptors. However, the main TNF ligands mediate their functional effects by 
binding to either TNFR1 or TNFR2 receptor sub-types 39. Activated TNFR1 recruits 
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TNFR-associated death domain (TRADD) which in turn recruits TNFR-associated 
factors (TRAFS) to activate the NFκB pathway. TNFR1 also stimulates the formation 
of a TRADD complex which contains FAS-associated death domain (FADD) and pro-
caspase 8. This leads to the activation of caspase 8 and the initiation of an apoptotic 
signalling cascade 59,60.  
 
Chemokine receptors are composed of 7-transmembrane domains and coupled to G-
proteins. The chemokine receptors CXCR1 to CXCR5 selectively bind certain CXC 
chemokines, whereas the CC receptors CCR1 to CCR9 bind CC chemokines 61. 
Intracellular signalling by chemokine receptors depend on the coupled-G proteins. G-
proteins are inactive when guanosine diphosphate (GDP) is bound to the G-protein 
sub-unit, however they become active when GDP is exchanged for guanosine 
triphosphate (GTP). During ligand binding, chemokine receptors associate with the G-
proteins allowing for the exchange of GDP to GTP. Subsequently, this activates a 
series of co-ordinated signalling events that lead to cellular responses 61. 
 
1.2.2 JAK-STAT pathway 
The JAK/ STAT pathway is the predominant signalling cascade that mediates the 
effects of cytokines, as well as growth factors. It directly translates an extracellular 
signal into a transcriptional response. The JAK family are non-receptor protein 
tyrosine kinases consisting of JAK1, JAK2, JAK3 and non-receptor protein kinase 2 
(TYK2). The STAT proteins comprise of STAT1 to STAT6. STAT4 exists in two 
forms, STAT4α and STAT4β. Additionally, there are two isoforms of STAT5, 
STAT5a and STAT5b, which are encoded by separate genes 62. STATs are latent 
cytoplasmic transcription factors that are activated following receptor 
phosphorylation. Activation of the JAK/STAT pathway occurs when ligand binding 
induces the multimerization of receptor subunits. Upon ligand-mediated receptor 
multimerization, two JAKS are brought into close proximity, allowing trans-
phosphorylation. Activated JAKs phosphorylate their associated receptors on specific 
tyrosine residues. Subsequently, STATs bind to the phosphorylated receptors and are 
themselves phosphorylated by the JAKs. Through interaction with a conserved Src-
homology 2 (SH2) domain, STATs form dimers. Phosphorylated STAT dimers can 
 25 
then enter the cell nucleus by a mechanism that is dependent on importin α-5 and the 
Ran nuclear import pathway. Once in the nucleus, dimerized STATs bind specific 
regulatory sequences to activate or repress transcription of target genes 63-65. In 
addition to the principal components of the JAK/STAT pathway, effector proteins and 
negative regulators can affect the signalling events. Effector proteins include signal-
transducing adapter molecules (STAMAS), which can facilitate the transcription of 
specific target genes. Classes of negative regulators include suppressors of cytokine 
signalling (SOCS), protein inhibitors of activated STATS (PIAS) and protein tyrosine 
phosphatases (PTPs) 63. 
 
Different cytokine receptors recruit a different combination of JAKs, which enables a 
diversity of signalling responses. However, JAKs are not an absolute determinant in 
cytokine signalling specificity as the same JAKs can be activated by different 
cytokines. The specificity for a particular STAT phosphorylation appears to be 
dictated by the STAT docking sites present in the receptors and not the activated 
JAKS. This is evidenced by the fact that different receptors can activate a common 
STAT even though they activate distinctively different JAKs. Moreover, it has been 
shown that chimeric receptors that bear different JAK binding sites can activate the 
same STAT protein 62. The phenotypes of STAT knock-out mice have revealed 
distinctive functions for the different STAT molecules. For example, STAT1 deficient 
mice display a severe defect in IFNγ-dependent immune responses against viruses. As 
the mice still retain the ability to other cytokines, it demonstrates the importance of 
STAT1 for mediating IFNγ-dependent pathways 66,67.  
 
1.2.3 NF-ΚB pathway 
The nuclear factor–κB (NF-κB) pathway serves as a pivotal mediator of inflammatory 
responses. NF-κB comprises a family of inducible transcription factors, including NF- 
κB1 (p50), NF-κB2 (p52), RELA (p65), RELB and C-Rel. NF-κB proteins normally 
exist as inactive cytoplasmic complexes bound by members of the inhibitor of κB 
(IκB) family, including IκBα. NF-κB activation occurs via the canonical and the non-
canonical NF-κB signalling pathways 68,69. The canonical pathway is activated by 
various cytokines including TNFα, IL-1 and IL-17 cytokine family members, as well 
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as T-cell receptor and B-cell receptor activation. The primary mechanism for the 
canonical NF-κB activation involves activation of TGFβ-activated kinase (TAK1) 
which in turn activates a trimeric IκB (IKK) complex. IKK is composed of catalytic 
(IKKα and IKKβ) and regulatory IKKγ, (also known as NEMO) subunits. Upon 
activation, IKK phosphorylates IκBα, triggering ubiquitin-dependent IκBα 
degradation in the proteasome. Subsequently, nuclear translocation of the canonical 
NF-κB family members, predominantly the p50/RelA and p50/c-Rel dimers are 
released and translocated to the nucleus 69.  
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Figure 1.1 JAK/STAT signalling pathway 
Binding of a type I or type II cytokine receptor to cytokine can induce the activation of JAKS. 
Subsequently, cellular substrates including one of the receptor chains is phosphorylated. This allows 
the recruitment of STAT proteins to the phosphorylated receptors and are themselves phosphorylated 
by the JAKS. Through STAT SH2 domains, they can dimerize, translocate to the nucleus and bind 
DNA. STAT-dependent responses can be differentially induced by accessory transcription factors. 
Suppressor of cytokine signalling (SOCS) and cytokine-inducible SH2- containing protein 1 (CIS1) 
can negative regulate cytokine signalling. Printed with permission from Leonard, W. (2001) Nature 65. 
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1.3 A brief history of IL-17 identification 
Having discussed cytokines in general, I will now focus on the IL-17 family, beginning 
with the discovery of each IL-17 family member. IL-17A, then referred to as cytotoxic 
T lymphocyte antigen 8 (CTLA8) was first discovered in a subtractive hybridization 
screen of a rodent T cell library 70. Subsequent work detected CTLA8 mRNA in a 
human CD4+ T cell clone and revealed it encodes a protein which displays cytokine 
like characteristics, including activation of NFkB and induction of IL-6 from 
fibroblasts, thus giving rise to its new term IL-17  71.  Proteomic and genome database 
searches led to the discovery of human proteins with similar amino acid sequences to 
IL-17A, including IL-17B (29% homology), IL-17C (23% homology) and IL-17E 
(17%) 72-74. Using nested rapid amplification of cDNA ends (RACE) polymerase chain 
reaction (PCR), IL-17F was cloned, bearing 50% homology to IL-17A. Expression of 
IL-17F was observed in activated CD4+ T cells and it was shown to induce IL-2 and 
TGF-β expression in endothelial cells 75. Completing the IL-17 family, Starnes et al. 
cloned IL-17D (25% homology to IL-17A) 74,76. IL-17A and IL-17F exist as 
homodimers. Due to the sequence homology of IL-17A and IL-17F and previous 
reports that cysteine knot family members can exist as heterodimers, it was 
hypothesised that IL-17A and IL-17F could form a heterodimer. Indeed, both mouse 
and human studies from 2005 onwards identified an IL-17AF heterodimer secreted by 
CD4+ T cells 77, 78. A timeline of the IL-17 family history is presented in Figure 1.2. 
 
Figure 1.2 Timeline of the key discoveries of the IL-17 family 
IL17A gene cloned as 
CTLA8 in a rodent T cell 
hybridoma.
Homology to an open 
reading frame encoded 





Human IL17A cDNA  cloned from 
a CD4+ T cell l ibrary.
63% amino acid homology with
murine CTLA8 and 72% homology
with HVS13.
IL-17A identified as a novel 
cytokine produced by activated 
CD4+ T cells 71.
2000
Identification of IL-17E 73.
IL-17D cloned using RACE 
PCR.
Highly expressed in skeletal 
muscle, brain, adipose 
tissue, heart, lung and 
pancreas 76.
2001
CD4+ Tcells producing IL-
17A, IL-17F and TNFα
identified as a separate 
lineage from Th1 and 




Over-expression of IL-17A and 
IL-17F in 293 T cells led to the 
production of IL-17A and IL-
17F homodimers and 
biologically active IL-17AF were 
identified. Naturally secreted 
IL-17AF were identified from 
mouse T cells 77.
Activated human CD4+ T cells 
shown to produce the IL-17AF 
heterodimer 78.
Human IL-17B and IL-17C cloned.
IL17B mRNA expressed in adult 
pancreas, small intestine and 
stomach, whereas IL17C mRNA 
not detected in these tissues 72.
IL-17F cloned via RACE 
PCR and shown to be 




1.4 Structure of IL-17 cytokines 
IL-17 family members share limited homology in their primary sequence, however 
elements of their secondary structure are preserved, especially in the four β-strands 
in the C-terminal region. Specifically, there are four cysteine and two serine residues 
highly conserved among IL-17 members, which are critical to forming a cysteine 
knot fold 79. To date, only three crystal structures have been resolved including IL-
17A with its neutralising antibody 80, IL-17F 79 and IL-17F with its receptor IL-
17RA 81. The crystal structure of IL-17F demonstrated it is a disulphide-linked 
homodimeric protein with a cysteine-knot fold, which is also found in the TGFβ, 
bone morphogenetic protein and nerve growth factor superfamilies 79,82. IL-17A and 
IL-17E are also disulphide-linked homodimeric proteins, however, their precise 
subunit interactions are not fully understood 83,84. Homodimeric proteins are formed 
post-transcriptionally, in the case of the IL-17AF heterodimer it is believed that 
when a T cell produces high levels of IL-17A and IL-17F monomeric proteins, IL-
17AF heterodimers can form. In concordance, no IL17AF mRNA can be detected 
77,85. While the majority of genes encoding the IL-17 family members are on 
different chromosomes, the IL17F gene is located adjacent to IL17A on chromosome 
6p12 74.  
 
1.5 IL-17 receptors and signalling 
The biological functions of the IL-17 cytokines are mediated via surface receptors on 
target cells. There are 5 members of the IL-17 receptor family, IL-17RA, RB, RC, RD 
and RE. It is thought that functional receptors exist as heterodimers, with IL-17RA as 
a common subunit. The IL-17RA and IL-17RC heterodimer has been reported as the 
receptor for IL-17A, IL-17F and IL-17AF 86. While IL-17RA is ubiquitously 
expressed in haematopoietic cell types, IL-17RC is preferentially expressed by non-
haematopoietic cells. Since IL-17A and IL-17F signalling requires IL-17RA and IL-
17RC, these cytokines mostly act on parenchymal cells such as fibroblasts, epithelial 
cells and endothelial cells 31. In addition research has shown IL-17F binds to IL-17RA 
with 100-1000 fold lower affinity than IL-17A 79. The heterodimeric receptor for IL-
17E consists of IL-17RA and IL-17RB. IL-17RB is expressed on Th2 cells, various 
endocrine tissues and the kidney 87. The receptor for IL-17B includes IL-17RB, 
although it is unknown if this receptor forms a complex with IL-17RA. Finally, the 
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receptor for IL-17C comprises an IL-17RE/ IL-17RA complex 31,88. Although an IL-
17RD/IL-17RA receptor complex has been identified the ligand is unknown. 
Similarly, the receptor for the IL-17D cytokine is unknown 31 (Figure 1.3). 
 
At the C-terminus of the IL-17 receptor is a conserved region known as the SEFIR 
(similar expression of fibroblast growth factor genes and IL-17Rs) domain. Following 
IL-17 stimulation, the cytosolic protein NFκB activator 1 (Act 1) is recruited to the 
IL-17 complex through homotypic interactions of the SEFIR domain. Act1 recruits 
TNFR-associated factor 6 (TRAF6) proteins, and acts as an E3 ligase, mediating the 
ubiquitination of TRAF6. This leads to the activation of the canonical nuclear factor-
κB (NFκB) pathway and mitogen-activated protein kinase (MAPK) pathways. A 
unique TRAF6 independent signalling pathway includes Act1 recruitment of TRAF2 
and TRAF5, which promotes the activation of an mRNA stability pathway by 
sequestering ASF/SF2 and recruiting the stabilizing factor HuR 89-92 (Figure 1.4). 
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Figure 1.3 IL-17 receptors.  
Schematic diagram showing the receptors identified for the IL-17 cytokine family. The majority of IL-
17 receptors exist in the form of a heterodimer with IL-17RA as a common sub-unit. The IL-17RA and 
IL-17RC heterodimer is the receptor for IL-17A, IL-17F and IL-17AF. The IL-17RA sub-unit also 
couples with IL-17RB to form the receptor for IL-17E, IL-17RE to form the receptor for IL-17C. IL-
17B signals via IL-17RB it is unknown if this couples with another receptor sub-unit. An IL-17D/IL-
17RA complex has been identified, however the ligand is unknown.  Printed with permission from 





Figure 1.4 IL-17RA:IL-17RC signalling pathway  
After stimulation with IL-17 cytokines Act1 and IL-17R interact via their respective SEFIR domains. This leads 
to the recruitment and ubiquitination of Act1 in a nondegradative way through Lys63-linked ubiquitnation. 
Subsequently, TAK1 and its binding partners TAB2 and TAB3 (TAB) are recruited and activate the IKK complex 
and NF-κB pathway. An alternative pathway involves phosphorylation of Act1 at Ser311 by IKKi. This generates 
a docking site which recruits TRAF2 and TRAF6. In the absence of IL-17 cytokines SF2 (ASF) binds to the 3’ 
UTR of CXCL1, causing its instability.  After IL-17 stimulation SF2 associates with the TRAF2-TRAF5-Act1 
complex, preventing the repression of CXCL1 mRNA. Printed with permission from May Nature Immunology 
(2011) 92. 
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1.6 Function of IL-17A, IL-17F and IL-17AF 
1.6.1 Individual function 
IL-17A is defined as a pro-inflammatory cytokine and its individual function has been 
extensively studied. Activation of NFκB and MAPK pathways in target cells by IL-
17A results in the transcription of pro-inflammatory genes. This leads to the secretion 
of pro-inflammatory cytokines (IL-6, TNFα, IL-1) 71, T cell and myeloid cell-
attracting chemokines (CCL20, CCL2 and CCL7) 94,95 and many neutrophilic 
granulocyte-attracting chemokines (CXCL1, CXCL2, CXCL5 and CXCL8) 71,96 from 
target cells including fibroblasts, epithelial  cells and synoviocytes. In addition, IL-
17A can strengthen granulopoiesis by up-regulating the expression of G-CSF and GM-
CSF in tissue cells, macrophages and T cells 97 and enhancing the secretion of 
antimicrobial peptides (defensins and S100 proteins) in target cells 98. Pathologically, 
IL-17A can contribute to joint degradation. IL-17A can elicit the production of matrix 
metalloproteinases (MMP1, MMP9 and MMP13) from target cells, which in turn 
drives the degradation of extracellular matrix within the joint 99,100. Osteoclastogenesis 
is a process that can ultimately lead to bone destruction. Bone-resorbing osteoclasts 
derive from the haemopoietic cells of the monocyte-macrophage lineage under the 
control of bone-forming osteoblasts. In the presence of M-CSF, the TNF family 
member RANKL (expressed on osteoblasts) and its receptor RANK (expressed on 
osteoblast precursor cells) are vital for inducing osteoclast differentiation 101. The 
osteoprotegerin (OPG) ligand is produced by a variety of cells including osteoblasts 
and acts as a soluble decoy receptor for RANK. Therefore, it inhibits 
osteoclastogenesis by competing against RANK 102. Reports have shown IL-17A 
increases RANKL expression and decreases OPG expression levels in osteoblasts and 
other target cells, which results in osteoclastogenesis and subsequent bone destruction 
103-105. Collectively, while IL-17A plays an important role in inflammation and host 
protection against specific pathogen, excessive activation of this pathway can 
contribute to inflammatory diseases. 
 
The function of IL-17F has not been as extensively studied as IL-17A. However, 
numerous reports have shown IL-17F to function similarly to IL-17A, albeit less 
potently than IL-17A.  Literature describes a hierarchy in inflammatory potential with 
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IL-17A eliciting the strongest inflammatory response, followed by IL-17AF and IL-
17F 77. IL-17 can upregulate pro-inflammatory mediators including IL-6, CXCL1, 
CXCL8, GM-CSF, CCL2, CCL7 and MMP13 from fibroblasts and epithelial cells 
106,107. Additionally, IL-17F has been shown to induce the production of IL-8 in normal 
epidermal keratinocytes. Mouse skin intradermally injected with IL-17F expressed 
high IL8 mRNA levels and histological examination of the mouse skin revealed 
marked neutrophilia in the dermis 108. In concordance, Sorbello et al. demonstrated 
that IL-17F was present in nasal biopsies from asthma patients and positively 
correlated with the neutrophil count 109. IL-17F has been shown to induce the 
expression of MMP-9 from epithelial cells, therefore it has the potential to contribute 
to bone destruction 110. Very limited studies which examine the function of the IL-
17AF heterodimer exist. However, it has been shown that IL-17AF induces IL-6 and 
CXCL1 secretion from mouse embryonic fibroblasts 77. 
 
1.6.2 Synergy between IL-17A, IL-17F and other pro-inflammatory 
cytokines 
One of the best-studied cytokines that synergises with IL-17A is TNFα. Studies have 
demonstrated that IL-17A can synergise with TNFα to induce increased levels of pro-
inflammatory mediators such as IL-6, IL-8 and CCL20 production from RA 
synoviocytes 83,111,112. Additionally,  IL-17A and can synergistically enhance the levels 
of GM-CSF from RA synoviocytes 100, G-CSF from human epithelial cells 113 and 
MCP-1 and macrophage inflammatory protein-2 (MIP-2) from mouse mesangial cells 
114. One report showed that IL-17A and TNFα enhanced MMP-2 and CXCR4 
expression by RA synoviocytes, leading to an increase in cell invasion as examined 
by transwell Matrigel invasion chambers 115. With regards to joint destruction, a study 
of TNF transgenic mice demonstrated that combined blockade of IL-17A and TNFα 
was more effective at providing bone protection from bone resorption than blockade 
of IL-17A or TNFα alone 116. This was associated with decreased RANKL expression 
on osteoblasts, increased osteoblast numbers and decreased osteoclast numbers 116. 
The suppression of collagen degradation in an RA ex vivo bone explant model was 
shown to be further enhanced with a triple combined blockade of TNFα, IL-1 and IL-
17A than blockade of either cytokine alone 117. In addition to TNFα, synergy between 
IL-17A and the pro-inflammatory cytokines IL-1β and IFNγ has been reported. The 
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combination of IL-17A and IL-1β was shown to enhance IL-6 production by RA 
synoviocytes 118 and increase CCL20 production by fibroblast-like synovial cells 119. 
Finally, an early study showed IL-17A and IFN-γ synergistically upregulated IL-6 and 
IL-8 production by keratinocytes and led to a subtle increase in expression of ICAM-
1, a ligand that binds LFA-1 on T cells to cause T cell adhesion to keratinocytes 91,120. 
 
Studies have demonstrated that IL-17F can significantly amplify its inflammatory 
potential by synergising with TNFα and IL-1β. Zrioual et al. revealed IL-17F 
synergises with TNFα to increase IL6, IL8 and CXCL5 mRNA levels from RA 
synoviocytes. While the combination of IL-17A and TNFα induces a higher fold 
increase in pro-inflammatory mRNA levels than IL-17F and TNFα, the effect of IL-
17F and TNFα synergy still remained potent 112.  Similar to IL-17A, the combination 
of IL-17F and TNFα can synergistically elevate levels of G-CSF from human 
epithelial cells 113. Additionally, IL-17F can synergise with both TNFα and IL-1β, 
enhancing the expression of MCP-1 and MIP-2 from mouse mesangial cells 114. 
Finally, it has been reported that IL-17AF and TNFα synergistically enhance the 
production of CXCL1 from macrophages 77. Literature has suggested that IL-17F is 
redundant to IL-17A due to the similar functional roles and lower potency of IL-17F 
31. However, a recent study by Glatt et al. demonstrated that dual neutralization of IL-
17A and IL-17F in Th17 supernatant reduced the pro-inflammatory signature of target 
cells to a greater extent that neutralization of IL-17A alone 121. This suggests that dual 
blockade of IL-17A and IL-17F is more effective at reducing inflammation than the 
blockade of IL-17A alone. 
 
1.6.3 Mechanism of synergy 
Mechanistically, the synergy of IL-17A and IL-17F with other cytokines is not fully 
understood. However, reports suggest it may occur through the ability of IL-17 
cytokines to stabilise mRNA transcripts. One report showed that IL-17A has the 
ability to extend the half-life of the unstable TNFα -induced IL8 mRNA, thereby 
leading to a synergistic increase in IL-8 protein expression and gene expression. It is 
suggested that IL-17A mRNA stabilisation is via a p38 MAPK-dependent pathway, 
evidenced by the fact that cells pre-treated with a p38 MAPK inhibitor displayed a 
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faster IL8 mRNA decay rate following IL-17A/ TNFα stimulation 122. In concordance, 
a study by Hartupee et al. demonstrated that IL-17A elicited a synergistic increase in 
CXCL1 mRNA expression by extending the half-life of the unstable TNFα-induced 
CXCL1 mRNA. Additionally, as Act1 over-expression resulted in CXCL1 mRNA 
stabilization, it is proposed that Act1 may be a common mechanism by which IL-17A 
enhances gene expression 96. The half-life of other mRNA transcripts including MIP2 
and GMCSF is also extended in response to IL-17A, implicating this as a common 
mechanism for IL-17A synergy 96. A recent report demonstrated that inhibition of 
phospholipase D enzymes in cultures of RA fibroblasts stimulated with IL-17A and 
TNFα led to decreased IL-6, IL-8 and CCL20 production, thereby suggesting these 
enzymes play a role in the synergisitic effect of TNFα and IL-17A 123. Currently, the 
mechanism of IL-17F synergy and whether it has the ability to stabilize mRNA has 
not been investigated. 
 
1.7 Function of the remaining IL-17 family cytokines 
1.7.1 IL-17E 
In contrast to the pro-inflammatory role of IL-17A and IL-17F, IL-17E is associated 
with Th2 responses. It promotes the production of type 2 cytokines such as IL-4, IL-5 
and IL-13 for eosinophil recruitment and contributes to host defense against helminth, 
parasitic infections and allergic disease development 84,124. Interestingly, IL-17E 
treatment protects mice from Experimental autoimmune encephalomyelitis (EAE) by 
suppressing IL-17A producing T cells in an IL-13 dependent manner 125. EAE is an 
animal model of brain inflammation, although it is mostly used as a model for multiple 
sclerosis, it is also a prototype for T cell-mediated autoimmune disease 126. This 
suggests IL-17E supports a cytokine environment that limits chronic inflammatory 
responses, an opposite role to IL-17A. The opposing roles of IL-17E and IL-17A are 
further supported by a report from Xu et al. When stimulated with dsRNA and IL-
17E, primary human nasal epithelial cells (HNECs) from patients with allergic rhinitis 
(AR) produced elevated levels of thymic stromal lymphopoietin (TSLP). TSLP is 
associated with asthma and its overexpression has been shown to correlate with 
disease severity. In contrast, IL-17A significantly inhibited double-stranded (ds) 
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RNA-induced TSLP production. Moreover, IL-17E was dominant to the inhibitory 
effect of IL-17A on TSLP regulation 127.  
 
1.7.2 IL-17C, IL-17B and IL-17D 
Numerous studies have revealed a role for IL-17C in regulating epithelial immune 
responses 128, maintaining mucosal barrier maintenance 129 and promoting Th17 
responses 130. Additionally, IL-17C has been implicated in lesional psoriasis skin 
formation 131,132. The biological function of IL-17B and IL-17D are less extensively 
studied. Bie et al. have recently reviewed current knowledge of IL-17B 133. Reports 
have identified a role for IL-17B in inflammation, upregulating the expression of 
TNFα and IL-1b from THP-1 cells and synergising with TNFα to enhance the 
production of G-CSF and IL-6 from fibroblasts 72,134. Additionally, a more recent study 
has linked IL-17B to germinal centre B cell migration 135. IL-17B has been detected 
in the arthritic paws of CIA mice and in human rheumatoid synovial tissue, suggesting 
it may play a role in inflammatory disease 134,136. IL-17D is the least studied IL-17 
family member. Initial reports showed IL-17D upregulated the expression of IL-6, IL-
8 and GM-CSF from endothelial cells 76. Interestingly, more recent studies have 
implicated IL-17D in tumor rejection. These studies have shown IL-17D to be highly 
expressed in certain tumors and induce MCP-1 production from tumor endothelial 
cells, leading to the recruitment of natural killer (NK) cells, which in turn promotes 




1.8  T cells 
One of the main cellular sources of IL-17A and IL-17F is CD4+ T cells. Before 
discussing IL-17 expressing T cells, an overview of T cells is provided. T cells play a 
central role in the adaptive immune system, orchestrating many aspects of the 
inflammatory response. T cells can be divided into two categories classically referred 
to as; cytotoxic CD8+ T cells and CD4+ T helper (Th) cells. CD8+ T cells can act 
directly to kill virally infected or transformed cells 140 and CD4+ T cells can provide 
signals that modulate the behaviour and function of other immune cells 141. Both CD4+ 
and CD8+ T cells derive from the common lymphoid progenitor cell in the bone 
marrow and mature and undergo thymic selection in the thymus. This process involves 
positive and negative selection based on interactions with major histocompatibility 
complex (MHC) and peptides derived from self-antigens. Subsequently, auto-reactive 
T cells are deleted and the T cell repertoire contains a diverse T cell receptor (TCR) 
expression, which promotes the protection against a vast number of foreign antigens 
142. The TCR expressed on T cells is a highly variable disulphide-linked membrane 
bound heterodimeric protein. In humans, the majority (95%) of T cells express a TCR 
formed of the highly variable α and β chains expressed as part of a complex with 
invariant CD3 chain molecules, these are referred to as αβ T cells. However, a minority 
of T cells express an alternate receptor composed of variant γ and δ chains (γδ T cells) 
143. The TCR confers antigen specificity to the cell, via recognition of antigen 
presented in the context of the major histocompatibility complex (MHC) by antigen-
presenting cells. The co-receptors CD4 (for T helper cells) and CD8 (for cytotoxic T 
cells) bind to invariant parts of MHC class II or I, respectively 144. 
 
1.8.1 T cell activation 
Following maturation in the thymus antigen-specific ‘naïve’ T cells exit into the 
periphery. They circulate via the secondary lymphoid organs and tissues including the 
spleen and lymph nodes. Here, they may encounter antigen presented by antigen 
presenting cells (APCs), which can include dendritic cells (DCs), monocytes, 
macrophages or B cells. APCs have the ability to collect antigens from the periphery 
and migrate to lymphoid tissues to display the antigen to lymphocytes. For full T cell 
activation a specific T cell firstly binds via its TCR to an antigen presented in the 
peptide groove of an MHC molecule on the APC. Antigens derived from the cytosol 
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of the cell are presented in the context of MHC class I molecules to CD8+ T cells, 
whilst antigens derived from exogenous proteins are presented in the context of MHC 
class II molecules to CD4+ T cells. However, it is important to note that the process 
of cross-presentation can occur, whereby some APCs can present exogenous antigens 
into the MHC class I pathway for presentation to CD8+ T cells 145 Ligation of co-
stimulatory molecules, such as CD28 which interacts with CD80 (B7.1) and CD86 
(B7.2) on the surface of APCs, provides a second signal which is necessary for 
efficient T cell activation 144. Another co-stimulation signal involves interaction 
between CD40L expressed on T cells and CD40 expressed on APCs 146. CD28-/-naïve 
T cells have been shown to be deficient in IL-2 secretion and proliferation when 
stimulated with a wide range of antigen concentrations and APC numbers, whereas 
CD40L-/- T cells respond normally in the presence of high antigen or high APC to T 
cell ratios and show defects only when stimulated with low antigen concentration or 
antigen concentration 146. This suggests that the predominant role of the CD40L/CD40 
interaction is to amplify an existing co-stimulation signal. Indeed, CD40L engagement 
of CD40 on APCs increases the APC expression of B7 molecules 147. Studies have 
shown that signalling via the TCR in the absence of co-stimulation can lead to the 
induction of anergy in the T cell 148. A CD28 homolog called cytotoxic T lymphocyte-
associated antigen 4 (CTLA4) exists. Similar to CD28 it binds to B7 molecules, 
however it binds with higher affinity and does not produce a stimulatory signal. As 
such, this competitive binding can prevent the CD28/B7 co-stimulatory signal 149,150.  
 
Following the recognition of the cognate antigen and MHC by a specific TCR, the T 
cell and APC form an immunological synapse and undergo actin-mediated membrane 
re-organisation 151. The TCR, co-stimulatory and adhesion molecules are grouped 
together at the site of the TCR-MHC interaction and form a large multimolecular 
structure referred to as the supramolecular activation complex (SMAC). The spatial 
segregation of the SMAC complex was first described by Monk et al. using 
deconvolution microscopy and has since been confirmed by others. They describe the 
SMAC complex comprising of a focal point of signalling molecules (cSMAC) 
surrounded by a ring of adhesion molecules including leukocyte function-associated 
molecule-1 (LFA-1) (pSMAC) 152,153. This arrangement supports strong and prolonged 
intracellular interactions 154. Arrangement of the TCR/peptide/MHC within the 
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cSMAC results in the phosphorylation of immunoreceptor tyrosine-based activation 
motifs (ITAMs) located on CD3 by the Src family kinases Lck and Fyn. This in turn 
leads to the recruitment and activation of ζ-chain-associated protein 70 (ZAP70) 155,156, 
which phosphorylates the scaffold proteins linker for activation of T cells (LAT)157 
and the cytosolic adapter protein leukocyte phosphorylation of 76kDa (SLP-76) 158. 
The adaptor protein GADS bring SLP-76 and LAT together 159. The GADS:SLP-76: 
LAT complex recruits phospholipidase-C-γ1 (PLCγ1), which is a key signalling 
molecule activated by the phosphorylation of Itk. Activated PLCγ1 hydrolyses the 
membrane lipid (phosphatidylinositol 4,5 bisphosphate) (PI(4,5)P2) forming the 
second messengers IP3 and DAG. These messengers are important for mediating the 
remaining down-stream signals which lead to T cell activation, including the 
activation of NFKB, NFAT and AP-1 to induce specific gene transcription, leading to 
cell proliferation, differentiation and cytokine production 160. Finally, the last signal 
involved in T cell activation involves cytokines. Cytokines drive the differentiation of 
T cells into specific subsets 144. The CD4+ T helper subsets will be discussed in more 
detail in section 1.8.3. 
 
1.8.2 Memory T cells 
Following APC presentation of a pathogenic antigen, naïve T cells become activated, 
proliferate and differentiate into T effector cells which can adopt functional roles 
aimed at clearing a host of infectious agent. These T effector cells are short-lived and 
their cell number rapidly declines once the primary response is over and the infection 
is cleared. However, a small pool of T cells with ‘memory’ for the pathogen remains 
161,162. Both CD4+ and CD8+ T cells have memory populations. Memory T cells have 
a potential of long-term survival and can rapidly respond should re-infection occur. 
They can be located in the secondary lymphoid organs (central memory (TCM) cells) 
or the recently infected tissues (effector memory (TEM cells). Compared with their 
naïve counter-parts, memory T cells demonstrate less strict requirements for activation 
via antigen and co-stimulation signals 162. In addition, memory T cells can elicit 
effector responses more rapidly than primary responding cells 163. In humans, naïve 
and memory T cells are distinguished by the CD45 isoform, with naïve T cells 
expressing CD45RA and memory cells expressing CD45RO 164. 
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1.8.3 T helper cell subsets 
Seminal work from Mosmann and Coffman first identified the existence of distinctive 
CD4+ Th subsets; Th1 and Th2 165. Th1 cells produce IFNγ, IL-2 and tumour necrosis 
factor-α TNFα, which promotes a cellular immune response resulting in T cell 
proliferation and the classical activation of macrophages 166. This subset of cells also 
has the ability to promote complement-fixing and opsonising antibodies 141. Naïve 
CD4+ T cells are driven towards a Th1 subset by IFNγ and IL-12, which signal via 
STAT1 and STAT4, respectively 167,168. T-bet is also a critical transcription factor for 
Th1 differentiation, inducing the production of IFNγ 169. In contrast, Th2 cells produce 
IL-4, IL-5 and IL-13 this promotes alternative macrophage activation and drives mast 
cell and eosinophil proliferation and activation.  Moreover, Th2 cells contribute 
towards immunity to extracellular pathogens such as helminths and primarily promote 
a humoral immune response 170. Th2 differentiation is dependent on IL-4, which 
activates STAT6 and GATA3 171. IFNγ and IL-4 have the ability to antagonize one 
another. For example, IFNγ can activate STAT1 leading to the expression of T-bet and 
studies have shown that T-bet is a repressor of Th2 differentiation. T-bet transduced 
into polarised Th2 cells can modulate their phenotype towards Th1, as evidenced by 
induction of IFNγ and repression of IL-4 172. The central paradigm of the Th subsets 
has since been expanded to include additional subsets such as Treg cells, Th17 cells, 
Th9, Th22, Th3 and T follicular helper cells (Tfh). 
 
Treg cells are a unique subset of Th cells, which are essential for the maintenance of 
immunological tolerance and the prevention of autoimmunity and chronic 
inflammation. Their suppressive function can be elicited via the production of the anti-
inflammatory cytokine IL-10 and their constitutive expression of the inhibitory co-
stimulation marker CTLA4 173. The cytokines IL-2 and TGF-β drive Treg 
differentiation by inducing the expression of the forkhead box P3 (FOXP3) 
transcription factor 174,175. FOXP3 is critical for the development, maintenance and 
function of Treg cells 176,177. Another regulatory lineage identified includes Th3 cells. 
Th3 cells were originally identified in murine models following the induction of oral 
tolerance to myelin basic protein (MBP). These cells suppressed MBP-specific Th1 
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effector cells in a TGF-β dependent, antigen non-specific mannerm178. In the presence 
of TGF-β, naïve CD4+ T cells can differentiate into Th9 cells and also produce IL-4 
and IL-10 179. 
 
While early studies implicated that IL-9 is produced by Th2 cells, reports emerged 
demonstrating that IL-9 is also produced exclusively by a Th9 lineage 180,181. Th9 
differentiation is dependent on the cytokines IL-4 and TGF-β and the transcription 
factors PU.1 and interferon-regulatory factor 4 (IRF4) 182-184. Th22 cells are 
characterised by their production of IL-22 without IFNγ, IL-4 and IL-17 185. Naïve 
CD4+ T cells can be driven towards the IL-22 lineage by IL-6 and TNFα 186 and the 
transcription factor aryl hydrocarbon receptor (AHR) 187. With their expression of the 
skin homing marker CCR4 and CCR10, Th22 cells play a critical role in skin diseases 
186. Tfh cells are located in secondary lymphoid organs including the lymph nodes, 
spleen and tonsil and they specifically provide help to B cells. They play an important 
role in the development of antibodies and memory B cells, germinal centre formation 
and affinity maturation 188. 
 
1.9 Th17 cells 
1.9.1 Th17 cell differentiation 
The most studied source of IL-17A is the CD4+ T helper type (Th17) subset. 
Following the discovery of IL-17A and the identification of activated human CD4+ T 
cells as IL-17A producers, a plethora of studies quickly defined the Th17 paradigm 
70,71. Studies have shown a combination of TGF-β and IL-6 can differentiate naïve 
mouse CD4+ T cells into the Th17 lineage 23,24,189. However, in the absence of IL-6, 
TGF-β inhibits Th17 differentiation and induces Foxp3 expression and Treg induction 
190. It has also been shown that the IL-2 cytokine family member, IL-21 co-operates 
with TGF-β to induce Th17 cells from naïve murine CD4+ T cells 191. In humans, 
studies have shown that TGF-β and IL-6 alone are not sufficient to induce Th17 cells 
192-194. Additional pro-inflammatory cytokines such as IL-1β or IL-21 are required for 
human Th17 differentiation, while IL-23 is important for lineage maintenance and 
survival 193,195. In addition to the generation of Th17 cells from naïve CD4+ T cells, 
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Th17 differentiation can also be induced from effector memory CD4+ T cells 192,196,197. 
Our lab shown that significant numbers of human IL-17A+ CD4+ T cells were induced 
by stimulating CD4+ CD45RO+ T cells through the TCR in the presence of LPS-
activated monocytes 197. Moreover, we have shown that periodontal pathogens 
promote an IL-17A+ CD4+ T cell response which is dependent, in part on IL-1β, IL-
23 and TLR2/ TLR4 signalling from CD14+ monocytes 198. Finally, a study 
demonstrated that upon sensing bacterial nucleotide oligomerization domain 2 
(NOD2)-ligand muramyldipeptide (MDP), dendritic cells promoted IL-17 production 
from memory CD4+ T cells via enhanced expression of IL-1β and IL-23 199. 
Collectively, these studies show that ligation of TLRs such as TLR2 and TLR4 leads 
to an up-regulation of Th17-polarizing conditions, which subsequently induces Th17 
differentiation.  
 
Th17 cells also produce IL-17F. Studies frequently report that IL-17F is co-expressed 
with IL-17A, however different IL-17 producing populations exist including IL-17A+ 
IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells 106,193. It is important 
to note that in general Th17 cells are determined by their ability to produce IL-17A 
and not IL-17F. Moreover, the majority of studies which investigate the differentiation 
of Th17 cells examine IL-17A+ CD4+ T cells and not IL-17F+ CD4+ T cells. One 
study by Wilson et al. has demonstrated that like IL-17A, human IL-17F+ CD4+ T 
cells are enhanced in the presence of IL-1β and IL-23 193. 
 
1.9.2 Transcriptional control of Th17 cells 
The main regulator of Th17 cells is the transcription factor retinoic acid (RA)- related 
orphan nuclear receptor γ (RORγt), which is encoded by the RORC gene 200. However, 
RORγt deficiency does not completely abolish Th17 cytokine expression 106. RA-
related orphan receptor α has also been acknowledged as a transcription factor critical 
for Th17 differentiation 201. STAT3 has been shown to be critical for Th17 
differentiation. ChIP-seq analysis has demonstrated STAT3 directly regulates the 
IL17A, IL17F and RORC as well as multiple other genes associated with Th17 
polarisation and survival 202. Mice that lack STAT3 in T cells have an impaired ability 
to generate Th17 cells 203. Other transcription factors which contribute in driving Th17 
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differentiation include basic leucine zipper transcription factor ATF-like (BATF) and 
interferon regulatory factor 4 (IRF4). BATF is a member of the activator protein 1 
(AP-1) transcription factor family that is regulated in Th cells following TCR 
activation. While BATF-/- mice displayed normal Th1 and Th2 differentiation, Th17 
differentiation was defective 204. IRF4 deficient mice displayed a defective Th17 
differentiation as a result of decreased RORγt expression 205. Studies have suggested 
that BATF and IRF4 co-operatively bind and govern chromatin accessibility, which 
enables RORγt binding to Th17 associated genes 89,206,207. Finally, hypoxia-inducible 
factor-1α (HIF-1α) has also been linked to Th17 differentiation. HIF-1α is induced 
upon TCR activation and its expression is increased under hypoxic conditions 
associated with tissue inflammation. It has been shown that HIF-1α directly binds and 
drives the transcription of RORγt and p300 (a histone acetyltransferase) to drive IL-
17A expression 208. 
 
1.9.3 Regulation of Th17 cells 
Cytokines have emerged as key negative regulators of Th17 cells. Reports have shown 
the Th1 and Th2 cytokines, IFNγ and IL-4 respectively, inhibit Th17 differentiation 
209,210. Harrington et al. showed that that the development of mouse Th17 cells from 
naïve CD4+ T cells was potently inhibited by IFNγ and IL-4, whereas committed Th17 
cells were resistant to IFNγ and IL-4 mediated-suppression 209. Titration of IFNγ led 
to a dose-dependent decrease in IL17A and IL17F mRNA levels present in mouse 
CD4+ T cells 211. In vivo, IFNγ deficient mice display increased frequencies of IL-
17A+ CD4+ T cells and IL-17A protein 210. In a human study, it has been shown that 
memory CD4+ T cells cultured with monocytes and LPS in the absence or presence 
of Th1 polarising conditions (recombinant IL-12 and IL-4 blocking antibody) leads to 
an up-regulation of IFNγ+ CD4+ T cells and IFNγ secreted protein, while IL-17A+ 
CD4+ T cells and IL-17A secretion is significantly decreased 192. Similarly, blockade 
of IFNγ in memory CD4+ T cell cultures stimulated with anti-CD3 and anti-CD28 
leads to an enhanced frequency of IL-17A+ CD4+ T cells 192.  Mechanistically, reports 
have shown the IFNγ-mediated suppression of Th17 cells can be via STAT1 and T-
bet dependent mechanisms 211,212. IFNγ propagates a JAK/STAT signalling cascade 
leading to the robust activation of STAT1 213. Additionally it drives the induction of 
the transcription factor T-bet 169. In concordance, gain-of-function mutations in STAT1 
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in patients suffering with chronic mucocutaneous candidiasis inhibited the 
development of IL-17A+ CD4+ T cells 214 and in Tbet knock-out mice (Tbx21-/-), T 
cells produce higher levels of IL-17A in response to TCR stimulation when compared 
to wild-type mice 215. Similar to IFNγ, other STAT1 activating cytokines can regulate 
Th17 responses including IL-27, a member of the IL-12 family of cytokines. In vitro 
studies have demonstrated IL-27 suppresses IL-6 and TGF-β induced Th17 
differentiation in a STAT1-dependent manner 216,217.  
 
Reports have also suggested that IL-2 has the ability to suppress Th17 development. 
Laurence et al. showed that genetic deletion or antibody blockade of IL-2 in mice 
promoted differentiation of IL-17A+ CD4+ T cells 218. Additionally, a characteristic 
of autoimmune disease associated with IL-2 deficiency is the over-production of IL-
17A in vivo 218. High doses of IL-2 in combination with TGF-β and retinoic acid have 
been shown to inhibit IL-17A expression via the induction of FOXP3 expression and 
skewing CD4+ T cell differentiation into Tregs 219,220.  However, it has also been 
reported that IL-2 can also inhibit IL-17A production independently of FOXP3 221,222. 
Studies have shown the effect of IL-2 appear to be largely associated with its 
downstream target STAT5 223. Deficiency in STAT5 displays similar aspects to IL-2 
deficiency. Mice with deletion of STAT5a and STAT5b exhibit widespread 
autoimmune disease linked with IL-17A over-production 218,223. The underlying 
mechanism has been attributed to the ability of STAT5 to directly compete with IL-
17A-inducing STAT3 to enhancers within the IL17A gene locus 222. Using chromatin 
immunoprecipitation (ChIP) sequencing it was shown that the presence of IL-2 led to 
increased binding of STAT5 across the IL17 locus and at all the sites in the IL17A 
locus this was correlated with significantly less binding of STAT3 222. In concordance, 
a recent mouse study demonstrated that phosphate and tensin homologue (PTEN) 
supports Th17 differentiation by suppressing IL-2 production. Pten deficient mice 
displayed an up-regulation of IL-2 and phosphorylation of STAT5, while STAT3 
phosphorylation was decreased. Collectively, this led to suppression of IL-17A+ 
CD4+ T cells 224. It is important to note that all of these reports investigate the role of 
IL-2 in mice. How IL-2 affects the frequency of IL-17A+ CD4+ T cells in humans is 
currently unclear. Few reports examine the effect of IL-2 on IL-17F+ CD4+ T cell 
frequencies. As literature often describes IL-17F to be co-expressed with IL-17A it 
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could be assumed that IL-17F expression is similarly suppressed by IL-2.  However, 
it has been shown using mouse cells that in the presence of high levels of IL-6 while 
addition of IL-2 decreases the percentage of IL-17A+ CD4+ T cells it has no effect on 
the frequency of IL-17F+ CD4+ T cells 222. 
 
CD28 co-stimulation is known to induce the expression of IL-2 and IFNγ. A study 
using mouse cells has shown that anti-CD28 mAb suppressed the differentiation of 
IL-17A+ CD4+ T cells in an IL-2 and IFNγ dependent mechanism 221. Moreover, 
Purvis et al. stimulated human CD4+ T cells with either high or low-strength 
stimulation via anti-CD3/CD28 beads or dendritic cells pulsed with superantigen in 
the presence of IL-1β, TGF-β and IL-23. They found that low-strength stimulation 
significantly enhanced IL-17A expression, whereas IL-17A expression was reduced 
when receiving a high-strength stimulation 225. Collectively, these reports demonstrate 
that IL-17A+ CD4+ T cells are induced upon low-strength T cell activation. As these 
studies examine the expression of IL-17A only, it is not known how high-strength T 
cell activation effects the expression of IL-17F from CD4+ T cells. In light of the study 
which suggests IL-2 may differentially effect IL-17A and IL-17F expression 222, how 
T cell signalling strength impacts IL-17F would be an interesting area to pursue. 
 
 
1.9.4 Phenotypic marker and cytokine profiles of IL-17A+ and IL-17F+ 
CD4+ T cells 
Studies have characterised Th17 cells by their expression IL-23 receptor (IL-23R), the 
chemokine receptor CCR6 and the lectin receptor CD161 226,227. Annunziato and 
colleagues showed that Th17 clones exhibit higher levels of the chemokine receptors 
CXCR4, CXCR6, CCR4 and CCR5 when compared to other clone types including 
Th1 and Th2. They also demonstrated that Th17 cells selectively expressed CCR6 226. 
CCR6 expression had been identified on B cells, dendritic cells (DCs) and memory T 
cells, however, the CCR6 ligand, CCL20 only exerts chemotactic activity on memory 
T cells 228. It has been shown that CCR6 expression in memory T cells is lost following 
prolonged TCR triggering 229. This suggests that the selective expression of CCR6 on 
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Th17 cells could be a result of the ability of Th17 cells to continue to express CCR6 
following prolonged antigen activation, thereby maintaining the ability to recruit in 
response to CCL20 226. CD161 is a C-type lectin-like receptor expressed in the 
majority of natural killer (NK) cells 230. Cosmi et al. demonstrated that the CD161 
gene is up-regulated in Th17 clones and in human peripheral blood (PB) and inflamed 
tissues all IL-17A+ RORC+ cells are contained within the CD161+ fraction of CD4+ 
T cells. However, not all CD161+ T cells produce IL-17A 231. It was also shown that 
IL-17A+ cells originate from the CD161+ (and not the CD161-) naïve CD4+ T cells 
of umbilical blood in response to IL-1β and IL-23 231. The exact function of CD161 is 
unknown, however, it has been suggested to play a role in transendothelial migration 
as CD161+ T cells migrate across endothelial cell monolayers to a greater extent than 
CD161- T cells 232. It has been implied that expression of CD161 is RORC-dependent. 
Naïve CD4+ CD161- T cells transduced with RORC produce IL-17A and up-regulate 
CD161 expression. In contrast, inhibition of RORC down-regulates IL-17A and 
CD161 expression on Th17 clones 233.  
 
IL-17A+ CD4+ T cells have been shown to co-express IL-17F, IFNγ, TNFα, GM-
CSF, IL-21, IL-22, IL-9 and IL-10. The presence and expression level of these 
cytokines depends on the cytokine milieu present upon Th17 differentiation 234-236. As 
previously mentioned, different IL-17 producing subsets exist including IL-17A+ IL-
17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells. In the current literature, 
there is a lack of characterisation of IL-17F+ CD4+ T cells and comparison of these 
cells vs. IL-17A+ CD4+ T cells. It is not known whether marker expression on IL-
17A+ vs. IL-17F+ CD4+ T cells may differ of whether one subset demonstrates a more 
inflammatory cytokine profile. Reports have previously demonstrated Th17 cells are 
a heterogeneous population, including ‘non-pathogenic’ and ‘pathogenic’ subtypes. 
McGeachy et al. shown that TGF-β and IL-6 promote the generation of non-
pathogenic Th17 cells, characterised by the production of IL-10 237. However, 
exposure to IL-23 can result in the conversion of non-pathogenic Th17 cells to 
pathogenic Th17 cells 238. Prostaglandin E2 and the Notch signalling molecule, RPBJ 
are also associated with driving Th17 pathogenicity 239,240.   Pathogenic Th17 cells are 
associated with a lack of IL-10 production and enhanced GM-CSF production 241. A 
study comparing the gene expression profiles of in vitro Th17 cells polarised by 
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cytokine combinations which induce non-pathogenic or pathogenic Th17 cells 
revealed 233 differentially expressed genes 242. Pathogenic Th17 cells display a higher 
gene expression level of pro-inflammatory chemokines and cytokines including 
CXCL3, CCL4, CCL5, IL3 and IL22. In contrast, non-pathogenic Th17 cells exhibit 
enhanced expression of genes encoding the immune suppressive IL-10 and the 
transcription factor IKZF3 242,243. 
 
 
1.10 Other IL-17A and IL-17F expressing cells 
1.10.1 IL-17A+ CD8+ T cells (Tc17 cells) 
Although Th17 cells are the best-characterised cellular source of IL-17A and IL-17F, 
various reports have demonstrated that other immune cells can produce these 
cytokines, one group of which are IL-17A+ CD8+ cytotoxic T (Tc17) cells. CD8+ T 
cells play a vital role in immune defence against intracellular pathogens and tumour 
surveillance. They primarily secrete TNFα and IFNγ and release cytotoxic granules 
including perforin and granzymes. Moreover, they can kill infected cells via Fas/FasL 
interactions. Similar to CD4+ T cells, different subpopulations of cytotoxic CD8+ T 
cells exist including Tc1, Tc2, Tc9, Tc17 and CD8+ Treg cells. IL-17A+ CD8+ T cells 
were first identified by Teunissen et al., whereby IL17A mRNA was detected in CD8+ 
T cells derived from psoriatic lesional skin 120. Subsequently, flow cytometry analysis 
revealed the presence Tc17 cells in psoriatic skin plaques 18. The requirements for 
differentiation and/or polarisation of Tc17 cells are not as well defined as Th17 cells, 
particularly in humans 244. One report demonstrated the induction of human IL-17A+ 
CD8+ T cells upon culture of naïve CD8+ T cells with recombinant TGF-β, IL-6, IL-
1β and IL-23 245. Moreover, mouse models have shown the importance of the 
transcription factors STAT3, IRF3 and IRF4 in the induction of Tc17 cells. Phenotypic 
profiling of IL-17A+ CD8+ T cells has revealed these cells can co-express IFNγ, 
TNFα, IL-21, IL-22 and GM-CSF 91. Although a IL-17A+ IL-17F+ CD8+ T cell 
population has not currently been reported, a recent study has revealed the presence 
of a mouse IL-17F+ IL-17A- CD8+ T cell population 246. A proportion of IL-17A+ 
CD8+ T cell subsets belong to a subset of innate T cells named mucosal-associated 
invariant T (MAIT) cells. MAIT cells express an invariant T cell receptor-α chain 
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(Vα7.2) that is restricted by the non-classical MHC class I molecule MHC-related 
protein (MR1) 247.  
 
1.10.2 γδ T cells and iNKT cells 
With regards to other T cells, a proportion of γδ T cells have been shown to produce 
IL-17A 248 and IL-17F 106  and share characteristic features of Th17 cells including 
CCR6 and RORγt expression 248. Invariant natural killer T (iNKT) cells characterised 
by their expression of NK1.1+ TCRαβ and invariant Vα14 chain expression have also 
been shown to produce IL-17A 249. 
 
1.10.3 Innate immune cells 
Immunohistological studies have identified IL-17A positive mast cells in human 
tissues including SpA synovial tissue 250, RA synovium 251  and psoriatic lesions 252.  
Interestingly, a study revealed that mast cells can capture and store IL-17A in 
intracellular granules, through a process of receptor-mediated endocytosis. Mast cells 
are then able to release bioactive IL-17A, although it remains to be fully explored what 
drives the IL-17A release 253. With regards to IL-17F, a recent study has shown that 
in oral tongue squamous cell carcinoma mast cells are a major source of IL-17F 254. 
However, it is currently not reported whether mast cells take up and store IL-17F. The 
role of neutrophils as a source of IL-17A is controversial. Neutrophils have been 
identified as a source of IL-17A in numerous mouse models of infection and 
autoimmune inflammation 255-257. Moreover, flow cytometry and immunofluorescence 
staining has determined the presence of IL-17A positive neutrophils in human 
psoriatic lesions 252. However, other mouse and human studies have failed to detect 
IL-17A+ neutrophils 258,259. Similar to mast cells, debates are ongoing as to whether 
IL-17A is transcribed in neutrophils or neutrophils capture IL-17A from the 
environment. Another source of IL-17A and IL-17F includes innate lymphoid cells 
type 3 (ILC3) 260,261. ILCs are a family of lymphoid-lineage cells that lack T and B cell 
receptors and display innate immune effector functions. In particular, ILC3s require 
RORγt, respond to IL-1β and IL-23 and also produce IL-22 262. Other non T-cells 
reported to express IL-17A includes paneth cells 263. 
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1.11 Cellular sources of IL-17B, IL-17C, IL-17D and IL-17E 
Human and mouse studies have reported the presence of IL17E mRNA in Th2-
polarised T cells 124. Moreover, in human studies IL17E transcripts have been 
identified in peripheral blood eosinophils and basophils. IL-5, GM-CSF and IL-3 were 
shown to induce IL-17E protein secretion by eosinophils. Moreover, IgE cross-linking 
triggered strong IL-25 production by basophils 264. IL-17E is also produced by mast 
cells upon IgE cross-linking 265. Finally, IL17E mRNA has been detected in mouse 
intestinal epithelial cells266 and rat macrophages 267. The cellular source of the 
remaining IL-17 cytokines is less well studied. Immunohistochemical analysis of the 
human spinal cord demonstrated that IL-17B protein is primarily localised to neurons 
268. IL-17C has been shown to be distinctly produced by epithelial cells 128. Finally, 
IL17D mRNA has been detected in resting CD4+ T cells and resting CD19+ B cells 
76. In summary, while IL-17A and IL-17F are detected by a similar profile of cell 
subsets, the remaining IL-17 cytokines display distinctly different cellular sources.  
 
Taken together the inflammatory function of IL-17A and IL-17F and their expression 
from immune cells, it became of significant interest to target these cytokines in 
immune-mediated diseases including inflammatory arthritis. Next, I will review 




1.12 Inflammatory arthritis 
Inflammatory arthritis is a group of diseases characterised by inflammation of the 
joints and often other tissues. These diseases include rheumatoid arthritis (RA) and 
spondyloarthritis (SpA). RA is the most common chronic inflammatory and 
destructive arthritis. It is characterised by persistent synovitis, systemic inflammation 
and the presence of autoantibodies including rheumatoid factor (which targets the Fc 
region of immunoglobulin G) and anti-citrullinated protein antibodies (APCA) (which 
are directed against citrullinated proteins). However, not all patients are positive for 
rheumatoid factor and APCA (seronegative RA) 269. SpA refers to psoriatic arthritis 
(PsA), axial SpA and non-radiographic axial SpA, reactive arthritis, enteropathic 
arthritis and undifferentiated SpA, all of which share clinical and immunological 
features. SpA subtypes are negative for autoantibodies and can include inflammation 
of the joint (peripheral and axial); skin, gut and eye 91. This project focuses on PsA. 
PsA is an assymetric arthropathy but can develop as polyarticular and symmetrical 270. 
Psoriasis is a chronic inflammatory disease of the skin and 10-20% of these patients 
have associated PsA. In contrast to RA and PsA, osteoarthritis (OA) is not an 
autoimmune disease but a degenerative joint disorder. Clinically, the condition is 
characterised by break-down of cartilage, which allows bones to rub against each 
other. This causes joint pain, tenderness, stiffness, limited movement and variable 
degrees of local inflammation. A combination of structural, mechanical and biological 
pathways contributes to OA pathology 271. Studies often compare RA and PsA to OA. 
 
1.12.1 Genetics of inflammatory arthritis 
1.12.1.1 RA 
RA is a complex disease. It can involve factors such as bacteria, viruses and 
autoantigens targeting heavy chain binding proteins and cyclic citrullinated peptides, 
which trigger disease in genetically susceptible individuals 269. Moreover, 
environmental factors such obesity, smoking and caffeine intake can increase the 
likelihood of disease 272. Concordance rates for RA were found between 12.3% and 
15.4% for monozygotic and 3.5% for dizygotic twins, suggesting that genetic factors 
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can impact susceptibility to disease,  273. In concordance, a genome-wide association 
study revealed 49 single nucleotide polymorphisms (SNPs) associated with RA 274.  
 
The HLA class II alleles are strongly associated with RA and contribute at least 30% 
of the total genetic effect 275. As HLA class II molecules play an important role in 
antigen presentation to CD4+ T cells, this suggests that predisposing CD4+ T cell 
repertoire selection, antigen presentation or alterations in peptide affinity might have 
a role in promoting autoreactive responses in RA. The HLA-DRB1 alleles *0101, 
*0102, *0401, *0408, *1001 and *1402 share a consensus sequence known as the 
‘shared epitope’ (SE). The conserved amino acid sequence can include QKRAA, 
QRRAA or RRRAA on the third hyper-variable region of the DRβ1 chain 276,277. 
Extensive evidence exists associating HLADRB1 alleles encoding the shared epitope 
to RA susceptibility and severity 278,279. The shared epitope hypothesis proposes that 
the shared epitope itself is directly involved in the pathogenesis of RA by allowing the 
presentation of an arithrogenic peptide to CD4+ T cells. It has also been proposed that 
HLA-SE alleles can influence the T cell repertoire to permit escape from tolerance or 
survival of auto-reactive clones, or HLA-SE alleles molecules can act as targets 
themselves for auto-reactive T cells 280. Interestingly, the association between SE-
encoding HLADRB1 alleles and RA has only been observed for ACPA-positive 
disease 281. In addition to HLADRB1 alleles that confer susceptibility to RA, other 
HLADRB1 alleles that protect against RA have been identified. A study by Carrer et 
al. demonstrated that the HLADRB*0402 allele, which contains a DERAA sequence 
was protective in RA. The presence of a DERAA sequence was a strong independent 
predictor of a better RA prognosis 282.  
 
Other non-HLA genetic associations have been implicated CD4+ T cells in the 
pathology of RA. The intra-cellular phosphatase protein tyrosine phosphatase non-
receptor type 22 (PTPN22) plays an important role in T and B cell signalling. Studies 
have shown the C1885T polymorphism of the PTPN22 gene  confers risk for RA as 
well as other diseases such as lupus, type I diabetes and others 283. Implicating the IL-
23/IL-17 axis in RA pathology, genetic studies have shown polymorphisms in the 
IL23R gene are associated with RA susceptibility 284 . Implicating Th17 cells in the 
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pathogenesis of RA, a genome-wide association study of RA revealed that a 
polymorphism in the CCR6 gene was associated with RA susceptibility. In 
concordance with the fact that CCR6 is a characteristic marker of Th17 cells, the RA 
CCR6 genotype displayed increased IL-17A protein in sera 285. 
 
1.12.1.2 PsA 
The strongest genetic susceptibility to SpA diseases, including PsA lies within the 
MHC class I region, particularly the HLA-B27 region 286. Other variants including 
HLA-cw6, HLA-B38 and HLA-B08 are associated with PsA 287,288. The association 
of a variety of HLA-B loci with PsA implies that genetic associations alter 
immunological processes. Considerable debate is ongoing on how variants in the 
HLA-B27 region can affect immunological mechanisms. The first and most 
extensively studied hypothesis is driven by the fact that MHC class I molecules present 
peptides to CD8+ T cells. It proposes that PsA and other SpA types including AS 
results from the ability of HLA-B27 to bind and present unique arthitogenic peptides 
to CD8+ cytotoxic T cells. In support of this theory, a studied demonstrated the 
presence of HLA-B27-restricted cytotoxic CD8+ T cells that could recognize both 
bacterially infected and uninfected target cells in the PB of reactive arthritis and AS 
289. Other studies have suggested that variants within the HLA-B27 locus can 
contribute to PsA/SpA pathology by promoting HLA-B27 homodimerization instead 
of heterodimerization with β2-microglobulin. Under normal physiological conditions 
HLA-B27 heavy chains form heterotrimer complexes with β2-microglobulin and 
intracellular peptides derived from viruses, bacteria or self-proteins. These 
heterotrimeric complexes (which form HLA-B27) are presented to the cell surface for 
antigen-recognition 290. However, HLA-B27 heavy chains can also form β2-
microglobulin-free disulphide-bonded heavy chain homodimers 291. Following 
endosomal recycling, HLA-B27 homodimers can be expressed at the cell surface and 
studies have shown they can be recognized by several innate immune receptors on T 
cells, NK cells and other APCs 292. Therefore, it has been proposed that interaction of 
HLA-B27 homodimers with T cells and NK cells can result in altered cell signalling 
and promote a pro-inflammatory response. One of the receptors which recognizes 
HLA-B27 homodimers includes the killer cell immunoglobulin-like receptor 3DL2 
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(KIR3DL2). Interestingly, IL-17A+ CD4+ T cells, which express KIR3DL2 have been 
identified in the blood and SF of AS patients 293. Importantly, co-culture of KIR3LD2+ 
IL-17A+ CD4+ T cells with HLA-B27 homodimer expressing APCs result in 
enhanced survival and proliferation of KIR3LD2+ IL-17A+ CD4+ T cells 293. These 
data implicate a link between MHC class I and the IL-23 – IL-17 axis. 
 
The IL-23-IL-17 axis has been highlighted by genetic association studies in PsA and 
psoriasis. Variants in the IL12B and IL23A region which encodes the IL-12p40 sub-
unit shared between IL-12 and IL-23 and the IL-23p19 sub-unit, respectively are 
associated with PsA and psoriasis 294,295. Additionally, variation within IL23R, 
encoding the IL-23 receptor is associated with PsA/psoriasis 295. Genome-wide 
association studies demonstrated that the IL23R R381Q gene variant is protective 
against psoriasis 296 and Di Meglio et al. showed that IL23R R381Q exerts its 
protective effects through selective attenuation of IL-23-induced Th17 cell effector 
function 297. These data demonstrated a critical role for IL-23/IL-23R signalling in 
generating a pathogenic Th17 response. Further supporting the IL-23-IL-17 axis in the 
genetic susceptibility of PsA is the identification of susceptibility variants in genes 
encoding key IL-23 and IL-17 signalling molecules including STAT3 298, TYK2 
(required for IL-23 signalling) 299 and TRAF3IP2 (encodes the IL-17 signalling 
molecule, Act1) 299. 
 
1.12.2 Synovial fibroblasts in inflammatory arthritis 
Although most of the research focuses on the role of immune cells in inflammatory 
diseases, the pathological role of stromal cells is increasingly recognised 300-304. 
Stromal cells are connective tissue cells, which build the structural framework of organ 
or tissues. The main type of stromal cell is fibroblasts. Fibroblasts play a key role in 
supporting normal wound healing 305. They are recruited to wound sites via chemo-
attractants such as platelet-derived growth factor (PDGF), IL-1β and TNFα, which are 
produced by platelets and macrophages as part of the inflammatory response. Once 
recruited to the wound site they produce MMPs that degrade the fibrin clot and replace 
it with extracellular matrix components such as collagen I-IV, XVIII, glycoproteins, 
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thrombospondin, lamin and hyaluronic acid. The secreted fibroblast matrix supports 
and regulates the migration and activity of fibroblasts and co-ordinates angiogenesis, 
granulation-tissue generation and epithelisation 305. In the healthy joint, synovial 
fibroblasts (also referred to as synovial-fibroblast-like cells) are located in the synovial 
sub-lining and lining layer and are one or two layers thick interspersed with tissue-
resident macrophages. Here, they produce extracellular matrix components of the 
synovial fluid (SF), which is vital for cartilage integrity and lubrication of the joint. In 
RA, the synovial sub-lining thickens and is infiltrated by immune cells. Synovial 
fibroblasts proliferate and become chronically activated 300.  
 
Strong evidence exists suggesting that synovial fibroblasts are aggressive drivers in 
the destructive process of RA 306-308. In response to inflammatory mediators (including 
IL-17A, IL-17F and TNFα) synovial fibroblasts can secrete a variety of pro-
inflammatory cytokines and chemokines including IL-6, IL-8, CCL2, CCL3, CCL4 
and CXCL10. Subsequently, this can lead to the recruitment of neutrophils, monocytes 
and T cells which can perpetuate inflammation. Synovial fibroblasts can also 
contribute to the pathology of RA by acting as innate immune cells. It has been 
demonstrated that synovial fibroblasts express TLR3 and TLR7 (which bind double-
stranded and single-stranded RNA, respectively) and the cytosolic pattern recognition 
receptors RIG-1 and MDA-5 (which recognise double-stranded RNA) 309. A study by 
Bretano et al. demonstrated that necrotic synovial fluid cells activate synovial 
fibroblasts via TLR3, which can lead to the production of high levels of IL-6, 
CXCL10, CCL5 and IFNβ 306. Studies have shown that interaction between synovial 
fibroblasts and T cells can elicit many different effects. Co-cultures of activated T cells 
with synovial fibroblasts led to increased IL-6 and IL-8 production by fibroblasts and 
in turn, increased production of IL-17A and IFNγ by T cells 307,310. Studies have also 
suggested that synovial fibroblasts can extend T cell survival, leading to persistence 
in inflammation in the RA joint. RA synovial T cells were rescued from spontaneous 
apoptosis in vitro by interaction with synovial fibroblasts 308.   
 
A characteristic feature of RA synovial fibroblasts in their ability to invade and destroy 
cartilage via the production of a disintegrin and metalloproteinase with 
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thrombospondin motifs (ADAMTS), MMPs and cathepsins. Pro-inflammatory 
cytokines such as IL-1β and TNFα present in the inflamed joint induce the production 
of these proteinases by fibroblasts 311. Interestingly, it has been shown that epigenetic 
changes maintain high production of MMPs in RA synovial fibroblasts 312. Evidence 
in the TNF transgenic (hTNFtg) mice suggests that loss of cartilage proteoglycan is 
required for the attachment and invasion of synovial fibroblasts to cartilage 313. 
Interestingly, a study in the severe combined immunodeficiency (SCID) mouse model 
demonstrated that RA synovial fibroblasts have the ability to migrate to cartilage at 
sites distant from their origin. These data support the hypothesis that destructive 
arthritis spreading between joints is mediated, in part, by the migration of synovial 
fibroblasts 301. 
 
It was originally thought that fibroblasts are a homogenous population, however data 
are emerging demonstrating that several different phenotypes of fibroblasts exist 302-
304. Work from Bertoncelj et al. identified that synovial fibroblasts from different 
anatomical locations exhibit significant differences in gene expression pattern, 
epigenetic marks and function 304. A significant number of differentially expressed 
transcripts between synovial fibroblasts of different locations were encoded in the 
homeobox (HOX) loci. Interestingly, it was shown that cluster analysis of RNA 
sequencing data using transcripts exclusively encoded in the HOX loci can cluster 
synovial fibroblasts according to joint location. In particular, synovial fibroblasts from 
proximal joints can be separated from synovial fibroblasts of distal joints. 
Functionally, while RA synovial tissues from hand joints expressed significantly 
higher levels of MMP13 than synovial tissues from the knees of RA patients, knee RA 
synovial fibroblasts induced higher levels of MMP1 in response to TNFα than that of 
upper extremity synovial fibroblasts. In summary, these data suggest that RA might 
manifest differently at different joint locations 304. A recent study has characterised 
CD90 (also known as THY1)- podoplanin (PDPN)+ and CD90+ PDPN+ fibroblast 
populations which are either CD34+ or CD34-. An increase in the PDPN+ CD90+ 
CD34- subset was observed around the sub-lining of RA synovial tissue. This was 
identified as a dominant change in the RA synovium, not observed in OA samples 303. 
While the majority of synovial fibroblast studies focus on RA, it is likely similar 
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results can be observed in synovial fibroblasts derived from the inflamed joint of PsA 
patients. 
 
1.12.3 Immune cells in inflammatory arthritis 
1.12.3.1 Innate immunity in RA 
In the synovial membrane and SF of RA patients, innate immune cells have been 
identified, including monocytes, macrophages, mast cells, natural killer cells and 
neutrophils. Moreover, these cells have been shown to contribute to the pathology of 
these diseases 314. Monocytes and macrophages are present in abundance in the 
rheumatoid joint. Studies have shown these cells have an activated phenotype with 
increased expression of HLA-DR 315, co-stimulatory molecules (e.g. CD80, CD86 and 
CD40), adhesion molecules (e.g. CD44 and CD45) 316 and chemokine receptors (e.g. 
CCR3 and CCR5) 317. Many monocyte/ macrophage functions can contribute to the 
immunopathology of RA. These include their potent ability to secrete pro-
inflammatory cytokines including TNFα, IL-6, IL-1β and MMPs into the SF which 
can lead to endothelial cell activation, acute phase reactions and cartilage damage 318. 
Moreover, monocytes can drive Th1 and Th17 responses by their ability to produce 
IL-12 and IL-1β/IL-6/IL-23, respectively. A report from our lab has shown that in vivo 
activated CD14+ monocytes derived from the inflamed joints of RA patients 
spontaneously and specifically promoted Th17 responses, compared with resting 
monocytes from the blood. This monocyte-induced Th17 differentiation was shown to 
be a TNFα and IL-1β-dependent mechanism 197. Reports have also demonstrated that 
activated monocytes or macrophages can positively or negatively influence the 
function of CD4+ Tregs via production of soluble mediators 318. For example, TNFα 
can decrease FOXP3 expression and reduce Treg cell function 319. Finally, 
monocytes/macrophages can contribute to the pathology of RA by recruiting or 
maintaining CD4+ T cells in the arthritic joint. Elevated expression of CXCL16 in the 
RA synovium either due to an enhanced influx of monocytes or an increased 
expression of CXCL16 by macrophages promotes recruitment of CXCR6+ T cells, 
which can exacerbate the inflammatory response in the synovium 320,321. Reports have 
demonstrated a potential role for monocytes in influencing the CCL20-CCR6 axis in 
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RA. Synovial monocytes can display enhanced expression of CCL20, which could 
subsequently lead to the recruitment of CCR6+ cells including Th17 cells 322,323.  
 
1.12.3.2 Adaptive immunity in RA 
The adaptive immune system plays a central role in the immunopathology of RA, as 
evidenced by the presence of auto-antibodies and the genetics of RA. Studies have 
showed that central and peripheral B cell tolerance checkpoints are defective in RA. 
Subsequently, there is an accumulation of auto-reactive B cells in the mature naïve B 
cell compartment 324. The pathogenic role of B cells in RA can occur via several 
mechanisms including autoantibody production, T cell activation and cytokine 
synthesis. Auto-reactive B cells present in RA can produce a wide range of auto-
antibodies, of which the most widely studied are rheumatoid factor and ACPA. 
Immune complexes consisting of immunoglobulins bound to their cognate antigens 
can be characteristic of RA 325. A significant proportion of immune complexes present 
in the RA joint consists of rheumatoid factor bound to the Fc portion of IgG 326. These 
immune complexes trigger the complement system, releasing chemotactic factors such 
as C5a, which leads to the recruitment of inflammatory cells via C5a receptors. As 
such, local inflammation and tissue damage is induced 327. B cells can also contribute 
to the pathology of RA by acting as efficient antigen presenting cells. In contrast to 
conventional APCs, which display no binding specificity for antigens, B cells capture 
antigens via antigen-specific surface immunoglobulin receptors. Following antigen 
internalisation and processing by specific B cells, antigens are presented to CD4+ T 
cells in an MHC- restricted manner, leading to CD4+ T cell activation 328. It has been 
suggested that T cell responses in RA synovitis are dependent on B cells. Treatment 
with a monoclonal anti-CD20 antibody (which depletes B cells) in SCID mice 
xenotransplanted with RA synovial tissue enriched in B cells led to the impairment of 
T cell activation and T-cell derived cytokines 329. Finally, it has also been 
demonstrated that B cells can contribute to the pathology of RA via the secretion of 
RANKL, which can trigger osteoclastogenesis 330. 
 
Early studies reported that T cells are the dominant cell population in RA synovial 
membranes 331,332. Moreover, T cells are abundant in the synovial membrane of RA 
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patients when compared with the synovial membrane of OA or healthy joints 332. 
Reports have shown that RA SF T cells predominantly bear the memory CD45 ‘RO’ 
phenotype, rather than the naïve ‘RA’ isoform. These cells have also been shown to 
express CD69 suggesting that they have recently been activated 333. Animal models 
have also provided evidence for the role of T cells in inflammatory diseases. Adjuvant 
arthritis is similar to RA; it is an inflammatory disease displaying extensive cartilage 
and bone destruction. This disease can be induced in rats by subcutaneous injection of 
Mycobacterium tuberculosis. A study showed that adjuvant arthritis is T cell 
dependent, with T cell clones capable of transferring disease to naïve recipients 334. 
Another mouse model study demonstrated that chronic autoimmune arthritis, similar 
to RA, developed as a result of mutations in ZAP70, which is a key signal transduction 
molecule in T cells. From this report, it was suggested that ZAP70 mutations may alter 
the thresholds of T cells to thymic selection, allowing positive selection of otherwise 
negatively selected self-reactive T cells. Therefore, thymic production of arthritogenic 
T cells  due to a genetic shift of the T cell repertoire towards high self-reactivity may 
play a fundamental role in the immunopathology of RA 335. 
 
It was originally thought that Th1 cells were the main drivers of RA. In the rheumatoid 
synovium considerable amounts of IFNγ were present, whilst IL-4 was absent 336,337 
and the  Th1 polarising cytokine IL-12 (formed of IL-23p35 and IL-12p40 sub-units) 
was detectable in RA SF 338. In experimental models the presence of Th1 cells also 
appeared to correlate to autoimmune disease. Collagen-induced arthritis (CIA) is the 
most commonly studied autoimmune model of RA, which is elicited in genetically 
susceptible strains of mice by immunisation with type II collagen emulsified in 
complete Freud’s adjuvant 339. In both CIA and EAE, blockade of IL-12p40 reduced 
the disease severity and inflammation 340,341.  Additionally, it was also shown that in a 
myelin basic protein induced form of EAE, IL-12p40 knock-out mice were resistant 
to disease 342.  
 
However, opposing the role of Th1 cells in driving RA, it was reported that loss of 
IFNγ signalling increased CIA severity 343,344. Furthermore, mice lacking IL-12p35 
were shown to exacerbate CIA 345. This indicated that IL-12p40 contributes to arthritis 
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in an IL-12 independent manner. IL-12p40 also combines with the IL-23p19 sub-unit, 
forming the IL-23 cytokine. Therefore, IL-12p40 deficient mice are deficient in both 
IL-12 and IL-23. Studies which compared IL-23p19 deficient mice and IL-12p35 
deficient mice soon revealed that many of the inflammatory functions which had been 
attributed to IL-12 were in fact due to the biological activities of IL-23. Cua et al. 
reported that IL-23 deficient (IL-23P19-/-) mice are resistant to EAE and Murphy et 
al. demonstrated that IL-23p19-deficient mice are resistant to the development of joint 
destruction in CIA 345,346. Linking the IL-23/IL-17 axis to autoimmune disease, 
Langrish et al. demonstrated that EAE-resistant IL-23a-/- mice displayed similar 
numbers of central nervous system- infiltrating IFNγ but not IL-17A expressing T cells 
347. 
 
1.12.3.3 Involvement of the immune system in PsA 
In comparison to RA, PsA synovial tissue contains less cellular infiltrate and displays 
a more vascular phenotype 348,349. Histological changes are characterised by 
endothelial swelling and vessel wall thickening 349. The role of T cells in the PsA joint 
has been highlighted by the beneficial effects of T-cell therapies such as ciclosporin 
and abatacept on the treatment of PsA 350,351. Cyclosporin inhibits the calcineurin-
dependent nuclear translocation of the transcription cytosolic proteins, nuclear factor 
of activated T cells, pre-existing (NFATp) and nuclear factor of activated T cells, 
cytoplasm (NFATc). Subsequently, this leads to the blockade of early T cell activation 
351. Abatacept is a soluble fusion protein consisting of the extra-cellular domain of 
human CTLA4 and a fragment of the Fc portion of human IgG1, which blocks the 
CD28/B7 pathway causing a near-complete inhibition of T cell proliferation 352. The 
association of PsA with MHC class I alleles provide evidence for a critical role in 
CD8+ T cells and suggest that the disease is driven by presentation of self-peptides by 
susceptibility MHC class I molecules to auto-reactive antigen-specific CD8+ T cells 
286. Unexpectedly, observations made in HIV also indicated the role of CD8+ T cells 
in PsA. In the advanced setting of HIV disease, whereby CD4+ T cells are depleted, 
PsA still occurred 353. CD8+ T cells derived from PsA SF have been shown to have an 
activated (HLA-DR+), memory (CD45RO+) phenotype with low CD25 expression 
levels, indicating a non-classical activation pattern 354.  
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Studies have investigated the mechanism of accumulation of T cells in the sites of 
inflammation. It has been of interest to investigate whether the joint T cells recognises 
a single or several antigens or whether it reflects secondary non-antigen-specific T cell 
recruitment mediated by chemokines released by the local joint inflammation. It has 
been suggested that recruitment of T cells into the PsA synovial compartment may be 
mediated by chemokines such as MCP-1. In the plasma of PsA patients, MCP-1 levels 
were increased in comparison to healthy individuals and a positive correlation was 
identified between SF-derived T cells and SF MCP-1 levels 355. If indeed recruitment 
of T cells was non-antigen specific, the T cells present at the site of inflammation 
would lack clonal expansions specific to the joint and primarily display a polyclonal 
repertoire similar to that of the blood. In contrast, a super-antigen present in the joint 
could elicit polyclonal expansion of both CD4+ and CD8+ T cell subsets. Finally, 
stimulation of T cell clones by a specific antigen would induce oligoclonal T cell 
expansions characterised by related sequence motifs in the CDR3 region 356. A study 
by Costello et al. investigated the TCRβ chain repertoire in paired samples of PB and 
SF from PsA patients. The study demonstrated that the αβ T cell repertoire of PsA SF 
CD8+ T cells contained an average of 32 major oligoclonal expansions in many 
variable genes of the TCRβ chain families, as evidenced by β-chain CDR3 length 
analysis. The majority of oligoclonal expansions were not present in the PB counter-
part, highlighting the immunologic specificity of the clonal events for the inflamed 
joint. The TCR repertoire of the CD4+ T cells derived from PsA SF contained fewer 
and smaller oligoclonal expansion predominantly restricted to the joint. Collectively, 
these data suggest that the accumulation of CD8+ T cells in the PsA joint is driven by 
antigen (likely auto-antigen) driven clonal expansion. Moreover, as clones are 
preferentially expressed in the joint, it is suggested that the inciting peptide antigen is 
selectively expressed in the joint or related tissues. The study demonstrated that CD4+ 
T cell oligoclonal expansion was also present in PsA SF, however, they were smaller 
in size and number compared with CD8 expansions 356. 
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1.12.4 Animal models showing the pathological role of IL-17A in arthritis 
Murine models of inflammatory arthritis have unequivocally demonstrated the 
pathogenic role of IL-17A in inflammatory arthritis 357. Seminal research blocked IL-
17A in the CIA mouse model (during the initial phase of arthritis) with a soluble IL-
17 receptor fusion protein, which resulted in the suppression of arthritis development 
and joint damage. In contrast, overexpression of IL-17A in CIA led to accelerated 
development and enhanced severity of synovial inflammation and joint damage 358. In 
concordance, another study demonstrated that blocking IL-17RA signalling provided 
complete protection against the development of CIA 359. As well as playing a role in 
the early stages of arthritis, it has been shown that IL-17A contributes to the effector 
phase of arthritis. Neutralising IL-17A after the onset of CIA significantly reduced 
disease severity, as evidenced by the suppression of joint damage in the knee and ankle 
joints. Suppressed joint damage was attributed to the significantly reduced systemic 
levels of IL-6 and decrease in IL-1β and RANKL+ cells 360. Another study by Lubberts 
et al. demonstrated that a lack of IL-17R signaling prevented full progression and 
persistence of chronic synovitis. This study involved a mouse model which begins as 
a macrophage-driven process but becomes T cell dependent with time. This involved 
repeated injections of gram-positive bacterial cell wall fragments (SCW) directly into 
the knee joint. While no difference in the acute phase of arthritis was observed in IL-
17R-/- mice vs. wild-type mice, IL-17R-/- prevented progression to chronic 
destructive synovitis. This was associated with a significant down-regulation of 
chemokines, selectins, cytokines and collagenase-3 in the synovium of IL-17R/- mice 
361.  
 
One of the early mouse-model studies investigating the role of IL-17F showed that in 
dextran sulfate sodium (DSS) induced colitis, IL17A knock-out mice exhibited severe 
disease symptoms, whereas IL17F knock-out mice were protective against disease 106. 
In contrast, in the EAE model IL17F knock-out mice had no affect on disease severity 
106. Similarly, blockade of IL-17F in CIA did not reduce the arthritis score 362. A 
combined blockade of IL-17A and IL-17F significantly reduced disease severity, 
however, no clear difference was observed between the blockade of IL-17A alone vs. 
combined IL-17A and IL-17F blockade. In contrast, a study in the experimental colitis 
mouse model showed that neutralization of both IL-17A and IL-17F ameliorated 
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colitis, whereas neutralization of IL-17A or IL-17F alone had a limited effect 363. This 
suggests that in certain environments dual IL-17A and IL-17F blockade may be more 
effective at reducing inflammation than blockade of IL-17A alone.  
 
1.12.5 The presence of IL-17A and IL-17F in inflammatory arthritis 
1.12.5.1 RA 
The link between IL-17A and RA pathology was established in 1999 by Chabaud et 
al, whereby IL17A mRNA expression was detected in RA synovial tissue and not OA 
tissue. Additionally, functional IL-17A was shown to be spontaneously produced by 
RA synovial explants and IL-17A producing cells were identified in T cell-rich areas 
of the synovium 364. Since then immunohistochemistry analysis has identified 
increased expression of IL-17A protein in RA vs. OA synovial tissue 111,365. Studies 
have also shown increased IL-17A production or frequency of IL-17A+ CD4+ T cells 
in the serum or SF of RA patients. RA patients showed significantly higher levels of 
IL-17A in the serum of RA patients vs. healthy controls 366 and levels of IL-17A in SF 
were significantly higher in RA patients than OA patients 103. Gullick et al. 
demonstrated that following ex vivo stimulation with PMA and ionomycin for 3 hours, 
IL-17A+ CD4+ T cells were significantly elevated in the PB from RA patients vs. 
healthy control. IL-17A+ CD4+ T cells were further enriched in the RA SF compared 
to RA PB, demonstrating that IL-17A is preferentially enhanced at the site of 
inflammation rather than systemically 367. Other studies have also observed increased 
frequencies of IL-17A+ CD4+ T cells in the PB and SF of RA patients vs. controls 
368,369. Studies have linked levels of IL-17A protein and IL-17A+ CD4+ T cells to RA 
severity. In comparison to patients in remission, patients with active disease had a 
higher percentage of IL-17A+ CD4+ T cells in RA synovial tissue. Moreover, the 
frequency of IL-17A+ CD4+ T cells, but not Th1 cells in SF positively correlated with 
CRP and local power doppler ultrasound-defined synovitis 367. 
 
Limited studies examining the presence of IL-17F in RA exist. A study by Zrioual et 
al. performed immunohistochemistry analysis on RA synovial tissue and identified 
the selective expression of IL-17F protein when compared with OA samples. 
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Additionally, they observed a more sustained staining for IL-17F compared with IL-
17A. IL-17F secreting cells were described to display a plasma cell-like morphology, 
similar to IL-17A expressing cells 112. Similar experiments performed by van Baarsen 
et al. also demonstrated the presence of IL-17F protein in RA synovial tissue, however 
similar IL-17F protein levels were also observed in healthy control and OA synovial 
tissue samples 365. 
 
While the presence of IL-17 cytokines in serum/ plasma samples has been 
undetectable in some cases 362, other studies have detected IL-17F 370,371. One study 
analysed plasma samples from RA and OA patients and revealed significantly 
increased levels of IL-17F in RA vs. healthy control samples 370. With regards to SF 
analysis, IL-17F levels were identified at significantly increased levels in RA and OA 
patients vs. healthy controls. However, no significant difference was observed 
between RA vs. OA SF 370. It is important to note that in this study, in contrast to 
robust data provided in other reports, IL-17A protein was identified at very low levels 
with no difference between RA vs OA or healthy control SF samples. A study by 
Sarkar et al. stimulated RA and OA PBMC for twenty-four hours with PMA and 
ionomycin. Similar to IL-17A, they identified IL-17F protein at increased levels in RA 
vs. OA PBMC supernatants. However, no IL-17A or IL-17F expressing cells were 
detectable via flow cytometry. With regards to this study it is important to question 
the physiological relevance and damage to cells following a twenty-four hour 
PMA/ionomycin stimulation period. The study also showed that no IL-17F protein 
was detectable in the supernatant of PMA/ionomycin stimulated RA SFMC or RA PB 
and SF CD3+ T cells 362. Collectively, it is clear the current literature lacks robust 
evidence demonstrating the presence of IL-17F in RA. The same holds true for IL-
17AF. The only reports for IL-17AF have demonstrated that very low levels of IL-
17AF are present in the SF of RA patients 370 and twenty-four hour PMA and 
ionomycin stimulated CD3+ T cells from RA PB display increased IL-17AF levels 




IL17A mRNA and IL-17A protein has been detected in the SF and synovial tissue of 
PsA patients. Out of fourteen PsA synovial tissue samples, IL17A mRNA was 
detectable in 9 samples 121 and IL-17A protein was detected at higher levels in PsA SF 
vs. PB 368. Circulating IL-17A+ CD4+ T cells are increased in the peripheral blood of 
patients with PsA 372. Additionally, it has been shown that there is a significant 
increase in the number of IL-17A+ CD4+ and IL-17A+ CD8+ T cells in the synovial 
fluid of PsA patients when compared with matched PB or osteoarthritis SF 373,374. A 
report from our lab demonstrated that the frequency of IL-17A+ CD4- T cells present 
in PsA SF positively correlated with the CRP level, ESR, DAS28 score and was 
increased in patients with erosive disease, suggesting a pathological role for IL-17A+ 
CD8+ T cells in RA 374. Within the IL-17A+ CD8+ T cell population in PsA SF, low 
frequencies of CD161+ Vα7.2 MAIT cells have been reported 374. Other cellular 
sources of IL-17A in PsA PB and SF include γδ T cells and ILC3s 375-377. IL-17RA 
expression has been shown to be increased in PsA vs. OA synoviocytes, suggesting 
that PsA synoviocytes are more responsive to levels of IL-17A (as well as IL-17F and 
IL-17AF) present in the inflamed joint 373. 
 
IL-17A+ T cells have been implicated as a key contributor to the pro-inflammatory 
state of psoriasis 378,379. Expression of IL17A mRNA and IL-17A protein has been 
shown to be increased in psoriatic lesions when compared with non-lesional skin 
380,381. A study by Kolbinger et al. detected high IL-17A protein levels in lesional skin 
from psoriasis patients, whereas no IL-17A was detectable in the skin of healthy 
volunteers. However, they detected low but detectable levels of IL-17A protein in the 
non-lesional skin of PsA patients, suggesting that there is an on-going IL-17A pathway 
activation in PsA non-lesional skin 382.  Di Meglio et al. showed that there was an 
accumulation of IL-17A+ CD8+ T cells in human psoriatic lesions and blockade of 
CD8+ T cells via a neutralising antibody prevented the development of psoriasis in a 
xenotransplantation mouse model 383. 
 
Similar to RA, current literature lacks robust data confirming the presence of IL-17F 
in PsA. Among the limited studies investigating IL-17F in PsA, Glatt et al. observed 
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detectable IL17F mRNA levels in six out of fourteen PsA synovial tissue samples 121. 
Van baarsen et al. observed increased IL-17F expression as measured by 
immunohistochemistry staining in PsA synovial tissue compared with OA synovial 
tissue 365. With regards to psoriasis, a study by Watanabe et al. performed western 
blotting analysis to demonstrate the presence of IL-17F protein in psoriatic lesions at 
higher levels than non-lesional controls. Moreover, similar results were observed by 
ELISA 108. A more recent study detected  elevated expression of IL17F mRNA in 
psoriatic lesional skin compared with healthy skin 382. To the best of my knowledge, 
no studies have investigated the presence of IL-17AF in PsA. 
 
1.13 IL-17 receptors in RA and PsA 
As previously discussed, IL-17A, IL-17F and IL-17AF signal through the IL-
17RA/IL-17RC heterodimer receptor complex. These receptors are critical in 
mediating cellular responsiveness to IL-17A, IL-17F and IL-17AF 31. In rheumatic 
diseases, IL-17RA and IL-17C have been reported to be upregulated systemically and 
at the site of inflammation, thus, having the ability to exacerbate the effect of IL-17A, 
IL-17F and IL-17AF. Microarray analysis revealed significant upregulation of both 
IL17RA and IL17RC mRNA expression in RA PBMC when compared with healthy 
volunteers 111. At the site of inflammation, immunohistochemical analysis has shown 
IL-17RA and IL-17RC receptors to be broadly expressed within the synovium of RA 
patients, located on stromal cells and infiltrating immune cells 111. Moreover, a study 
that compared IL-17RA expression in RA, PsA and OA synovicytes via flow 
cytometry and western blot observed IL-17RA expression to be significantly higher in 
RA and PsA when compared with OA 373. 
 
1.13.1 The presence of IL-17B, IL-17C, IL-17D and IL-17E in RA and PsA 
Studies have highlighted a possible role of the remaining IL-17 family members in 
inflammatory arthritis. Immunohistochemistry and qPCR analysis revealed that 
neutrophils contained significant levels of IL-17B in the RA synovium 134. Moreover, 
a study by Yamaguchi et al. identified IL17B and IL17C mRNA expression in the CIA 
arthritic paw. Adoptive transfer of IL-17B- and IL-17C-transduced CD4+ T cells 
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exacerbated arthritis. Finally, in CIA mice neutralisation of IL-17B inhibited arthritis 
development and bone destruction 136. IL-17C is strongly linked to skin, being 
produced and acting upon epithelial cells. Substantial evidence implicates IL-17C in 
lesional psoriasis skin formation. Johnston et al. shown IL-17C protein to be 
abundantly expressed in human lesional psoriasis skin and co-localise with 
keratinocytes and epithelial cells. In concordance, mice engineered to overexpress IL-
17C keratinocytes develop psoriasis-like dermatitis 132. Little evidence exists on the 
presence of IL-17D in inflammatory arthritis. Interestingly, a recent report has 
suggested a pro-inflammatory role of keratinocyte-derived IL-17E in psoriasis 384. 
 
1.14 Biologics in RA and PsA 
There are three main groups of treatment for inflammatory diseases: non-steroidal 
anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying anti-
rheumatic drugs (DMARDs). DMARDs are grouped into conventional DMARDs and 
biologic therapies. Conventional DMARDs include methotrexate, 
hydroxychloroquine, leflunomide and sulphasalazine and are often first-line therapy 
385. They can be used individually or in combination with other DMARDs or biologic 
therapies. A study showed that the combination of methotrexate in combination with 
sulfasalazine and hydroxychloroquine demonstrated greater efficacy in early RA and 
patients with an inadequate response to methotrexate (non-responders), however, 
caution must be taken regarding toxicity 386. Extensive research into understanding the 
pathology and involvement of pro-inflammatory cytokine production in RA and PsA 
has allowed for the development of biologic therapies. Biologic therapies have 
revolutionised the management of inflammatory arthritis, directly targeting molecules 
and cells involved in the pathogenesis. The TNFα inhibitor, infliximab was the first 
biologic therapy to be licensed. Infliximab is a chimeric anti-TNF monoclonal 
antibody with murine variable regions and a human IgG1 constant region 387, which 
demonstrated efficacy in RA and PsA 388,389. This was closely followed by other TNFα 
inhibitors including etanercept, adalimumab, golimumab and certolizumab, all of 
which have shown to be effective in the treatment of RA and PsA. Although, TNF 
inhibitors have shown great success, not all patients respond. Clinical improvement 
after TNF inhibition is observed in approximately in 60% - 70% of patients who 
previously failed conventional DMARDS. At present, it is not fully understood why 
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30% to 40% of patients do not respond 390. Current studies are aiming to identify 
features which can predict anti-TNF responders vs. non-responders. 
 
With strong evidence linking the IL-23/IL-17 axis in the immunopathology of RA and 
PsA, biological therapies targeting this pathway have been developed including 
ustekinumab, a human immunoglobulin G1κ monoclonal antibody that binds to the 
p40-subunit shared by IL-12 and IL-23 391,392. Ustekinumab has demonstrated efficacy 
in PsA and psoriasis. While ustekinumab displayed less efficacy in PsA than TNF 
inhibitors 393, it was the first therapy to be more effective than TNF inhibitors in the 
treatment of psoriasis 394. In contrast, ustekinumab has not been shown to reduce the 
signs and symptoms of RA 395. Anti-IL-17A directed therapies including secukinumab 
(anti-IL-17A mAb) and ixekizumab (anti-IL-17A mAb) have demonstrated efficacy 
in PsA and psoriasis. These biologics are now FDA approved and have shown success 
in patients who failed to respond to TNF inhibitor treatment 396-399. In RA however, 
secukinumab and ixekizumab have failed to show consistent results 400-402. The 
biologic brodalumab is directed at IL-17RA and therefore inhibits the signalling of 
both IL-17A and IL-17F aswell as IL-17C and IL-17E. Blockade of IL-17RA has 
shown good efficacy in PsA and psoriasis 403,404, however in patients with active RA 
and an inadequate methotrexate response, no clinical response to brodalumab were 
observed 405. As IL-17E has demonstrated anti-inflammatory potential 125, it is 
important to consider that blockade of IL-17E signalling by brodalumab may be a 
disadvantage, dampening brodalumab’s ability to reduce inflammation. Bimekizumab 
is a humanized monoclonal IgG1 antibody that selectively neutralizes IL-17A, IL-17F 
and IL-17AF.  This agent has demonstrated good efficacy in a proof-of-concept study 






1.15 Thesis rationale and thesis outline 
As evidenced by the literature, IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-
17A- CD4+ T cell populations exist; however, it is unknown whether there are factors 
that can preferentially skew Th17 cells to be IL-17F producing. Moreover, IL-17F 
expressing CD4+ T cells have not been extensively characterised and it is unknown 
whether there are distinct phenotypic or functional differences between IL-17A and 
IL-17F CD4+ T cells. Reports have shown that IL-17F is less potent at inducing 
inflammation when compared with IL-17A. However, studies have suggested dual IL-
17A and IL-17F blockade is more effective at reducing inflammation than blockade 
of IL-17A alone 121,363. Finally, while strong evidence implicates IL-17A in the 
immunopathological role of inflammatory arthritis, robust evidence for IL-17F is 
lacking. This literature research provided us with the rationale to further characterise 
IL-17F and IL-17F+ CD4+ T cells. 
In summary the main aims of this thesis were to: 
1. Investigate what drives IL-17F expression from CD4+ T cells and perform 
phenotypic characterisation of IL-17F+ CD4+ T cells. Here I hypothesise that 
IL-17A+ and IL-17F+ CD4+ T cells are differentially regulated. 
2. In the context of RA and PsA, investigate the functional role of IL-17F 
alongside IL-17A and investigate the hypothesis that dual IL-17A and IL-17F 
blockade is more effective at reducing inflammation than IL-17A. 
3. Investigate the hypothesis that IL-17F is present and plays a role in RA and 
PsA. 
 
In the first chapter, in vitro healthy CD4+ T cell cultures were set up to explore what 
drives IL-17F expression. This section begins by expanding upon previous work of 
the lab, assessing the effect on LPS-activated monocytes in driving IL-17A and IL-
17F expression. Moreover, the effect of anti-CD3 and anti-CD28 titration on induction 
of IL-17A and IL-17F expressing CD4+ T cells was investigated. Mass cytometry 
(CyTOF) was performed to provide an initial insight into whether IL-17A and IL-17F 
CD4+ T cells display different cytokine profiles. 
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Chapter 4 explores the individual and combinatorial role of IL-17A, IL-17F, IL-17AF 
and TNFα in synovial fibroblast assays. Moreover, the effect of single and dual IL-
17A and IL-17F blockade on the inflammatory response of fibroblasts was assessed 
across multiple culture systems. Due to an increasing need to separate IL-17A+ and 
IL-17F+ CD4+ T cells for functional assays and further characterisation, an IL-17A 
and IL-17F secretion assay was developed in collaboration with UCB. Finally, the 
function of IL-17B, IL-17C, IL-17D and IL-17E on synovial fibroblasts was 
examined. 
 
The final results chapter (Chapter 5) predominantly aims to identify the presence of 
IL-17F in inflammatory arthritis. Using Luminex and ELISA techniques the presence 
of IL-17A, IL-17F, IL-17AF and other pro-inflammatory cytokines in matched serum 
and SF samples from RA and PsA patients was assessed. Additionally, we examined 
the presence of IL-17A and IL-17F producing CD4+ T cells and other immune cell 
subsets in RA and PsA PB and SF. This was further examined at a molecular level. 
Finally, the presence of IL-17 producing cells in RA synovial tissue was assessed.  
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2 Materials and Methods 
2.1 Sample Isolation 
Ethical approval for the use of peripheral blood from healthy donors and peripheral 
blood, synovial fluid and synovial tissue from RA, PsA and OA patients was obtained 
from the Bromley Research Ethics Committee (06/Q0705/20). Healthy control 
subjects were recruited amongst university staff.  Patients with RA, PsA and OA were 
recruited from the Guy’s and St Thomas’ Foundation NHS Trust Rheumatology 
outpatient clinic. Informed consent was obtained for each sample taken from both 
healthy controls and patients. At the time of sample isolation patients were assessed 
using the Disease Activity Score in 28 joints (DAS28). This score is calculated using 
a number of assessment criteria including the number of tender and swollen joints, the 
erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP) level. 
 
2.1.1 PBMC and SFMC Isolation 
Peripheral blood mononuclear cells (PBMC) were isolated from healthy individuals 
or RA/ PsA patients using density gradient centrifugation. Blood was diluted 1:1 with 
PBS (Gibco, Invitrogen, UK) and carefully pipetted over a layer of 15mls lymphoprep 
(2:1 ratio) (Alere, UK) in a 50ml falcon centrifuge tube. The tubes were then spun in 
a centrifuge at 1600rpm for 20 minutes and no brake. Once centrifuged, the PBMC 
interphase layer was carefully removed with a Pasteur pipette. Cells were washed 
twice in 50mls PBS and counted with Trypan Blue (Gibco, Invitrogen, UK). 
Synovial fluid (SF) from RA/PsA joints was removed by needle aspiration by the 
clinicians and collected into sterile tubes. Depending on the sample viscosity, SF was 
diluted between 1:1 – 1:10 with PBS. As described with blood, SF was layered over 
lymphoprep, centrifuged and the synovial fluid mononuclear cells (SFMC) interphase 
layer was collected with a Pasteur pipette. SFMC were washed twice in 50mls PBS 
and any synovial debris was removed by passing the SFMC suspension through 70µm 
cell strainers. Cells were counted with trypan Blue. 
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2.1.2 Cryopreservation and thawing of PBMC and SFMC 
In some cases, healthy PBMC or RA/PsA PBMC and SFMC were cryopreserved and 
stored in liquid nitrogen in cryovials containing 1ml freezing media, made up of foetal 
calf serum (FCS) (Gibco, Invitrogen, UK) and 10% Dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich). When required, frozen vials were quickly thawed in a water bath at 
37oC. The cell suspension was then added to pre-warmed media, washed and counted. 
 
2.1.3 Serum and synovial fluid isolation 
For serum samples, blood from healthy volunteers or RA/PsA/OA patients was 
collected in a no additive serum tube (Fisher Scientific, UK) and stored at 4oC for 1-2 
hours. The tube was centrifuged (1600rpm, 10 minutes) and the serum was decanted 
into a new falcon tube. This process was repeated until no red blood cells were seen. 
For cell-free SF samples, 1.5mls of SF was centrifuged at 1200rpm for 10 minutes and 
the supernatant was removed from the cell pellet. Final serum or SF samples were 
stored at -80oC before being analysed by luminex or ELISA. 
 
2.1.4 Isolation of cells from synovial tissue 
Synovial membrane tissue samples were collected via arthroscopic biopsy from the 
joints of RA patients. Samples were transferred on a damp gauze to the laboratory 
tissue culture hood and immediately cut into small pieces (1-2mm), discarding any fat. 
Tissue samples were kept moist with MACS buffer (PBS supplemented with 0.5% 
BSA (Sigma-Aldrich) and 2mM EDTA (Sigma-Aldrich). Next, 500mg – 3g of cut 
tissue was placed into a C-tube (Miltenyi Biotec) and an enzyme mastermix was added 
according to manufacturer’s instructions (Milteni Biotec, multi-tissue dissociation kit 
1). C-tubes were then loaded on to a gentleMACS dissociator (Miltenyi Biotec). The 
programme used comprised of 29 seconds mechanical digestion, 45 – 60 minutes 
incubation at 37oC with gentle mixing and 27 seconds mechanical digestion. Once the 
programme had finished, the digestion reaction was quenched by adding the same 
volume of culture media: Roswell park memorial institute media (RPMI) 1640 (Gibco, 
Invitrogen, UK) supplemented with 10% FCS (Gibco, Invitrogen, UK), 100 units/ml 
penicillin, 100μg of streptomycin/ml) (Gibco, Invitrogen, UK) and 1% glutamine 
(Gibco, Invitrogen, UK) and 20μl/ml ethylenediaminetetraacetic acid (EDTA). To 
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remove tissue debris, the cell suspension was first passed through a 100µm cell 
strainer. MACS buffer was used to help pass the cell suspension through the strainer. 
This cell suspension was then passed through a 70µm cell strainer. Finally, cells were 
centrifuged (1600rpm for 8 minutes) and counted with trypan blue. 
 
2.1.5 Synovial tissue explant culture 
In-house fibroblast cell lines were obtained from RA or PsA synovial membrane tissue 
samples. Synovial membrane tissue samples were collected via arthroscopic biopsy 
from the joints of RA or PsA patients. Samples were transferred to the laboratory on 
a damp gauze and then immediately cut into small pieces. Whilst tissue pieces were 
left wet in culture media (Dulbecco Modified Eagle Medium (DMEM) (Gibco, 
Invitrogen, UK) supplemented with 20% foetal calf serum (FCS) (Gibco, Invitrogen, 
UK), 100 units/ml penicillin, 100μg of streptomycin/ml) (Gibco, Invitrogen, UK), 2% 
glutamine (Gibco, Invitrogen, UK) and 1mg/ml Fungizone (Gibco, Invitrogen, UK), 
explant plates were prepared. Wells of a 6 well plate were evenly coated with 1ml 
sterile 0.1% bovine gelatin (Sigma, UK) in distilled water and allowed to set for 30 
minutes at RT. Any excess gelatin was carefully removed with a Pasteur pipette, 
leaving a thin film of set gelatin remaining on the well surface. A piece of tissue 
(approximately 1mm3) was placed in the centre of each well and 1ml of supplemented 
DMEM was carefully added. Tissue explants were incubated at 37oC for 5% CO2 and 
supplemented DMEM media was replenished every 3 days. When fibroblasts had 
grown out of the synovial tissue and expanded to 80% confluency on the well surface, 
they were transferred to a T175 flask. This involved removing and discarding the 
synovial tissue and detaching the adherent fibroblasts by adding 300μl Trypsin-EDTA 
(Thermo Fisher Scientific, UK) for 5 minutes at 37oC. When the fibroblasts were 
detached, Trypsin was neutralised with the addition of 700μl supplemented DMEM. 
The 1ml fibroblast suspension was then added to a T175 flask to a total volume of 
20ml supplemented DMEM.  
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2.2 Cell separation 
2.2.1 CD14+ monocyte isolation 
Isolation of CD14+ monocytes was performed using CD14 Microbeads (Miltenyi 
Biotec, UK). The number of PBMCs required for separation was calculated and 
resuspended in 90μl per 107 cells MACS buffer. Next, 10μl of CD14+ microbeads 
were added per 107 cells, the suspension was thoroughly mixed and incubated at 4oC 
for 15 minutes. After incubation, the suspension was diluted with MACS buffer with 
10-20x the labelling volume and centrifuged at 1200rpm for 10 minutes (4oC). For 
CD14+ selection an LS column (Miltenyi Biotec) was placed in a magnet and pre-wet 
with 3mls of MACS buffer. The cell pellet was resuspended in 1ml MACS buffer and 
applied to the column. Once the cell suspension passed through the column another 
3mls of MACS buffer was applied, this wash step was repeated three times. The 
purified CD14+ monocytes captured within the column were then eluted. This was 
done by removing the column from the magnet and plunging 5mls of MACS buffer 
through. Cells were then counted using Trypan Blue and stained for purity with CD14 
(Miltenyi Biotec, UK), CD3, CD4, CD8 and CD19 (Biolegend, UK). In general, the 
purity was >95% of all cells within the live gate. A representative dot plot is shown in 
Figure 2.1. 
 
2.2.2 CD4+ T cell isolation 
Isolation of CD4+ T cells was performed using a CD4+ T cell isolation kit (Miltenyi 
Biotec). The number of PBMCs required for separation was calculated and 
resuspended in 40μl MACS buffer per 107 cells. The CD4+ T cell population was 
negatively isolated via magnetic separation. In brief, the cells were incubated with a 
cocktail of biotin-conjugated monoclonal antibodies (mAb) against CD8, CD14, 
CD16, CD19, CD36, CD56, CD123, TCRγ/δ and glycophorin (10μl/107 cells) for 10 
minutes at 4oC. After 10 minutes beads coated with an anti-biotin antibody were added 
(10μl/107 cells), mixed and incubated at 4oC for 15 minutes. After incubation the 
suspension was diluted with MACS buffer with 10-20x the labelling volume and 
centrifuged for 10 minutes at 1200rpm. For CD4+ T cell isolation an LS column 
(Miltenyi Biotec) was placed on a magnet and pre-wet with 3mls MACS buffer. The 
suspension was applied to the column, followed by 3ml of MACS buffer which had 
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been used to rinse the suspension tube. The CD4+ T cells collected were counted using 
Trypan Blue and stained for purity with CD3, CD4, CD8 (Biolegend) and CD14 
(Miltenyi Biotec, UK). In general, the purity for CD4+ T cells was >97 % (Figure 2.1). 
 
2.2.3 Sorting immune cell populations from PBMC and SFMC 
To sort immune cell subsets from PBMC and SFMC for RNA analysis, PBMC and 
SFMC isolation was performed as described in section 2.1.1 and approximately 5-20 
x106 cells were incubated simultaneously with viability dye eFluor 506 (1:1000) 
(eBioscience, UK), CD4 PerCp-Cy5.5, CD3 PE-Cy7, CD19 PE, CD8 PB (Biolegend, 
UK) and CD14 APC-Vio 770 (Miltenyi Biotec, UK) in PBS for 30mins at 4 oC. Cells 
were then washed and resuspended in MACS buffer. Based on the expression of 
extracellular markers, CD3+ CD4+ CD8- T cells were sorted using a FACSAria II 
(BD Biosciences). Sorted immune cell populations were stored in TRIzol (Invitrogen, 
UK) for analysis of RNA expression. An example of the sorting gating strategy is 




Figure 2.1 Cell purity. 
PBMCs from healthy donors were isolated using density gradient centrifugation, CD14+ monocytes 
were isolated via positive selection and the remaining CD14- cells were enriched for CD4+ T cells. To 
assess cell purity, small aliquots of isolated CD4+ T cells and CD14+ monocytes were stained with 
PECy7-CD3, PerCPCy5.5-CD4, APC-Cy7-CD14, PB-CD8 and APC-CD19. One representative 
example is shown for (A) purified CD4+ T cells and (B) purified CD14+ monocytes. Purity of CD4+ 








































2.3 Cell culture 
Human PBMC or SFMC were cultured in culture medium: Roswell park memorial 
institute media (RPMI) 1640 (Gibco, Invitrogen, UK) supplemented with 10% foetal 
calf serum (FCS) (Gibco, Invitrogen, UK), 100 units/ml penicillin, 100μg of 
streptomycin/ml) (Gibco, Invitrogen, UK) and 1% glutamine (Gibco, Invitrogen, UK). 
RA and PsA fibroblasts were cultured with DMEM (Gibco, Invitrogen, UK) 
supplemented with either 10% or 20% foetal calf serum (FCS) (Gibco, Invitrogen, 
UK), 100 units/ml penicillin, 100μg of streptomycin/ml) (Gibco, Invitrogen, UK), 2% 
glutamine and fungizone (Gibco, Invitrogen, UK). 
 
2.3.1 CD4+ T cell/CD14+ monocyte co-cultures 
0.5x106 bulk CD4+ T cells were cultured with 0.5x106 autologous CD14+ monocytes 
in a 48 well plate in a total volume of 1ml culture medium. Soluble anti-CD3 mAb 
(Janssen Cilag, UK or Biolegend, UK) was added at 100ng/ml in the absence or 
presence of 100ng/ml LPS (Invitrogen, Sigma, UK), in some experiments 1μg/ml 
adalimumab (ADA) (Abbvie, UK) was added. Co-cultures were incubated for 3 days 
at 37 oC, 5% CO2. 
 
2.3.2 PBMC cultures 
1x106 PBMC were cultured with soluble anti-CD3 in the absence or presence of 
human recombinant (hr) IL-1β  (10ng/ml) (Peprotech, UK) and hrIL-23 (20ng/ml) 
(R&D, UK) and the absence or presence of soluble anti-CD28 (BD, UK) in a total 
volume of 1ml of culture medium. In some experiments, plate-bound anti-CD3 was 
used. To prepare plate-bound anti-CD3 plates, anti-CD3 was coated in each plate well 
at 1.25μg/ml in PBS for a minimum of 2 hours at 37oC. Wells were washed three times 
with PBS before cells were plated. 
 
2.3.3 CD4+ T cell only cultures 
In all CD4+ T cell cultures, plate-bound anti-CD3 was used. In some experiments, 
1x106 bulk CD4+ T cells were cultured in the absence or presence of hrIL-1β 
(10ng/ml) and hrIL-23 (20ng/ml) and the absence or presence of soluble anti-CD28 in 
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a total volume of 1ml of culture medium. Other experiments involved titration of 
soluble anti-CD28 (0-2μg/ml) and plate-bound anti-CD3 (0-2 μg/ml) in cultures of 0.2 
x106 bulk CD4+ T cells in a 96 well plate with a total volume of 200µl in culture 
medium with IL-1β  (10ng/ml) and IL-23 (R&D, UK). Finally, in some experiments 
CD4+ T cells were incubated with anti-IL-2 (1-5μg/ml) (R&D, UK) and/ or anti-IFNγ 
(1-5μg/ml) (Biolegend, UK). Cultures were incubated at 37 oC at 5% CO2 for 3 days, 
unless otherwise stated.  
 
2.3.4 Fibroblasts 
2.3.4.1 General fibroblast cell-line maintenance 
RA and PsA fibroblast cell lines were either generated in-house (as described in 
section 2.1.3) or received as a kind gift from the Anca Catrina lab, Karolinska Institute. 
Fibroblast cell lines were frequently set up from a cryopreserved stock aliquot, 
however, in some cases, they were immediately grown and used from a tissue explant 
culture. To set up a fibroblast cell line from cryopreserved stock, fibroblast cryovials 
were sat in a water bath at 37oC and when completely thawed, the cell suspension was 
immediately transferred to a 15ml falcon tube containing 9ml of pre-warmed culture 
media; DMEM + 20% FCS +100 units/ml penicillin + 100μg of streptomycin/ml + 
2% glutamine + 1mg/ml fungizone. Fibroblasts were then centrifuged at 1200rpm for 
10 minutes. After resuspending the cell pellet in 1ml of culture media, fibroblasts were 
transferred into a T175 flask to a total volume of 20ml culture media. Fibroblasts were 
kept at 37 oC at 5% CO2 and culture media was replenished every 3 days. After the 
first 3 days of setting up a cell line from a cryopreserved stock, the FCS in DMEM 
media was reduced to 10%. When fibroblasts reached approximately 80% confluency, 
the T175 flask was washed twice with 10ml PBS and incubated for 5 minutes at 37 oC 
with 2.5ml Trypsin-EDTA. Once all the fibroblasts were detached, 7.5ml culture 
media was added to the flask, the cell suspension was transferred to a 50ml falcon tube 
and cells were counted using Trypan blue. Whilst some fibroblasts were set up for a 
functional experiment (as described in the next section), others were transferred back 
into a T175 flask and allowed to grow in the new passage. Fibroblast cell lines were 
kept and used between passage 2 and 8.  
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2.3.4.2 Fibroblast assays 
10x103 fibroblasts were seeded per well in a 96-well flat-bottom plate in total volume 
of 200μl DMEM culture media and incubated for 24 hours at 37oC with 5% CO2. 
Taking care not to disturb the adhered fibroblasts, the supernatant was removed and 
discarded. Human recombinant cytokines (IL-17A, IL-17F, IL-17AF, TNFα, IL-17B, 
IL-17C, IL-17D, IL-17E) were added either individually or in combination to the 
fibroblasts at the indicated concentrations. In some experiments, supernatants from 
CD4+ T cells cultured in vitro were added to the fibroblasts at indicated percentages. 
Additionally, stimulated CD4+ T cells were cultured with fibroblasts at a variety of 
ratios. In some of the experiments described, blocking antibodies were added at the 
indicated concentrations. Table 2.1 and 2.2 lists the human recombinant cytokines and 
blocking antibodies used. 
All fibroblast cultures had a final volume of 200μl and were incubated for 24 hours at 
37oC with 5% CO2. Fibroblast supernatants were collected and stored at -80
oC before 
























Fibroblast cell culture 
IL-17A Peprotech 
IL-17F R&D 
IL-17AF Miltenyi Biotec 
TNFα Miltenyi Biotec 
IL-17B R&D 










IL-2 Goat IgG R&D 








Anti-IL-17A Human (h) 
IgG1 
UCB In-house 
Anti- IL-17F hIgG1 UCB In-house 
Combined anti-IL-
17A and IL-17F 
(Bimekizumab) 







2.4 Flow cytometry 
2.4.1 Compensation controls 
In all flow cytometric settings, single-stained compensation controls were used to 
optimise fluorescence compensation settings. To prepare these controls, BD 
CompBeads (BD Biosciences, UK) were stained with fluorescently conjugated 
antibodies, according to manufacturer’s instructions. For viability dye compensation 
controls, a mixture of live and heat-killed (1 minute, >65oC on heat block cells were 
used). 
 
2.4.2 Extracellular staining 
In some experiments, extracellular marker and cytokine expression was analysed from 
fresh or cryopreserved cells (PBMC, SFMC or CD4+ T cells) following a 3 hour ex 
vivo. stimulation with phorbol 12-myristate 13-acetate (PMA) (50ng/ml) (Sigma-
Aldrich, UK), ionomycin (750ng/ml) (Sigma-Aldrich, UK) and Golgi stop (monensin) 
(BD, UK) or Golgi plug (brefeldin A) (BD, UK) (following manufacturer’s 
guidelines). PMA and ionomycin stimulation is one of the most widely applied 
methods for activation of T cells. PMA activates protein kinase C, while ionomycin is 
a calcium ionophore, which synergises with PMA to enhance PKC activation 1. 
Monensin and Brefeldin A prevent cytokine secretion. Monensin prevents protein 
secretion by interacting with the Golgi transmembrane Na++/ H+ transport, while 
brefeldin A redistributes intracellularly produced proteins from the cis/medial Golgi 
complex to the endoplasmic reticulum 2. In vitro PBMC/ SFMC or CD4+ T cell 
cultures, described in section 2.3, were also re-stimulated with PMA, ionomycin and 
monensin or brefeldin, Both ex vivo and in vitro cultures were stimulated for 3 hours 
at 37oC with 5% CO2.  
 
Following stimulation, cells were transferred into 1.5ml eppendorff tubes and 
washed in PBS. Next, cells were simultaneously stained with the relevant 
extracellular markers: CD14 (Miltenyi Biotec, UK) and CD8 (Biolegend, UK) and 
fixable viability dye (either eFluor450 (1:1000) or eFluor780 (1:2000) (eBioscience, 
UK)) in PBS and incubated for 30 minutes at 4oC. After incubation, cells were 
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washed in 500μl of FACS buffer (PBS supplemented with 0.5% BSA and 0.001% 
sodium azide (Sigma-Aldrich). Next, cells were fixed with 2% paraformaldehyde 
(PFA) for 15 minutes at 4oC. Following incubation cells were washed in 500μl of 
FACS buffer. 
 
2.4.3 Intracellular cytokine staining 
To perform intracellular cytokine staining (ICCS), cells were washed in 500μl of 
permeabilisation (SAP) buffer (0.5% Saponin (Sigma-Aldrich) in FACS buffer) and 
centrifuged for 3.5 minutes at 8,000rpm. Cells were then incubated at 4oC in the 
presence of the chosen antibodies (all antibodies listed in Table 2.3) in a total volume 
of 100μl SAP buffer for 30 minutes. As CD4 is internalised upon PMA/ionomycin 
stimulation and αCD3 binds to the same epitope as the CD3 flow cytometry antibody, 
both CD4 and CD3 were stained intracellularly. To distinguish cytokine-producing 
populations, fluorescence minus (FM) controls were used. Following incubation, cells 
were washed twice with 500μl of SAP buffer and once with 500μl FACS buffer. The 
final cell pellet was resuspended in 200μl of FACS buffer and analysed using the BD 
FACS Canto II flow cytometer, LSR Fortessa or BD FACSymphony. Figure 2.3 
illustrates the gating strategy used for intracellular staining aswell as example flow 






Figure 2.2 Gating strategies for intracellular staining. 
 (A) Gates were first set around lymphocytes based on SSC-A vs FSC-A properties. The lymphocyte 
gate was further analysed for uptake of the viability dye, either eFluor506 or eFluor780 to determine 
live vs. dead cells. Next, CD14+ monocytes were excluded by gating on CD14- cells. In some 
experiments, the viability dye was stained in the same fluorescent channel as CD14, allowing 
monocytes and dead cells to be simultaneously excluded in a ‘dump’ channel.   Within live CD14- 
cells, CD3+ CD4+ T cells were selected and a FSC-W/FSC-A gate was applied allowing the 
exclusion of doublet CD4+ T cells. Gated within single CD4+ T cells, (B) shows representative dot 

































































































2.4.4 IL-17A secretion assay 
To isolate IL-17A+ CD4+ T cells, CD4+ T cells were cultured for 3 days with IL-1β, 
IL-23, anti-CD3 mAb and anti-CD28 mAb. After 3 days, cells were re-stimulated with 
PMA (50ng/ml) and ionomycin (750ng/ml) for 1.5 hours. This was followed by an IL-
17A secretion assay (Miltenyi Biotec) according to manufacturer’s instructions. Using 
a BD FACS ARIA sorter, IL-17A+ CD4+ T cells or IL-17A- CD4+ T cells were sorted 
and collected. Sorted cells were either cultured directly with synovial fibroblasts (as 
described in section 2.4.3.2) or incubated for 24 hours in RPMI media (200x103 cells 
in 200μl). 
 
2.4.5 Development of UCB IL-17A and IL-17F capture assay 
To isolate IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells a 
capture assay was developed. A number of optimisation experiments were performed, 
however the following section describes the final optimised method. Due to UCB 
proprietarity, description of the method remains brief. 
 
UCB developed a bespoke anti-CD45 Fab Y fragment aswell as Fab X fragments 
which recognise IL-17A (both the IL-17A homodimer and the IL-17AF heterodimer) 
and IL-17F (IL-17F homodimer only). To form IL-17A and IL-17F capture 
complexes, Fab X anti-IL-17A and Fab X anti-IL-17F were individually incubated 
with Fab Y CD45 at a 1.5 (Fab X):1 (Fab Y) ratio in PBS and incubated for 1 hour at 
37oC. CD4+ T cells were stimulated in vitro with IL-1β and IL-23 and then re-
stimulated with PMA and ionomycin (described in section 2.3.2). Stimulated cells 
were then incubated simultaneously with Fab complex A and Fab complex F in cold 
X-vivo media on ice for 15 minutes. In a 50ml falcon tube, cells were washed with 
50ml of warm X-vivo media and centrifuged for 5 minutes at 400xg. After discarding 
the supernatant, cells were resuspended in 50ml warm X-vivo media. To prevent non-
specific binding, CD4+ T cells were split into multiple 50ml falcon tubes (maximum 
of 6x106 CD4+ T cells in each 50ml falcon tube). Cells were then incubated for 45 
minutes at 37 oC, whilst rotating on a MACS mix rotator (Biolegend, UK). After 
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incubation, 0.5M EDTA was added directly into each cell suspension and inverted. 
This was to prevent cell sticking and cell loss. Cells were then centrifuged for 5 
minutes at 400xg. All supernatants were discarded and multiple cell pellets were 
pooled into one falcon tube. Cells were washed with 50ml ice cold PBS + EDTA and 
centrifuged for 5 minutes, 400xg at 4oC. The supernatant was discarded and the wash 
step repeated. In X-vivo media, cells were incubated with CD4 PerCP Cy5.5 
(Biolegend, UK), CD3 FITC (Biolegend, UK), CD8 PE Cy7 (Biolegend, UK), IL-17A 
APC (eBioscience, UK) and IL-17F PE (eBioscience, UK) for 30 minutes on ice. Cells 
were washed twice in 50ml ice cold PBS + EDTA. Prior to sorting, the cell pellet was 
resuspended in 1ml PBS+ EDTA and stained with DAPI viability. IL-17A+ IL-17F-, 
IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells were sorted using a FACSAria 
II (BD Biosciences). A gating strategy is shown in Figure 3.4. Sorted immune 
populations were stored in RNA lysis buffer (Qiagen) for analysis of IL-17A and IL-






















Conjugate Isotype Clone Per 100μl stain Manufacturer 
CD3 PE-Cy7 mIgG1k UCHT1 1μl Biolegend 
CD3 BUV395 mIgG1 SK7 1μl BD 
CD4 PerCP-Cy5.5 mIgG1 SK3 1μl Biolegend 
CD8 PB mIgG1 RPA-T4 1μl Biolegend 
CD14 APC Vio 770 mIgG2a TUK4 5μl Miltenyi 
CD19 PE mIgG1 3G8 1μl Biolegend 
CD45RO PB mIgG2a UCHL1 1μl Biolegend 
CD25 PE mIgG1 M-A251 1μl Biolegend 
CD127 FITC mIgG1 A019D5 1μl Biolegend 
CD161 BV605 mIgG1 HP-3G10 3μl Biolegend 
CCR6 APC mIgG1 11A9 5μl BD 
IL-17A PE mIgG1 BL168 1μl Biolegend 
IL-17A APC RatIgG2a eBio17B7 1μl eBioscience 
IL-17F AF488 Goat IgG Poly5166 5μl Biolegend 
IL-17F PE Rat IgG1 SHLR17 1μl eBioscience 
IL-17AF PB mIgG1 20LJS09 5μl eBioscience 
IFN-γ PerCp Cy5.5 mIgG1k 4S.B4 1μl Biolegend 
IFN-γ AF488 mIgG1 4S.B3 1μl eBioscience 
TNFα APC mIgG1k MAb11 1μl Biolegend 
TNFα EF450 mIgG1 Mab11 1μl eBioscience 
IL-10 AF647 RatIgG1 JES3-9D7 1μl Biolegend 
GM-CSF PB RatIgG2a BVD2-21C11 1μl Biolegend 
IL-2 FITC RatIgG2a MQ1-17H12 5μl Biolegend 
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2.5 Mass cytometry (CyTOF) 
CyTOF is a variation of flow cytometry which replaces flurochrome conjugated 
antibodies with antibodies labelled with heavy metal ion tags. This allows for a larger 
antibody panel in single samples, without significant spillover between channels. 
Readout is by time-of-flight mass spectrometry 406. 
 
Ex vivo. stimulated RA/PsA PBMC and SFMC (1-8x106 cells) were washed once with 
PBS in eppendorf tubes. After centrifugation for 5 minutes at 8000rpm, cell pellets 
were resuspended in 5mM Cell-ID Cisplatin (Fluidigm) in PBS and incubated for 5 
minutes at RT. Cisplatin allows for the discrimination of live and dead cells by its 
ability to enter the compromised cell membranes of dead cells and bind to protein 
nucleophiles. The reaction was quenched with MaxPar cell staining buffer, using 5 
times the volume of the cell suspension. Cells were then centrifuged for 5 minutes at 
8000rpm and washed once with PBS. Next, cells were fixed in 500μl PFA for 5 
minutes at RT. After one wash in PBS, cells were washed again in permeabilisation 
buffer and then stained intracellularly with all metal conjugated antibodies (Table 2.4) 
in permeabilisation buffer for 1 hour at RT. Samples were washed once with 
permeabilisation buffer and twice with PBS. Until acquisition, cells were stored at 4oC 
in 500μl 2% PFA. On the day of acquisition, cells were washed with PBS and then 
incubated for 20 minutes at RT with Cell-ID Intercalator-Ir (Fluidigm) to intercalate 
DNA. Before acquisition on CyTOF Helios, cells were washed twice with PBS and 












Metal Isotype Per 100μl 
stain 
CD8 146Nd RPA-T8 
 
2μl 
CD4 145Nd RPA-T4 
 
2μl 
CD11c 159Tb 3.9 
 
2μl 
CD123 151Eu 6H6 
 
2μl 
CD16 148Nd 3G8 
 
2μl 
CD14 160Gd 61D3 
 
2μl 
CD56 173Yb CMSSB 
 
2μl 
CD45 154Sm HI30  
 
2μl 
CD19 142Nd HIB19 
 
2μl 
CD3 170Er UCHT1 
 
2μl 
HLA-DR 174Yb L243 
 
2μl 
IL-17A 156Gd eBio64CAP17 
 
2μl 
IL-17F 153Eu SHLR17 
 
2μl 
IL-22 166Er IL22JOP 2μl 
GM-CSF 164Dy BVD2-21C11 
 
2μl 
IL-10 158Gd JES3-9D7 
 
2μl 
TNFα 155Gd Mab1 
 
2μl 
IFNγ 163Dy 45-15 
 
2μl 
IL-4 150Nd MP4-25D2 
 
2μl 
IL-13 175Lu JES10-5E2 2μl 
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2.6 Cytokine analysis 
2.6.1 Enzyme-linked immunosorbent assay (ELISA) 
A variety of cytokines including IL-17A, IL-17F, IL-17AF, IL-6 and IL-8 were 
detected in samples using ELISA. A full list of ELISA kits used is shown in Table 2.2. 
The ELISAs were performed according to manufacturer’s instructions; generally, 
different manufacturer kits followed the same protocol. 
 
Ninety-six-well Nunc MaxiSorp microplates (Thermo Fisher Scientific) were coated 
overnight at 4oC with capture antibody diluted in coating buffer. After washing 4 times 
with washing buffer (PBS + 0.05% Tween-20 (Thermo Fisher Scientific, UK), non-
specific binding was prevented by blocking plates with assay diluent (PBS + 10% BSA 
(Sigma Aldrich, UK) for 1 hour at RT.  Standards were prepared by performing seven 
two-fold dilutions of the top standard (provided with kit) with assay diluent and 
samples were diluted appropriately in assay diluent. Plates were washed 4 times with 
assay wash buffer and 100µl of diluted standards (added in duplicate) and samples 
were added and incubated for 2 hours at RT. Plates were washed 4 times again, before 
incubated with detection antibody diluted in assay diluent for 1 hour at RT. Following 
another 4 washes and a final 1-minute soak, 100µl 3,3’,5,5’-tetramethylbenzidine 
(TMB) substrate solution was added. When a gradual colour change was observed 
amongst the standards, the reaction was stopped with 50µl 1M sulphuric acid (Sigma-
Aldrich, UK). Using either a Wallac 1420 microplate reader (Perkin Elmer, Waltham 
, MA, USA) or A SPARK 10M plate reader (Tecan, UK),  microwell absorbance was 
read at 450nm. The optical density (OD) values of all standards were used produce a 







Table 2.5 ELISA kits used in this thesis 
 
 
Cytokine Manufacturer Top standard 
IL-17A • Biolegend (detects IL-17A 
homodimer and IL-17AF 
heterodimer) 







IL-17F eBioscience (detects IL-17F 
homodimer only) 
2000pg/ml 
IL-17AF eBioscience (detects IL-17AF 
heterodimer only) 
4000pg/ml 
IL-2 Biolegend 500pg/ml 
IFNγ Biolegend 500pg/ml 
IL-6 Biolegend 500pg/ml 





Figure 2.3 ELISA standard curve. 
For each analyte a two-fold dilution of standard was performed, providing a standard curve. Assay 
diluent served as a blank (0 pg/ml) and a standard curve was included on each ELISA plate. Standard 
absorbance values were used to generate a trendline and y=X equation, where X is the unknown sample 
concentration. In general, the R2 value was not lower than 0.99. After calculating unknown sample 
concentrations, any sample dilutions made were taken into account by multiplying the concentration 
value with the dilution factor. 
 











































The principle of Luminex is similar to ELISA, however, luminex offers the benefit of 
detecting multiple cytokines and proteins in a sample simultaneously. Luminex 
technology is based on polystyrene or magnetic beads that are internally dyed with red 
and infrared fluorophores of differing intensities. Each dyed bead is given a unique 
bead region or number allowing for the discrimination of beads. Individual bead sets 
are coated with a capture antibody specific for a certain analyte. Multiple analyte-
specific beads can then be incubated with a sample in a well of a 96 well plate, 
allowing for the detection of a variety of analytes simultaneously. 
 
Cytokine levels in serum and synovial fluid samples were measured  using the Bio-
Plex Pro™ Human Th17 Cytokine Panel 15-Plex (Bio-Rad, UK) according to the 
manufacturer’s instructions. In brief, the diluted bead cocktail was added to the wells 
of a 96-well plate, followed by the addition of standards (in duplicate) and 
appropriately diluted samples. After securely covering with a foil plate sealer, plates 
were incubated for 2 hours at RT on a plate shaker set at 800 +/-rpm. After adding 
wash buffer to each well, the plate was secured on a magnetic separator block and 
allowed to sit for 3 minutes. This was to ensure the magnetic beads are held in place 
by the magnetic separator block. Whilst the luminex plate was on the magnetic 
separator block, the wash buffer was discarded. The luminex plate was removed from 
the magnetic separator block and the wash procedure was performed for an additional 
2 times. Diluted biotin detection antibody  was added to the plate and incubated for 1 
hour at RT on the plate shaker (800+/-500 rpm). After performing the wash step 3 
times, streptavidin-PE was added to the plate and incubated for 30 minutes at RT on 
the plate shaker (800+/-500 rpm). Luminex plates were acquired on a FLEXMAP 3D 
instrument (Luminex, US). 
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2.7 Quantitative polymerase chain reaction (qPCR) 
2.7.1 RNA Isolation 
In some experiments, total RNA was isolated with a micro-RNA kit (Qiagen, UK) 
according to the manufacturer’s protocol. For samples which had been lysed in trizol, 
a chloroform extraction was performed. This involved adding 200μl of chloroform to 
thawed trizol cell lysates and shaking vigorously for 15 seconds. After incubating at 
room temperature for 3 minutes, samples were centrifuged for 20 minutes, maximum 
speed at 4oC. The upper translucent aqueous layer was then transferred to a new RNase 
free eppendorf. To assist with RNA precipitation and visualisation, 1μl of glycoblue 
was added to each sample. Next, 500μl of ice cold propanol was added to each sample 
and vigorously shaken for 15 seconds. Samples were incubated at -20oC for either 30 
minutes or overnight. Samples were centrifuged for 30 minutes, maximum speed at 
4oC. At this stage, the RNA formed a visible blue pellet. After discarding the 
supernatant, 1ml of ice cold 70% ethanol was added to each sample and centrifuged 
for 10 minutes, maximum speed at 4oC. The supernatant was discarded and the RNA 
pellet was resuspended in 250μl of ice cold 70% ethanol and centrifuged for 10 
minutes, maximum speed at 4oC. To evaporate any residual ethanol remaining after 
removal of the supernatant, the RNA pellet was air-dried for 5 minutes. The RNA 
pellet was then resuspended in RNase free water. RNA concentration and quality was 
measured using the Nanodrop 2000 spectrophotometer (Thermo Scientific). The ratio 
of absorbance at 260nm and 280nm and at 260nm and 230nm was used to assess RNA 
purity. Pure RNA will exhibit a 260/280 ratio of  >2.0, however, accepted values are 
in the range of 1.7-2.1. The 260/230 ratio is an indication of contamination, while 
expected values are in the range of 1.8-2.2, a lower ratio indicates guanidine 
thiocyanate contamination. RNA that met the quality criteria was then DNase treated 
and reverse transcribed. 
 
2.7.2 DNase treatment and cDNA reverse-transcription 
To remove any residual genomic DNA that might be contained in RNA samples, 
DNase treatment was performed. DNase I is an endonuclease that non-specifically 
cleaves DNA to release di-, tri- and oligonucleotide products. It acts on single and 
double stranded DNA, chromatin and RNA: DNA hybrids. To each RNA sample 
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(maximum concentration 1μg), 1μl of 10x reaction buffer with MgCl2 and 1μl of 
DNase I was added, mixed well and incubated on a heat block for 30 minutes at 37oC. 
To inactivate the DNase I, 1μl of EDTA was added to the RNA sample and incubated 
at 65oC for 10 minutes. EDTA chelates ions in the digestion buffer, that are required 
for DNase I activity. Thus, DNase I can be heat-inactivated without loss of RNA. RNA 
concentration levels were analysed by nanodrop. 
Reverse transcription was performed using the high capacity cDNA reverse 
transcription kit (Applied Biosystem, Carlsbad, CA, USA) according to 
manufacturer’s instructions. Until qPCR was performed, cDNA was stored at -80oC. 
 
2.7.3 qPCR protocol and analysis 
qPCR reactions were performed using primers for human  IL-17A and IL-17F  
(Integrated DNA technologies IDT, Heverlee, Belgium) and the SensiMix SYBR No-
ROX kit according to the manufacturer’s protocol. Reactions were peformed on a 
7900HT Fast Real-Time PCR system (Applied Biosystems). Thermocycler conditions 
included an initial holding at 95 oC for 10 minutes, which was followed by a cycling 
program of 95oC for 15 seconds, 60oC for 30 seconds and 72oC for 30 seconds. Data 
were analysed using the Applied Biosystems RQ manager software version 1.2.2. To 
normalise for differences in the amount of total RNA in each sample, the ACTB gene 
was used as an endogenous control. For each sample, the mean cycle threshold (CT) 
for replicates was calculated. Gene expression was calculated as the difference (ΔCT) 
between the mean CT value of the sample for the target gene and the mean CT value 
of the same sample for the endogenous control (ACTB). Relative gene expression was 
expressed as 2-ΔCT. 
 
Table 2.6 Primers using in this thesis 
Target Forward Reverse 
Human 
IL-17A 
TCC CAC GAA ATC CAG GAT GC GCA TGT TCA GGT TGA CCA TCA 
Human 
IL-17F 





Statistical differences were calculated with Prism 7.0 software (GraphPad, San Diego, 
CA). The D’Agostino and Pearson omnibus normality test was used to test the 
normality of data sets. This was followed by statistical significance testing using the 
appropriate tests as described in figure legends. Data sets with n values <8 were tested 
non-parametrically. P values < 0.05 were considered statistically significant.  
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3 Investigating the expression of IL-17F in healthy CD4+ 
T cells in vitro 
 
3.1 Introduction 
The best-studied source of IL-17A and IL-17F is a specific subset of CD4+ T cells, 
named Th17 cells. As previously discussed in the introduction Th17 differentiation is 
dependent on signals from IL-6, transforming growth factor β (TGFβ), IL-1β and IL-
21, while IL-23 is important for lineage maintenance 189,238,407. Reports from our lab 
have shown that in vitro LPS-activated monocytes induce Th17 responses in co-
cultured CD4+ T cells in a TNFα and IL-1β dependent manner 192,198. Stimulation of 
T cells with LPS-triggered monocytes resulted in both an increased percentage of IL-
17A+ CD4+ T cells and an increase in IL-17A secretion 4. Studies have also shown 
that low-strength T cell activation enhances Th17 development 5-6. The majority of 
these studies, however, analysed the expression of IL-17A and not IL-17F. Few reports 
investigate what drives IL-17F expressing CD4+ T cells. In literature, IL-17F is 
generally described as a cytokine co-expressed with IL-17A. The overall aim of the 
first part of this chapter was to investigate whether IL-17A and IL-17F are induced in 
a similar manner or whether there are elements of differential regulation. To achieve 
this, the following questions were addressed: 
• What drives IL-17F expression in CD4+ T cells? 
• Does the strength of T cell activation affect IL-17F expression? 
 
The second part of this chapter characterises IL-17F+ CD4+ T cells. Human IL-17A+ 
CD4+ T cells have been extensively characterised. They have been shown to express 
the markers CCR6 and CD161 and co-express other cytokines including TNFα, IFNγ, 
GM-CSF and IL-10. However, there remains a lack in literature of an in-depth 
phenotypic characterisation of IL-17F+ CD4+ T cells. This includes phenotypic 
comparison of IL-17A+ vs. IL-17F+ CD4+ T cells. In this section, the following 
question was addressed: 




3.2.1 Induction of IL-17F expressing CD4+ T cells 
3.2.1.1 Ex vivo analysis of IL-17A and IL-17F expressing CD4+ T cells 
I first investigated whether IL-17F+ CD4+ T cells could be detected following an 
ex vivo stimulation of healthy donor bulk CD4+ T cells. Bulk CD4+ T cells were 
incubated for 3 hours with PMA, ionomycin and GolgiStop then cells were stained 
to assess intracellular cytokine expression and analysed by flow cytometry. Figure 
3.1 is a representative plot for the gating strategy applied. As shown in Figure 3.2, 
fluorescence minus (FM) controls were used to set gates to depict positive cytokine 
expression. In 6 donors, a range of IL-17A+ CD4+ T cell frequencies was detected 
following ex vivo stimulation (from 0.2 – 1.9%). In contrast, all donors showed 






Figure 3.1 Representative gating strategy following ex vivo stimulation of 
CD4+ T cells. 
Healthy donor bulk CD4+ T cells were stimulated for 3 hours with PMA, ionomycin and 
GolgiStop. Cells were stained with fluorescently-conjugated antibodies against extracellular 
markers and intracellular cytokines. In this sample gating, cells were first gated for lymphocytes 
(SSC-A vs FSC-A). The lymphocyte gate was further analysed for uptake of the Live/Dead 
eFluor780 stain to determine live vs. dead cells. Within live cells, a FSC-W/FSC-A gate was 























Figure 3.2 Assessing IL-17A+ and IL-17F+ CD4+ T cell frequencies following 
ex vivo stimulation. 
Healthy donor bulk CD4+ T cells were stimulated for 3 hours with PMA, ionomycin and GolgiStop 
and then assessed for intracellular IL-17A and IL-17F cytokine expression. To set the gates for 
positive cytokine expression, fluorescence minus controls were used. (A) Representative dot plots 
showing FM controls and the frequencies of IL-17A and IL-17F expressing cells within the total 
CD4+ T cell population in ex vivo-stimulated samples. (B) Cumulative data for the frequency of 



































































3.2.1.2 In vitro activated monocytes increase both IL-17A+ CD4+ T cell 
and IL-17F+ CD4+ T cell frequencies and IL-17A and IL-17F 
secretion 
Next, we examined factors which could induce IL-17F expressing CD4+ T cells 
and IL-17F secretion. I first expanded on previous work published by the lab which 
assessed the effect of LPS-activated monocytes on IL-17A induction 4, 22. Healthy 
CD4+ T cells were co-cultured with autologous CD14+ monocytes and stimulated 
with anti-CD3 mAb in the absence or presence of LPS for three days. After 
incubation, supernatants were collected and stored at -80°C before being tested by 
ELISA. The remaining cells were then re-stimulated and an intracellular cytokine 
stain (ICCS) was performed. CD4+ T cell cytokine expression was then analysed 
by flow cytometry. Figure 3.3 displays a representative gating strategy. Similar 
gating strategies were used for all other in vitro cultures. 
 
When compared to medium control conditions, addition of LPS to T cell/monocyte 
co-cultures led to a 1.6-fold increase in the frequency of IL-17A+ CD4+ T cells 
and a 3.2-fold increase in IL-17A secretion (Figure 3.4). This correlates with 
previous results from our lab 4. LPS stimulation also resulted in a 3.4-fold increase 
in IL-17F+ CD4+ T cell frequencies and a 1.8-fold increase in IL-17F secretion 
(Figure 3.4). Flow cytometric analysis showed the frequency of IL-17A+ CD4+ T 
cells was higher than IL-17F+ CD4+ T cells in both the control (approximately 
3.16 vs. 0.40%, respectively) and LPS conditions (approximately 5.05 vs. 1.34%). 
Flow cytometric analysis indicated all IL-17F+ CD4+ T cells highly co-expressed 
IL-17A. No single positive IL-17F+ CD4+ T cells were identified. Therefore, in 
this T cell/monocyte co-culture system we observed two distinct populations, IL-
17A+ IL-17F- CD4+ T cells and double positive IL-17A+ IL-17F+ CD4+ T cells. 
 
To assess the effect of addition of LPS to co-cultures on other cytokines, 
supernatants were analysed by luminex (Figure 3.5). We observed an increase in 
IL-1β, IL-6 and IFNγ protein levels in LPS treated conditions. Additionally, we 
observed an increase in IL-23 levels, however statistical significance was not 
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achieved. TNFα was detected in both the control and LPS conditions but levels 






Figure 3.3 Representative gating strategy for in vitro cultures. 
In this sample gating, 0.5 x 106 bulk CD4+ T cells were co-cultured with monocytes at a 1:1 ratio 
in the presence of anti-CD3 mAb (100ng/ml) and LPS (100ng/ml). After three days cells were 
stimulated with PMA/ionomycin and Golgi stop. Cells were stained with antibodies against 
extracellular markers and cytokines of interest. In this representative plot, cells were first gated for 
lymphocytes (SSC-A vs FSC-A).  A ‘dump’ gate was then applied, whereby the viability dye and 
CD14 antibody were on the same fluorchrome, allowing for the simultaneous exclusion of dead 
and CD14+ cells. Next, a FSC-W/FSC-A gate was applied allowing the exclusion of doublet CD4+ 





















Figure 3.4 LPS-activated monocytes induce an increase in IL-17A and IL-
17F expressing CD4+ T cell frequencies and corresponding cytokine 
secretion. 
Bulk CD4+ T cells (0.5x106) were co-cultured 1:1 with autologous monocytes and stimulated with 
anti-CD3 mAb (100ng/ml) in the absence (control) or presence (LPS) of LPS (100ng/ml). After 3 
days cells were re-stimulated and assessed for intracellular cytokine expression. (A) Representative 
dot plots and (B) cumulative data show frequencies of IL-17A (n=17) and IL-17F (n=17) within 
the total CD4+ T cell population. (C) Levels of IL-17A (n=7) and IL-17F (n=7) expressing cells 
detected in culture supernatant (collected prior re-stimulation) via ELISA. Upper blue and red 
dashed lines indicate the upper and lower detection limits, respectively. Data were analysed using 
matched-pairs signed rank test.
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Figure 3.5 Elevated levels of IL-1β, IL-6 and IFNγ are detected in CD4+ T 
cell / LPS-activated CD14+ monocyte co-cultures. 
Bulk CD4+ T cells were co-cultured 1:1 with autologous monocytes and stimulated with anti-CD3 
mAb (100ng/ml) in the absence (control) or presence (LPS) of LPS (100ng/ml). Supernatants were 
collected and IL-1β (n=9), IL-23 (n=9), IL-6 (n=9) and IFNγ (n=9) levels were detected by 
luminex. Upper blue and red dashed lines indicate the upper and lower detection limits, 
respectively. Data were analysed using matched-pairs signed rank test. 
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3.2.1.3 CD3 and CD28 stimulation in the presence of IL-1β and IL-23 
induces IL-17A and IL-17F CD4+ T cell frequencies and 
corresponding cytokine secretion 
IL-1β and IL-23 are well-characterised Th17 polarising cytokines, which have 
been previously described to induce IL-17F 7. Our LPS-activated monocyte/CD4+ 
T cell co-culture system, which induced IL-17F+ CD4+ T cells, also showed 
increased protein levels of IL-1β and IL-23 in comparison to control conditions. 
With this in mind, I investigated the role of IL-1β and IL-23 in inducing IL-17A 
and IL-17F. 
 
Bulk CD4+ T cells were cultured with soluble anti-CD28 mAb, replacing the co-
stimulation signal provided by the CD14+ monocytes, and plate-bound anti-CD3 
mAb. Cultures were set up in the absence or presence of the human recombinant 
cytokines, IL-1β (10ng/ml) and IL-23 (20ng/ml). Following 3 days incubation, cell 
culture supernatants were removed for ELISA analysis. Cells were then re-
stimulated and ICCS was performed analysing cytokine expression. Addition of 
IL-1β and IL-23 led to an increase in the frequency of IL-17A (1.7-fold) and IL-
17F (3.7-fold) expressing CD4+ T cells (Figure 3.6A & B). In this culture system, 
three distinct IL-17 populations were observed; IL-17A+ IL-17F-, IL-17A+ IL-
17F+ and IL-17F+ IL-17A- CD4+ T cells. In line with this, ELISA analysis 
showed an increase in IL-17A and IL-17F protein present in IL-1β and IL-23 
stimulated conditions (Figure 3.6C). However, in three out of the six samples, IL-
17A was below the detection limit. Therefore, for a more accurate analysis these 









Figure 3.6 IL-1β and IL-23 enhance the frequency of IL-17A+ and IL-17F+ 
CD4+ T cells. 
Bulk CD4+ T cells were cultured with platebound anti-CD3 mAb (1.25μg/ml) and soluble anti-
CD28 mAb either in the absence or presence of IL-1β (10ng/ml) and IL-23 (20ng/ml) for 3 days. 
Cells were re-stimulated and assessed for intracellular cytokine expression. (A) Representative dot 
plots and (B) cumulative data show frequencies of IL-17A (n=9) and IL-17F (n=9) expressing cells 
within the total CD4+ T cell population. (C) Levels of IL-17A (n=6) and IL-17F (n=6) detected in 
culture supernatant (prior re-stimulation) via ELISA. Red dashed lines indicate the lower detection 
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3.2.1.4 Assessing the correlation between flow cytometry cytokine 
expression and protein levels 
PMA together with ionomycin is one of the most widely applied methods for 
activation of T cells. However, as PMA and ionomycin stimulation is very strong, 
researchers question whether it truly reflects what is happening physiologically in 
the cell. In our CD4+ T cell/monocyte co-cultures and CD4+ T cell only cultures, 
supernatant was collected prior to PMA and ionomycin stimulation and cells were 
then stimulated with PMA and ionomycin for flow cytometry analysis. To 
investigate whether cells still reflect the physiological events after a PMA and 
ionomycin stimulation, IL-17A+ or IL-17F+ CD4+ T cell frequencies (measured 
post PMA/iono re-stimulation) in each culture system were correlated with the 
secretion of IL-17A and IL-17F in the culture supernatant (measured prior to 
PMA/ionomycin re-stimulation). 
 
As shown in Figure 3.7, in all culture conditions, a positive correlation was 
observed between the percentage of IL-17A+ CD4+ T cells and the secretion of 
IL-17A as well as between the percentage of IL-17F+ CD4+ T cells and IL-17F 
secretion (Figure 3.7). These results indicate that cells still display their 






Figure 3.7 Correlation analysis of intracellular flow cytometry staining vs. 
ELISA. 
(A) 0.5 x 106 of bulk CD4+ T cells were cultured with anti-CD3 mAb and 0.5 x 106  monocytes in 
the absence (-LPS) or presence (+LPS) of LPS for three days. (B) Bulk CD4+ T cells were cultured 
with platebound anti-CD3 mAb (1.25μg/ml) and soluble anti-CD28 either in the absence or 
presence of IL-1β (10ng/ml) and IL-23 (20ng/ml) for 3 days. In both experiments, culture 
supernatant was analysed by ELISA and cells were re-stimulated and analysed by ICCS and flow 
cytometry. Results show the percentage of IL-17A+ cells plotted against the concentration of IL-
17A (pg/ml) and the frequency of IL-17F+ cells plotted against the concentration of IL-17F 
(pg/ml). Upper blue and red dashed lines indicate the upper and lower ELISA detection limits, 
respectively. Statistical analysis was performed using Spearman’s correlation coefficients for 
nonparametric data. 
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3.2.1.5 IL-17AF heterodimer expressing CD4+ T cell frequencies and IL-
17AF secretion are enhanced in IL-1β/IL-23 stimulated cultures 
As discussed in the introduction, in addition to the IL-17A and IL-17F homodimer, 
an IL-17AF heterodimer exists. I sought to determine whether the IL-17AF 
heterodimer was present in the CD4+ T cell -/+ IL-1β/ IL-23 culture. 
Manufacturers describe both IL-17A and IL-17F flow cytometry antibodies used 
in this project to have cross-reactivity towards the IL-17AF heterodimer. 
However, the IL-17AF heterodimer flow cytometry antibody used here has no 
reported cross-reactivity for either the IL-17A or IL-17F homodimer. Preliminary 
experiments (data not shown) showed that the IL-17AF heterodimer flow 
cytometry antibody can be simultaneously used with the IL-17A and IL-17F 
homodimer antibodies with no effect on cytokine detection. 
 
As shown in Figure 3.8, flow cytometry analysis revealed IL-17AF expressing 
CD4+ T cells to be present in the control conditions and further enhanced in the 
presence of IL-1β and IL-23 (2.9-fold) (Figure 3.8A & B). In accordance, using 
an ELISA specific for the IL-17AF heterodimer only, IL-17AF protein was 
detected at elevated levels in IL-1β and IL-23 cultures vs. control conditions 
(Figure 3.8C). 
 
Taking into account the reported cross-reactivity of both IL-17A and IL-17F flow 
cytometry antibodies for the IL-17AF heterodimer, it was assumed any IL-17AF 
CD4+ T cells would be detected within the IL-17A+ IL-17F+ double positive 
CD4+ T cell population. With this in mind, I wanted to assess how many IL-17A+ 
IL-17F+ CD4+ T cells co-expressed the IL-17AF heterodimer. As shown in Figure 
3.8 D & E, the majority of IL-17A+ IL-17F+ CD4+ T cells co-expressed the IL-
17AF heterodimer (approximately 89%). We hypothesise that this population 
produces both the IL-17A and IL-17F homodimers and the IL-17AF heterodimer. 
IL-17AF was not detected in IL-17A- IL-17F- and IL-17A+ IL-17F- CD4+ T cell 
populations. Unexpectedly, IL-17F+ IL-17A- CD4+ T cells were shown to co-
express levels of IL-17AF (approximately 20%). This is unexpected as IL-17AF+ 
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cells should also be detected by the IL-17A flow cytometry antibody. This may be 





Figure 3.8 IL-17AF expressing CD4+ T cells are enhanced by IL-1β and IL-
23. 
Bulk CD4+ T cells were cultured with platebound anti-CD3 mAb (1.25μg/ml) and soluble anti-
CD28 either in the absence or presence of IL-1β (10ng/ml) and IL-23 (20ng/ml) for 3 days. 
Supernatants were collected for IL-17AF protein analysis by ELISA and cells were re-stimulated 
and assessed for intracellular cytokine expression. (A) Representative dot plots showing the 
frequencies of IL-17AF+ cells within total CD4+ T cells (n=5) (B) cumulative ICCS data (n=5). 
(C) Levels of IL-17AF detected in culture supernatant (prior re-stimulation) via ELISA (n=6). Red 
dashed lines indicate the lower detection limit. (D) Representative gating strategy analysing 
percentage of IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells co-
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3.2.1.6 CD28 co-stimulation promotes the frequency of IL-17F expressing 
CD4+ T cells 
Reports have shown that a strong CD28 co-stimulation signal down regulates IL-
17A+ CD4+ T cell frequency 6. I was interested to explore the effect of CD28 co-
stimulation on the frequency of IL-17F expressing CD4+ T cells. To investigate 
this, bulk CD4+ T cells from healthy donors were cultured with plate-bound anti-
CD3 mAb in the absence or presence of anti-CD28 mAb for 3 days. At first, this 
was performed in the absence of IL-1β and IL-23. As displayed in Figure 3.9A, 
addition of anti-CD28 did not lead to a significant change in the frequency of total 
IL-17A+ CD4+ T cell frequencies. Although a small increase in total IL-17F+ 
CD4+ T cell frequencies was observed, proportions were very small. Addition of 
IL-1β and IL-23 (Figure 3.9B) led to higher detectable levels of IL-17A+ and IL-
17F+ CD4+ T cell frequencies. In the presence of IL-1β and IL-23, addition of 
anti-CD28 mAb showed no effect on the frequency of total IL-17A+ CD4+ T cell 
frequencies. In contrast, addition of anti-CD28 mAb led to a significant increase 
in the percentage of total IL-17F expressing CD4+ T cells. When examining the 
distinct subsets, it was observed that CD28 co-stimulation signal down-regulates 
the frequency of IL-17A+ IL-17F- CD4+ T cells, while enhancing the frequency 
of IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells (3.9B, right panel). 
 
To further investigate the effect of CD28 co-stimulation bulk CD4+ T cells were 
cultured with platebound anti-CD3 mAb, IL-1β and IL-23 in the presence of 
increasing doses of soluble anti-CD28 mAb (0-2μg/ml) for 3 days. Following re-
stimulation with PMA and ionomycin, cells were assessed for IL-17A and IL-17F 
cytokine expression. In line with our previous results, titration of anti-CD28 mAb 
led to a dose-dependent decrease in the percentage of IL-17A+ IL-17F- CD4+ T 
cells, whilst increasing IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cell 
frequencies (Figure 3.10 A & B). Culture supernatants, taken prior to PMA and 
ionomycin re-stimulation, were analysed by ELISA (Figure 3.10 C). As expected, 
titration of anti-CD28 led to a dose-dependent increase in IL-17F homodimer and 
IL-17AF heterodimer protein secretion. Based on our flow cytometry data, we 
predicted IL-17A homodimer protein secretion would have remained unchanged 
with the addition of anti-CD28. However, it unexpectedly led to a dose-dependent 
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increase in IL-17A homodimer secretion. Although different ELISA antibody 
affinities make it difficult to draw comparisons between levels of different 
cytokines, we did detect significantly higher levels of IL-17F vs. IL-17A and IL-
17AF.  
 
It was speculated that the increase in IL-17A protein secretion in response to the 
presence of anti-CD28 was due to the kinetics of the assay. To address this, bulk 
CD4+ T cells were cultured with platebound anti-CD3 mAb, IL-1β and IL-23 in 
the presence or absence of anti-CD28 mAb for 1, 2, 3 or 4 days. After the selected 
time points, cells were re-stimulated and assessed for IL-17A and IL-17F cytokine 
expression (Figure 3.11). We observed that there were higher percentages of total 
IL-17A+ and IL-17F+ CD4+ T cells in both control and anti-CD28 conditions at 
day 4 vs. day 1.  At day 1, there was no difference in the frequency of IL-17A+ 
CD4+ T cells between anti-CD28 mAb treated and untreated conditions. However, 
at day 2, conditions stimulated with anti-CD28 mAb displayed a higher percentage 
of IL-17A expressing CD4+ T cells.  In agreement with our previous day 3 data, 
there was no difference in frequencies of IL-17A+ cells in the absence or presence 
of anti-CD28 mAb. The frequency of IL-17A+ CD4+ T cells was decreased in the 
presence of anti-CD28 mAb at day 4. Based on this result, we propose that the 
increase in IL-17A protein secretion identified at day 3 was an accumulation of 
anti-CD28 mAb driven IL-17A observed by flow cytometry at day 2. 
 
Throughout the time course, frequencies of IL-17F+ CD4+ T cells remained 





Figure 3.9 CD28 co-stimulation enhances IL-17F expression by CD4+ T 
cells. 
 (A) Bulk CD4+ T cells were cultured with platebound anti-CD3 mAb either in the absence or 
presence of soluble anti-CD28 mAb for 3 days (n=4). (B) Bulk CD4+ T cells were cultured with 
platebound anti-CD3 mAb, soluble anti-CD28 either in the absence or presence of IL-1β and IL-
23 for 3 days (n=9). In both experiments, cells were re-stimulated and assessed for IL-17A and IL-
17F cytokine expression. Results show the cumulative frequencies of total IL-17A+ and IL-17F+ 
CD4+ T cells and IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F- IL-17A+ CD4+ T cell 
populations. Data were analysed using matched-pairs signed rank test. P values are represented as 
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Figure 3.10 CD28 co-stimulation increases IL-17F+ CD4+ T cell frequencies 
in a dose-dependent manner. 
Bulk CD4+ T cells (0.2x106 ) were cultured with platebound anti-CD3 mAb, IL-1β and IL-23 in 
the presence of increasing doses of soluble anti-CD28 mAb (0-2μg/ml). After 3 days cells were re-
stimulated and assessed for intracellular cytokine expression. (A) Representative dot plots show 
the percentages of IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- cells within total 
CD4+ T cells and (B) box-whisker plots represent data from n=6 individual donors. Prior to re-
stimulation cell culture supernatants were collected and analysed for IL-17A, IL-17F and IL-17AF 
protein via ELISA, (C) displays cumulative ELISA data (n=6). Upper blue and red dashed lines 
indicate the upper and lower ELISA detection limits, respectively. Statistical analysis was 
performed using Friedman test with comparison to control (0μg/ml) by Dunn’s Multiple 


































































































































































1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
























5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
























1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0

























Figure 3.11 Assessing the kinetic effect of CD28 co-stimulation on protein 
expression. 
Bulk CD4+ T cells (1x106) were cultured with platebound anti-CD3 mAb, IL-1β and IL-23 in the 
absence or presence of anti-CD28 mAb for 1, 2, 3 or 4 days. Cells were re-stimulated and assessed 
for intracellular cytokine expression. Results show the frequencies of total IL-17A+ and IL-17F+ 
cells within total CD4+ T cells (n=3 mean ± SEM). 
 
 




















































3.2.1.7 Investigating the effect of CD3 stimulation on IL-17A and IL-17F 
expression 
Next, the effect of CD3 stimulation on the frequency of IL-17A and IL-17F 
expressing CD4+ T cells was assessed. Titration of plate-bound anti-CD3 mAb in 
3 day cultures with IL-1β, IL-23 and anti-CD28 mAb increased the frequency of 
IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells in a dose-dependent manner 
(Figure 3.12A &B). In the case of IL-17A+ IL-17F- CD4+ T cells, while there was 
an initial increase in the frequency of cells upon the addition of anti-CD3 mAb 
(0.039μg/ml), increasing the anti-CD3 concentration had no further effect on the 
population frequency.  
Following the 3 day culture, supernatants were collected and analysed for IL-17A 
and IL-17F homodimer and IL-17AF heterodimer protein levels. As depicted in 
Figure 3.12C, titration of anti-CD3 mAb led to a dose-dependent increase in IL-
17A, IL-17F and IL-17AF. 
Similar to our CD28 co-stimulation data, further investigation is required to fully 
understand the effect of CD3 mAb stimulation on IL-17A. However, our data 
clearly show increased concentrations of anti-CD3 mAb lead to both enhanced 
frequencies of IL-17F expressing CD4+ T cells and IL-17F protein secretion. 
Taken together with our CD28 co-stimulation data we postulate that strong T cell 




Figure 3.12 Increasing doses of anti-CD3 mAb leads to an increase in IL-17F+ 
CD4+ T cells and IL-17F secretion. 
Bulk CD4+ T cells (0.2 x106)  were cultured with soluble anti-CD28 mAb, IL-1β and IL-23 and in 
the presence of increasing doses of platebound anti-CD3 mAb (0-5μg/ml). After 3 days cells were 
re-stimulated and assessed for intracellular cytokine expression. (A) Representative dot plots show 
the percentages of IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- cells within total 
CD4+ T cells and (B) box-whisker plots represent data from n=5 individual donors. (B) Levels of 
IL-17A (n=3), IL-17F (n=4) and IL-17AF (n=4) detected in culture supernatant (prior re-
stimulation) via ELISA.  
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3.2.1.8 Investigating the role of IL-2 in regulating IL-17A and IL-17F 
expression 
CD28 signalling is reported to enhance cytokine production from CD4+ T cells, 
including IL-2 and IFNγ 8. Moreover, it has been shown that neutralisation of IL-
2 and IFNγ leads to increased IL-17A production from CD4+ T cells 6. Although 
a decrease in total IL-17A+ CD4+ T cells with increased CD28 co-stimulation was 
not observed, it was of interest to examine the effect of IL-2 and IFNγ on IL-17A 
and IL-17F CD4+ T cell frequencies. We hypothesised that the CD28-driven 
enhancement of IL-17F+ CD4+ T cell frequency is mediated by IL-2 and/ or IFNγ. 
To begin, protein levels of IL-2 and IFNγ in cultures of stimulated CD4+ T cells 
with increasing doses of anti-CD28 and anti-CD3 mAb were assessed. As depicted 
in Figure 3.13A, titration of anti-CD28 and anti-CD3 led to a dose-dependent 
increase in IL-2 supernatant protein levels. Similar results were observed for IFNγ 
supernatant protein levels, Figure 3.13 B. 
 
In the next experiments, I focused on the role of IL-2 and IFNγ in the CD28-
mediated IL-17F response. IL-2 and IFNγ were blocked in CD4+ T cultures 
stimulated with anti-CD28 mAb, anti-CD3 mAb, IL-1β and IL-23. Prior to this, 
optimal blocking antibody concentrations and the effect of isotype controls were 
assessed (Figure 3.14). Results showed 1μg/ml of both anti-IL-2 mAb and IFNγ 
mAb resulted in efficient blockade of IL-2 and IFNγ, respectively. Furthermore, 
addition of an isotype control for anti-IL-2 mAb (goat IgG1) and anti-IFNγ mAb 
(mouse IgG1) did not consistently affect the percentage of CD4+ T cells 
expressing IL-17A or IL-17F.  
 
No significant changes in total IL-17A+ CD4+ T cell frequencies were observed 
in the absence or presence of anti-CD28 mAb or in cultures supplemented with 
anti-CD28 mAb and IL-2 blocking antibody (Figure 3.15 A & B). However, while 
addition of anti-CD28 mAb promoted total IL-17F+ CD4+ T cell frequency 
(approximately 1% vs. 1.7% in the absence vs. presence of anti-CD28 mAb), this 
effect was abrogated by blockade of IL-2 (approximately 1%). Similarly, blockade 
of IL-2 suppressed the anti-CD28 mAb mediated inhibition of IL-17A+ IL-17F- 
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CD4+ T cells and the anti-CD28 mAb mediated promotion of IL-17F+ IL-17A- 
and in part IL-17A+ IL-17F+ expressing CD4+ T cells. These data suggest that 
the anti-CD28 mAb driven increase in IL-17F is mediated by IL-2. 
 
As depicted in Figure 3.16 A & B, addition of anti-IFNγ mAb blocking antibody 
in conditions supplemented with IL-1β, IL-23, anti-CD28 mAb and anti-CD3 mAb 
did not significantly alter the frequency of total IL-17A expressing CD4+ T cells. 
Furthermore, in comparison to anti-CD28 mAb alone, a combination of anti-CD28 
mAb and anti-IFNγ mAb only resulted in a slight reduction in IL-17F expressing 
CD4+ T cells (1.73 vs 1.4%, respectively). Further flow cytometric analysis 
revealed that addition of anti-IFNγ mAb suppressed the anti-CD28 mediated 
inhibition of IL-17A+ IL-17F- CD4+ T cells (Figure 3.16 C). Additionally, to 
some extent IFNγ blockade reduced the anti-CD28 mAb mediated enhancement 
of IL-17F+ IL-17A- CD4+ T cells. These data suggest IFNγ may play a role in 
skewing IL-17A/ IL-17F sub-populations. As shown in Figure 3.17, a combined 
blockade of IL-2 and IFNγ had no further effect on IL-17A and IL-17F CD4+ T 






Figure 3.13 Titration of anti-CD28 and anti-CD3 mAb leads to a dose-
dependent increase in IL-2 and IFNγ secretion. 
Bulk CD4+ T cells (0.2x106) were cultured with (A) platebound anti-CD3 mAb, IL-1β and IL-23 
in the presence of increasing doses of soluble anti-CD28 mAb (0-2μg/ml). After 3 days culture 
supernatant was removed and measured for IL-2 (n=3) and IFNγ (n=3). (B) 0.2x106 bulk CD4+ T 
cells were cultured with soluble anti-CD28 mAb, IL-1β and IL-23 in the presence of increasing 
doses of platebound anti-CD3 mAb (0-5μg/ml). After 3 days culture supernatant was removed and 
measured for IL-2 (n=3) and IFNγ (n=1). Upper blue and red dashed lines indicate the upper and 
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Figure 3.14 Isotype controls do not affect IL-17A+ or IL-17F+ CD4+ T cell 
frequencies. 
Bulk CD4+ T cells were cultured with anti-CD3 mAb, IL-23 and IL-1β in the absence or presence 
of anti-CD28 mAb. In the presence of anti-CD28 mAb, (A) 1 or 5μg/ml of anti-IL-2 blocking 
antibody or (B) 1 or 5μg/ml of anti-IFNγ blocking antibody was added. Following a 3 day 
incubation, supernatants were collected and IL-2 (n=2) or IFNγ (n=1) protein levels were analysed 
by ELISA. Bulk CD4+ T cells were cultured with anti-CD3 mAb, IL-23 and IL-1β in the absence 
(control) or presence of  (C) IL-2 blocking antibody isotype (goat IgG1, 1μg/ml) or (D) IFNγ 
blocking antibody isotype, (mouse IgG1, 1μg/ml). After 3 days cells were re-stimulated and 
assessed for intracellular cytokine expression. Cumulative data shows the frequencies of total IL-
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Figure 3.15 IL-2 blockade reduces IL-17F+ CD4+ T cell expression. 
Bulk CD4+ T cells were cultured with anti-CD3 mAb, IL-23 and IL-1β in the absence or presence 
of anti-CD28 mAb and anti-IL-2 mAb (1μg/ml). After 3 days cells were re-stimulated and assessed 
for intracellular cytokine expression. (A) Representative dot plots and cumulative data showing 
the frequencies of (B) total IL-17A+ and IL-17F+ CD4+ T cells (n=6) and (C) IL-17A+ IL-17F-, 
IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells (n=6). Statistical analysis was performed 
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Figure 3.16 Exploring the effect of IFNγ blockade on IL-17A and IL-17F 
expressing CD4+ T cells. 
Bulk CD4+ T cells were cultured with anti-CD3 mAb, IL-23 and IL-1β in the absence or presence 
of anti-CD28 mAb and anti-IFNγ mAb (1μg/ml). After 3 days cells were re-stimulated and assessed 
for intracellular cytokine expression. (A) Representative dot plots and cumulative data showing 
the frequencies of (B) total IL-17A+ and IL-17F+ CD4+ T cells (n=6) and (C) IL-17A+ IL-17F-, 
IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells (n=6). Statistical analysis was performed 
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Figure 3.17 Dual blockade of IL-2 and IFNγ has no further effect on IL-17A 
and IL-17F CD4+ T expressing cells than IL-2 blockade alone. 
Bulk CD4+ T cells were cultured with anti-CD3 mAb, IL-23 and IL-1β in the absence or presence 
of anti-CD28 mAb, anti-IL-2 mAb (1μg/ml) and anti-IFNγ mAb (1μg/ml). After 3 days cells were 
re-stimulated and assessed for intracellular cytokine expression. Cumulative data show the 
frequencies of IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells (n=6). 
Statistical analysis was performed using Friedman test with comparison to control (+ anti-CD28 
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3.2.1.9 PMA and ionomycin re-stimulation does not affect the frequency of 
total IL-17F+ CD4+ T cells 
Unpublished data from UCB suggests that PMA and ionomycin re-stimulation 
may affect IL-17A+ and IL-17F+ CD4+ T cell frequencies differently. I sought to 
investigate the effect of PMA and ionomycin on IL-17A and IL-17F expressing 
cells in our culture system. 
 
CD4+ T cells were cultured for 3 days with anti-CD28, anti-CD3, IL-1β and IL-
23. Cells were then re-stimulated for 3 hours with golgi stop in the absence or 
presence of PMA and ionomycin. Cells were stained and intracellular cytokine 
expression was assessed. Firstly, as depicted in Figure 3.18, the data revealed that 
in this culture system, IL-17A and IL-17F can be detected at significant 
frequencies without the addition of PMA and ionomycin. Addition of PMA and 
ionomycin enhanced the percentage of IL-17A+ CD4+ T cells (2.2-fold). 
However, the frequency of total IL-17F+ CD4+ T cells remained unchanged. 
Furthermore, whilst PMA and ionomycin increased IL-17A+ IL-17F- and IL-
17A+ IL-17F+ CD4+ T cell frequencies, it led to a small reduction in IL-17F+ IL-
17A- CD4+ expressing CD4+ T cells. These data further indicate that there are 




Figure 3.18 Re-stimulation with PMA and ionomycin has no effect on the 
frequency of IL-17F expressing CD4+ T cells. 
 Isolated CD4+ T cells were cultured with anti-CD3 mAb, αCD28 mAb, IL-23 and IL-1β. After 3 
days, cells were re-stimulated with golgi stop either in the presence or absence of PMA and 
ionomycin. Cells were stained and intracellular cytokine expression was assessed. (A) 
Representative dot plots and (B) cumulative data show frequencies of IL-17A (n=6) and IL-17F 
(n=4) within the total CD4+ T cell population. (C) Results show the cumulative frequencies of IL-
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3.2.2 Phenotypic characterisation of IL-17F+ expressing 
CD4+ T cells 
A lack in current literature of the phenotypic characterization of IL-17F+ CD4+ T 
cells and their comparison with IL-17A+ CD4+ T cells provided us with the 
rationale to perform these experiments. The second part of this chapter investigates 
the marker expression and cytokine profile of IL-17A+ IL-17F-, IL-17A+ IL-
17F+, IL-17F- IL-17A- CD4+ T cells.  
 
3.2.2.1 CCR6 and CD161 marker expression on IL-17A+ and IL-17F+ 
CD4+ T cells 
IL-17A+ CD4+ T cells have previously been reported to be CD45RO+ memory 
cells 4. By performing an extracellular CD45RO stain on CD4+ T cells cultured 
with IL-1β and IL-23, it was observed that all IL-17 populations, IL-17A+ IL-17F-
, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells were CD45RO+ memory 
cells (n=2, data not shown).  To further charaterise IL-17F+ CD4+ T cells and 
draw comparisons with IL-17A+ CD4+ T cells, their surface marker expression 
was analysed, including the Th17 associated markers CCR6 and CD161. 
 
Experiments showed that a three day in vitro culture and PMA and ionomycin re-
stimulation down-regulates CD161 and CCR6 CD4+ T cell surface marker 
expression (data not shown, n=2). As a three day culture with IL-1β and IL-23 is 
necessary to induce IL-17F+ CD4+ T cell populations, CD161 and CCR6 marker 
expression was analysed following a 3 day culture without a PMA and ionomycin 
re-stimulation. As illustrated in Figure 3.19, in two out of four donors, IL-17A+ 
IL-17F- CD4+ T cells displayed a higher expression level of CD161 in comparison 
to levels observed on IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells. 
However, in the remaining two donors, expression levels of CD161 were only 
slightly higher than observed with IL-17A- IL-17F- CD4+ T cells. Similarly, the 
expression levels of CD161 was not enriched on IL-17A+ IL-17F+ and IL-17F+ 
IL-17A- CD4+ T cells when compared with IL-17A- IL-17F- CD4+ T cells. 
Expression levels of CCR6 were enriched on all IL-17 producing CD4+ T cells 
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and few variations were observed between the IL-17A+ IL-17F-, IL-17A+ IL-





Figure 3.19 Expression of CCR6 and CD161 on IL-17A and IL-17F CD4+ T 
cells. 
Bulk CD4+ T cells were incubated with golgistop either in the presence of PMA and ionomycin at 
day 0 or day 3 following culture with anti-CD3 mAb, αCD28 mAb, IL-23 and IL-1β. Cells were 
assessed for intracellular cytokine expression. (A) Representative dot plots showing the percentage 
of CD161+ and CCR6+ cells within total CD4+ T cells. (B) Gating within IL-17A+ IL-17F-, IL-
17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells the co-expression of CD161 (n=4) and CCR6 












































































3.2.2.2 IL-17A and IL-17F expressing CD4+ T cells display different 
cytokine profiles 
The next aim was to compare the cytokine profiles of IL-17A and IL-17F CD4+ 
T cell populations. An initial experiment included performing mass cytometry 
(CyTOF) to provide a broad overview of the co-expression of cytokines in IL-17A 
and IL-17F CD4+ T cell populations. These data are displayed and discussed in 
Appendix 7.1. 
 
The co-expression of IFNγ, TNFα, GM-CSF and IL-10 was assessed by flow 
cytometry in IL-17A and IL-17F populations induced in bulk CD4+ T cell cultures 
stimulated for 3 days with IL-1β and IL-23. Co-expression analysis was only 
performed when there were over three hundred events in the IL-17 population. IL-
17A+ IL-17F- and IL-17A+ IL-17F+ CD4+ T cells displayed similar high co-
expression levels of TNFα, while IL-17F+ IL-17A- CD4+ T cells exhibited 
slightly lower co-expression levels of TNFα (Figure 3.20). Moreover, co-
expression levels of IFNγ were significantly higher in IL-17A+ IL-17F+ and IL-
17F+ IL-17A- vs. IL-17A+ IL-17F- CD4+ T cells. However, IL-17A+ IL-17F- 
CD4+ T cells displayed the highest percentage of cells co-expressing GM-CSF vs. 
IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells. Interestingly, IL-17A+ IL-
17F+ and IL-17F+ IL-17A- CD4+ T cells exhibited lower co-expression levels of 
IL-10 when compared with IL-17A+ IL-17F+ CD4+ T cells.  
 
Our next aim was to investigate the cytokine profile of IL-17A and IL-17F CD4+ 
T cell populations in a different culture system. Therefore, the co-expression of 
pro-inflammatory cytokines IFNγ, TNFα, GM-CSF and IL-10 were assessed in 
IL-17A+ IL-17F- and IL-17A+ IL-17F+ CD4+ T cells from LPS-activated 
monocyte/ CD4+ T cell co-cultures. It is important to note, in this culture system, 
only two IL-17 populations are present – IL-17A+ IL-17F- and IL-17A+ IL-17F+ 
CD4+ T cells. Flow cytometry showed that similar percentages of IL-17A+IL-
17F- and IL-17A+IL-17F+ cells co-expressed TNFα (78±4% vs. 75±5%, 
respectively), IFNγ (25±4% vs. 30±2%) and GM-CSF (39±6% vs. 40±5%). 
However, similar to the IL-1β and IL-23 CD4+ T cell cultures, IL-10 co-
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expression was significantly reduced in IL-17A+IL-17F+ vs. IL-17A+IL-17F- 
CD4+ T-cells (1±0.2% vs. 3±0.6%) (Figure 3.21). 
 
Our lab has previously demonstrated that TNF inhibitor (TNFi) stimulate a 
significant proportion of IL-17A+ CD4+ T cells to co-express IL-10 9. Therefore, 
it was of interest to investigate the effect of anti-TNF drugs on the frequency of 
IL-17A+ IL-17F+ CD4+ T cells and if this population was resistant to a TNFi-
mediated increase in IL-10. Using the same published culture conditions, CD4+ T 
cells were cultured with CD14+ monocytes, anti-CD3 mAb in the absence or 
presence of anti-TNF drug, adalimumab (ADA). Flow cytometric analysis 
indicated that in comparison to medium controls, co-cultures treated with ADA 
displayed increased frequencies of IL-10+ cells in both IL-17A+ IL-17F-  (4 vs. 
18 %, respectively) and IL-17A+ IL-17F+ CD4+ T cells (2 vs. 16 %, respectively) 
(Figure 3.22). It is important to highlight in 2 independent experiments, treatment 
with ADA did not induce a sufficient amount of IL-17A+IL-17F+ CD4+ T cells 
for co-expression analysis (< 300 cells). No difference in IFNγ co-expression was 
observed between control vs. ADA conditions in IL-17A+ IL-17F and IL-17A+ 






Figure 3.20 IL-17A and IL-17F expressing CD4+ T cells display different 
cytokine profiles. 
Bulk CD4+ T cells were cultured with anti-CD3 mAb, αCD28 mAb, IL-23 and IL-1β. After 3 
days, cells were re-stimulated and assessed for intracellular cytokine expression. (A) 
Representative dot plot of IL-17A and IL-17F CD4+ T cell populations. Following gating within 
IL-17A- IL-17F-, IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells, the 
co-expression of other cytokines was analysed.  (B) Results show cumulative data for the co-
expression of TNFα (n=6), IFNγ (n=8), GM-CSF (n=5) and IL-10 (n=6). Data were analysed 
using Friedman test with Dunn’s Multiple Comparisons test. P values are represented as follows: 
* P <0.05, ** P <0.01. 



















































































































































Figure 3.21 IL-17A+ IL-17F+ CD4+ T cells display a lower co-expression of 
IL-10 in comparison to IL-17A+ IL-17F- CD4+ T cells. 
Bulk CD4+ T cells were co-cultured 1:1 with autologous monocytes and stimulated with anti-CD3 
mAb (100ng/ml) and LPS (100ng/ml). After 3 days cells were re-stimulated and assessed for 
intracellular cytokine expression. Gating within IL-17A+ IL-17F- and IL-17A+ IL-17F+ CD4+ T 
cells the co-expression of other cytokines was analysed. (A) Representative dot plots and (B) 
cumulative data showing the percentage of IL-17A+ IL-17F- and IL-17A+ IL-17F+ CD4+ T cells 
which co-express TNFα (n=4), IFNγ (n=8), GM-CSF (n=4) and IL-10 (n=8).  Data were analysed 
using the Wilcoxon matched-pairs signed rank test. 
 
 













































































































































Figure 3.22 Anti-TNF treatment increases co-expression of IL-10 in IL-17A+ 
IL-17F- and IL-17A+ IL-17F+ CD4+ T cells. 
Bulk CD4+ T cells were co-cultured 1:1 with autologous monocytes and stimulated with anti-
CD3 mAb (100ng/ml) and anti-TNF (ADA) (1µg/ml). After 3 days cells were re-stimulated and 
assessed for intracellular cytokine expression. (A) Cumulative data showing the percentage of 
total IL-17A and IL-17F cells within total CD4+ T cells. Gating within IL-17A+ IL-17F-, IL-
17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells the co-expression of IL-10 and IFNγ was 
analysed. (B) Representative dot plots and (C) cumulative data for IL-10 and IFNγ in IL-17A+ 









































































Data presented in this chapter confirms that IL-1β and IL-23 are important for driving 
IL-17F expression. Expanding upon this, the data demonstrate for the first time that in 
the presence of IL-1β and IL-23, titration of anti-CD28 mAb in CD4+ T cell cultures 
leads to an increase in IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells, while 
frequencies of IL-17A+ IL-17F- CD4+ T cells are reduced. This anti-CD28 mAb 
effect was shown to be mediated by IL-2. Novel data demonstrate that IL-17A and IL-
17F CD4+ T cells display different cytokine profiles. Most interestingly, IL-17A+ IL-
17F+ and IL-17F+ IL-17A- CD4+ T cells display a significantly lower IL-10 co-
expression level and significantly higher IFNγ co-expression levels when compared 
to IL-17A+ IL-17F- CD4+ T cells. Overall, the data presented in this chapter suggest 
IL-17A and IL-17F may be differentially regulated and IL-17A+ and IL-17F+ CD4+ 
T cells may have distinct functional differences. 
 
As discussed in the introduction, our lab has shown that LPS-activated monocytes can 
enhance the frequency of IL-17A+ CD4+ T cells 192.  Additionally, studies have shown 
IL-1β can drive human IL-17A+ CD4+ T cell differentiation, whilst IL-23 is important 
for lineage maintenance. IL-17F is often described to be co-expressed with IL-17A, 
however, limited studies investigating the induction of IL-17A include IL-17F. One 
study from Wilson et al. demonstrated that IL-1β and IL-23 drives the expression of 
IL-17F from human CD4+ T cells 193. Data presented in this chapter expand upon the 
work of the lab and that of Wilson et al. and show that addition of LPS to CD4+ T 
cell/ CD14+ monocyte co-cultures leads to an increase in the percentage of both IL-
17A+ and IL-17F+ CD4+ T cells and an increase in IL-17A and IL-17F secretion. 
Moreover, two IL-17 populations were observed, IL-17A+ IL-17F- and IL-17A+ IL-
17F+ CD4+ T cells. Luminex analysis of the co-culture supernatant revealed increased 
protein levels of IL-1β, IL-23, IL-6 and IFNγ in LPS-treated conditions vs. controls. 
In this study, the importance of IL-1β and IL-23 in inducing IL-17F was further 
investigated by moving to a different culture system whereby human recombinant IL-
1β and IL-23 cytokines were added. Future research to expand on how LPS-activated 
monocytes induce IL-17F could include blockade of IL-1β, IL-23 and other cytokines 
in the LPS culture system. Moreover, the expression of co-stimulation markers (for 
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example CD80) could be analysed, as it may be possible LPS drives the up-regulation 
of these markers and henceforth T cell activation and IL-17 production. 
 
Addition of IL-1β and IL-23 human recombinant cytokines to CD4+ T cell stimulated 
with anti-CD28 mAb and anti-CD3 mAb significantly enhanced the frequency of IL-
17A+ and IL-17F+ CD4+ T cell and IL-17A and IL-17F secretion. This confirms that 
IL-1β and IL-23 are important drivers in both IL-17A and IL-17F expression from 
CD4+ T cells. Interestingly, in this culture system three IL-17 populations are 
observed IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells. 
An IL-17F+ IL-17A- CD4+ T cell population was not present in the CD4+ T cell/ 
CD14+ monocyte co-culture. It is possible the anti-CD28 mAb elicited a stronger co-
stimulation signal than the LPS-activated monocytes which drove the induction of IL-
17F+ IL-17A- CD4+ T cells. Another explanation could be that the higher 
concentrations of IL-1β and IL-23 induced IL-17F+ IL-17A- CD4+ T cells. The results 
presented also demonstrate that addition of IL-1β and IL-23 recombinant cytokines to 
CD4+ T cell cultures leads to an increase in IL-17AF+ CD4+ T cell frequencies and 
IL-17AF protein secretion. Preliminary CyTOF results indicate the IL-17AF 
heterodimer is highly expressed by the IL-17A+ IL-17F+ CD4+ T cell population 
(Appendix 7.1). It is hypothesized that the IL-17A+ IL-17F+ CD4+ T cells produce 
IL-17A, IL-17F and IL-17AF, although the lack of an IL-17A homodimer specific 
antibody prevents this being confirmed. In this study we focused on the role of IL-1β 
and IL-23 in inducing IL-17F and IL-17AF expression. Future work could involve 
assessing the role of other previously described Th17 cytokines (IL-6, TGF-β and IL-
21) in IL-17F and IL-17AF induction. 
 
Reports in the literature have demonstrated that IL-17A+ CD4+ T cells are promoted 
with low-strength T cell activation 225,221. In contrast to the literature, addition of anti-
CD28 mAb did not lead to a consistent decrease in the frequency of total IL-17A+ 
CD4+ T cells. Instead, no consistent effect was observed. This difference may be 
attributed to different cell culture conditions or human vs. mouse cells. A discrepancy 
between the IL-17A ICS and ELISA data was observed. While there was no difference 
in the frequency of IL-17A+ CD4+ T cells at day 3 in the absence or presence of anti-
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CD28, IL-17A protein secretion was increased in the presence of anti-CD28. We have 
attributed this result to the kinetics of the assay. Our results suggested that there is an 
increase in the frequency of IL-17A+ CD4+ T cells in the presence vs. absence of anti-
CD28 during early time-points of the 3 day cultures, which can account for the 
increased accumulation of IL-17A protein detected at day 3. How T cell activation 
affects IL-17F expression has not been previously reported. Data in this thesis 
demonstrate that addition of anti-CD28 mAb to CD4+ T cell cultures significantly 
increases the frequency of total IL-17F+ CD4+ T cells and IL-17F and IL-17AF 
protein secretion. Interestingly, titration of anti-CD28 mAb increased the frequency of 
IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells, while decreasing the frequency 
of IL-17A+ IL-17F+ CD4+ T cells.  
 
Similar results were observed with anti-CD3 mAb. Titration of anti-CD3 mAb in 
CD4+ T cell cultures led a dose dependent increase in the frequency of IL-17A+ IL-
17F+ and IL-17F+ IL-17A- CD4+ T cells. However, in the case of IL-17A+ IL-17F- 
CD4+ T cells, while there was an initial increase with a small concentration of anti-
CD3 mAb, further increasing the concentration had little effect on IL-17A+ IL-17F- 
CD4+ T cell frequency. In light of this data, I hypothesise that high-strength T cell 
stimulation induces IL-17F. Of course, with the current experiments we cannot 
confirm an increase in anti-CD28 or anti-CD3 mAb led to a stronger T cell activation. 
This could be confirmed by analysing the up-regulation of the activation marker CD69 
or by investigating the phosphorylation of T cell activation components, ZAP 70 or 
LAT by western blot. An increase in CD69 marker expression or phosphorylation of 
ZAP 70 or LAT could then be correlated with IL-17F+ CD4+ T cell frequency. 
 
To investigate the mechanism by which high-strength T cell activation can drive IL-
17F expression, IL-2 and IFNγ was blocked in CD4+ T cell cultures stimulated with 
IL-1β, IL-23 and anti-CD28. Firstly it is important to note that in contrast to the 
literature 218,221, blockade of IL-2 led to no consistent differences in the frequency of 
IL-17A+ CD4+ T cells. One explanation for the lack of response to IL-2 blockade 
could be that the levels of IL-2 present in the culture were too low. To investigate this, 
future work could involve examining the effect of adding titrated amounts of human 
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recombinant IL-2 to stimulated CD4+ T cells. If indeed IL-2 down-regulates the IL-
17A response in humans, we would expect to observe the frequency of IL-17A+ CD4+ 
T cells dose-dependently decreasing upon the addition of IL-2. As the majority of the 
reports which implicate IL-2 in down-regulating IL-17A+ CD4+ T cells are in mice 
218,221,222, another explanation for these results could be that the role of IL-2 in humans 
may differ. Indeed, in contrast to the role of IL-2 in mice Amadi-Obi et al. 
demonstrated that in human PBMC isolated from the blood of active uveitis patients, 
IL-2 enhanced IL-17A production by memory CD4+ T cells.   
 
In contrast to the results of IL-17A, our results demonstrated that blockade of IL-2 
reduced IL-17F+ CD4+ T cell frequencies to similar levels observed in the absence of 
anti-CD28. This demonstrated that the CD28-mediated increased in IL-17F+ CD4+ T 
cell expression was mediated by IL-2. Collectively these data indicate that IL-17A and 
IL-17F are differentially regulated. To confirm the role of IL-2 in IL-17F induction, it 
can be investigated if the reverse result (a dose-dependent increase in IL-17F+ CD4+ 
T cells) is observed upon addition of human recombinant IL-2. IL-2 has been shown 
to induce the production of other cytokines from T cells such as TNFα 408. Therefore, 
it may of interest to demonstrate whether the IL-2-mediated induction of IL-17F 
expression is a direct or indirect mechanism. This could include performing a Luminex 
on the supernatants of CD4+ T cells cultured in the absence or presence of anti-CD28 
and identifying cytokines other than IL-17F and IL-2 which are upregulated in the 
presence of anti-CD28. If for example TNFα is elevated in the presence of anti-CD28, 
the effect of blocking TNFα on the frequency of IL-17F+ CD4+ T cells can be 
assessed.  
 
Evidence from mouse 209-211 and human 192 studies have shown that IFNγ can decrease 
the frequency of IL-17A+ CD4+ T cells and IL-17A protein secretion. Despite 
detectable levels of IFNγ observed in CD4+ T cell cultures and efficient blockade of 
IFNγ following addition of a neutralising antibody, the data presented in this thesis 
showed no difference in the frequency of IL-17A+ CD4+ T cells in CD4+ T cell 
cultures stimulated with IL-1β, IL-23, anti-CD28 and anti-CD3 in the absence or 
presence of anti-IFNγ. These conflicting results may reflect differences in animal vs. 
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human Th17 differentiation as the strongest evidence for the role of IFNγ in regulating 
the IL-17A response derive from murine studies. However, it is important to also 
consider that the majority of mouse reports examine the effect of IFNγ on naïve CD4+ 
T cells 210 and the human study by Evans et al. investigates the role of IFNγ on memory 
CD4+ T cells 192. In this study bulk CD4+ T cells were used. Therefore, future studies 
could involve performing the same experiment on separate cultures of isolated naïve 
CD45RA+ and memory CD45RO+ CD4+ T cells. Similar to IL-17A, blockade of 
IFNγ did not show a consistent effect on the frequency of IL-17F+ CD4+ T cells. 
 
Data presented in this chapter show that while re-stimulation with PMA and 
ionomycin increases the frequency of total IL-17A+ CD4+ T cells, it has no effect on 
the frequency of total IL-17F+ CD4+ T cells. More specifically, PMA and ionomycin 
enhances IL-17A+ IL-17F- and IL-17A+ IL-17F+ CD4+ T cell frequencies and 
decreases IL-17F+ IL-17A- CD4+ T cells. The reason why PMA and ionomycin 
increases the frequency of IL-17A and not IL-17F remains unclear. One explanation 
may be that the signalling pathways stimulated with PMA and ionomycin does not 
elicit an IL-17F response. These data, alongside observations made from titration of 
anti-CD3 mAb and anti-CD28 mAb, clearly demonstrate that IL-17A and IL-17F 
expression from CD4+ T cells are not always enhanced simultaneously. Moreover, the 
data presented indicate IL-17A and IL-17F may be differentially regulated. 
 
Melton et al. have previously reported differential regulation of IL-17A and IL-17F. 
In their study primary human B cell and peripheral blood mononuclear cell co-cultures 
were stimulated with anti-IgM and superantigens to promote a Th17 response, as 
evidenced by IL-17A and IL-17F secretion. Co-cultures were incubated with 
pharmacologic modulators, which inhibit multiple pathways. Results revealed IL-17A 
production from CD4+ T cells was decreased following inhibition of the PI3K/ mTOR 
pathway, while prostaglandin EP receptor agonists, including PGE2, increased levels 
of IL-17A. In contrast, PGE2 inhibited IL-17F production. However, TLR2 and TLR5 
agonists selectively increased levels of IL-17F 409. Differential regulation of IL-17A 
and IL-17F is also supported in a study by Gomez-Rodrigues et al., whereby CD4+ T 
cells deficient in the TCR signalling kinase Itk led to a decreased IL-17A expression 
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whilst exerting no effect on the expression of IL-17F 410. Finally, a very recent report 
implicated that IL-17A and IL-17F are frequently unequally regulated, evidenced by 
the fact that IL-1β preferentially drives a mouse IL-17A+ CD4+ T cell profile, 
whereby TGF-β predominantly drives an IL-17F profile 246  In the final discussion 
chapter, I discuss how future work can investigate whether IL-17A and IL-17F are 
differentially regulated. 
 
The second focus of this chapter was to compare the marker and cytokine profile of 
IL-17A+ and IL-17F+ CD4+ T cells to identify whether there were any key differences 
between these populations. In line with literature 196, we observed that CCR6 marker 
expression was enriched on IL-17A and IL-17F expressing cells, however no 
consistent different was observed between the IL-17 populations themselves.  In two 
out of four donors the IL-17A+ IL-17F- CD4+ T cell population displayed higher 
levels of CD161 when compared with IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ 
T cell populations. To confirm these results, this experiment should be repeated 
additional times. Identifying differences in IL-17A+ and IL-17F+ CD4+ T cell 
populations may enable these populations to be separated without the need of a 
secretion assay. In this study only a limited number of markers was explored, however 
future work could examine the expression of chemokine receptors previously 
associated with Th17 cells including CXCR4, CXCR6, CCR4 and CCR5. 
 
Literature describes Th17 cells to produce an array of cytokines alongside IL-17A, 
including IL-17F, TNFα, IFNγ, GM-CSF, IL-21, IL-22, IL-9 and IL-10. Cytokine 
presence and expression levels are dependent on the cytokine milieu present upon 
Th17 differentiation 234-236. Novel data in this chapter show that IL-17A+ IL-17F-, IL-
17A+ IL-17F+ and IL-17F+ IL-17A+ CD4+ T cells display different cytokine profiles. 
In CD4+ T cell cultures with IL-1β and IL-23, IL-17A+ IL-17F+ and IL-17F+ IL-
17A- display significantly lower frequencies of IL-10 and higher frequencies of IFNγ 
when compared with IL-17A+ IL-17F- CD4+ T cells. Moreover, IL-17A+ IL-17F- 
CD4+ T cells display a higher frequency of GM-CSF when compared with IL-17F+ 
IL-17A- CD4+ T cells. A lower frequency of IL-10 was also observed in IL-17A+ IL-
17F+ CD4+ T cells vs. IL-17A+ IL-17F- CD4+ T cells in CD4+ T cell/ CD14+ 
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monocyte cultures stimulated with LPS, demonstrating this result it not only observed 
in IL-1β and IL-23 conditions. However, no differences in IFNγ or GM-CSF cytokine 
co-expression levels were observed. Different cytokine profile results observed in 
CD4+ T cell + IL-1β and IL-23 vs. CD4+ T cell/ CD14+ monocyte + LPS cultures 
may be attributed to the different IL-17 cytokine profiles. Firstly, no IL-17A+ IL-17F- 
CD4+ T cells are present in the CD4+ T cell/ CD14+ monocyte + LPS culture. 
Moreover, the IL-17A+ IL-17F+ CD4+ T cells in this culture are all highly expressing 
IL-17A, whereas in the CD4+ T cell + IL-1β and IL-23 cultures, there is more variation 
in IL-17A expression levels. 
 
These results suggest IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- 
CD4+ T cells may have different functional properties. An interesting finding is that 
IL-17F+ CD4+ T cells display a lower frequency of IL-10 suggesting these cells are a 
more inflammatory Th17 population. Indeed, the ‘pathogenic’ Th17 population are 
characterised by a lack of IL-10. However, they are also characterised by their 
expression of GM-CSF, of which, IL-17A+ IL-17F- CD4+ T cells display a higher 
level of GM-CSF in comparison to IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T 
cells. Nevertheless, IL-17F+ CD4+ T cells also demonstrated higher levels of IFNγ 
when compared with IL-17A+ IL-17F- CD4+ T cells. To the best of our knowledge, 
the cytokine profile of the different IL-17A/IL-17F CD4+ T cell populations has not 
been characterised previously. A recent mouse study demonstrated that TGF-β 
induced higher frequencies of IL-17F+ CD4+ T cells, suggesting that expression of 
IL-17F from CD4+ T cells is associated with non-pathogenic Th17 cells 246. However, 
the study did not characterise the cytokine profile of IL-17F+ CD4+ T cells. A recent 
study by Aschenbrenner et al. performed RNA-seq on human Th17-IL-10 and Th17-
IL-10+ clones. While several genes associated with the ‘non-pathogenic’ Th17 
phenotype were highly expressed in Th17-IL-10+ cells, genes associated with the 
‘pathogenic’ Th17 phenotype were highly expressed in Th17-IL-10- cells. 
Interestingly, in line with our data IL17F was highly expressed in Th17-IL-10- cells 
when compared to Th17-IL-10+ cells. In contrast, IL17A was preferentially expressed 
in Th17-IL-10+ cells. Th17-IL-10- cells were also linked with high expression levels 
of IFNG 411. The study also demonstrated that Th17-IL-10- cells have the ability to 
polarise monocytes into an inflammatory M1 phenotype, whilst Th17-IL-10+ cells 
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induced an M2 anti-inflammatory phenotype 411. In summary, work from this thesis 
and other studies 246,411 highlight that performing molecular and functional 
characterisation of isolated IL-17A/IL-17F CD4+ T cell sub-populations would be 
interesting area of research to pursue. This is further discussed in the final discussion 
chapter. 
 
The next chapter explores the individual and combinatorial function of IL-17A, IL-
17F and IL-17AF. Moreover, with the increasing need to separate IL-17A+ IL-17F-, 
IL-17A+ IL-17F+ and IL-17F- IL-17A+ CD4+ T cells, I describe the development 
of an IL-17F secretion assay. 
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4 Investigating the contribution of IL-17F to inflammation 
 
4.1 Introduction 
The IL-17 cytokines mediate their biological function via surface receptors on target 
cells. The IL-17 receptor family consists of IL-17RA, IL-17RB, IL-17RC, RD and 
RE. Functional IL-17 receptors exist as heterodimers, with IL-17RA as a common 
subunit. IL-17A, IL-17F and IL-17AF share the same IL-17RA and IL-17RC 
heterodimer receptor. These cytokines typically act on fibroblasts, epithelial cells and 
endothelial cells 31.  
 
The activation of NFκB and MAPK pathways in target cells by IL-17A, IL-17F and 
IL-17AF results in the transcription of pro-inflammatory genes. IL-17A and IL-17F 
have been shown to induce the production of the pro-inflammatory cytokines (IL-6, 
TNFα and IL-1) 71, T cell and myeloid cell-attracting chemokines (CCL20, CCL2 and 
CCL7) 94,95 and many neutrophilic granulocyte-attracting chemokines (CXCL1, 
CXCL2, CXCL5 and CXCL8) 71,96 from target cells. IL-17A, IL-17F and IL-17AF 
can exert potent synergistic effects in the presence of other cytokines (including 
TNFα) to augment pro-inflammatory responses 112. 
 
Literature describes a hierarchy in inflammatory potential with IL-17A homodimers 
eliciting the strongest inflammatory response, followed by IL-17AF heterodimers, and 
then IL-17F homodimers 78. In fact, studies have suggested that IL-17F is largely 
redundant to IL-17A. However, it has been shown that neutralization of both IL-17A 
and IL-17F significantly reduced T cell-mediated colitis development, whereas 
neutralisation of IL-17A or IL-17F alone was inefficient at reducing disease severity, 
indicating a potential role for IL-17F in inflammatory disease pathology 363. Moreover, 
a recent study demonstrated that dual neutralization of IL-17A and IL-17F leads to a 
greater reduction on Th17 cell culture supernatant induced IL-6 and IL-8 secretion by 
PsA fibroblasts 121. The overall aim of this chapter was to assess the function of IL-
17F and whether it has the potential to contribute to the immunopathology of 
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inflammatory arthritis, specifically RA and PsA. This aim has been addressed in the 
following ways: 
 
• Assessment of the individual and combinatorial role of IL-17A, IL-17F, IL-
17AF and TNFα in synovial fibroblast assays. 
• Investigating the effect of single and dual IL-17A and IL-17F blockade on the 
inflammatory response in a variety of culture systems. 
• Developing an IL-17F secretion assay to allow further analysis of the 
functional role of IL-17F producing cells. 
 
This chapter predominantly explores the inflammatory capacity of IL-17A, IL-17F 
and IL-17AF. However, it is concluded with a brief investigation of the function of 





4.2.1 Examining the IL-17 receptor gene expression profile in RA and 
PsA synovial fibroblasts. 
To begin work on this chapter, a publicly available dataset (GEO accession number: 
GSE29746) was mined to investigate the gene expression of all IL-17 receptors 
(IL17RA, IL17RB, IL17RC, IL17RD and IL17RE) on synovial fibroblasts derived from 
RA. Moreover, RA IL-17R expression was compared to that of OA or healthy 
controls. Figure 4.1A displays data whereby microarray expression profiling was 
performed in human synovial fibroblasts from healthy, OA and RA synovial tissues. 
In this data set, all IL-17 receptors genes were present in healthy, OA and RA synovial 
tissues and they displayed a very similar gene expression profile. Gene expression 
levels of IL17RC were the lowest and demonstrated the least variability between 






Figure 4.1 Gene expression of the IL-17 receptors in healthy control, OA and 
RA synovial fibroblasts. 
This figure displays a publicly available dataset (GEO accession number: GSE29746), whereby 
synovial fibroblasts were obtained from patients with RA (RA SF) (n=9) and sex and age matched adult 
healthy donors (HC SF) (n=11) and OA donors (n=11). Synovial fibroblasts were collected under 
similar sub-confluent conditions 24 hours after serum addition. Microarray analysis was then performed 
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4.2.2 Assessing the individual and combinatorial function of IL-17A, IL-
17F and IL-17AF on synovial fibroblasts 
The next aim was to investigate the individual roles of IL-17A, IL-17F, IL-17AF and 
TNFα in RA and PsA synovial fibroblast cultures. RA and PsA synovial fibroblasts 
were seeded in a 96 well plate and allowed to rest for 24 hours. Next, fibroblasts were 
incubated with human recombinant IL-17A, IL-17F, IL-17AF, TNFα and vehicle 
controls at the indicated concentrations. Following 24 hours incubation, the 
supernatant was collected and analysed by ELISA for IL-6 and IL-8 protein levels. In 
total 3 different RA fibroblast cell lines (i.e originating from different donors) and 4 
different PsA fibroblast cell lines were used in this thesis. Not all cell lines were used 
in each experiment. At a steady state, no consistent differences were observed between 
IL-6 or IL-8 secretion in RA vs. PsA fibroblasts. In general, there were modest 
variations in IL-6 and IL-8 secretion across all cell lines. Moreover, in some cases 
fibroblasts derived from the same cell line secreted different protein levels at a 
different passage. These variations may be attributed to the health of the cells at the 
time of seeding and the extent of inflammation in the joint from which the fibroblasts 
were derived. 
 
As shown in Figure 4.2, IL-17A, IL-17F, IL-17AF and TNFα all induced a dose-
dependent increase in IL-6 secretion by fibroblasts. In line with literature, a hierarchy 
in inflammatory potency of the IL-17 cytokines was observed: IL-17A elicited higher 
levels of IL-6 in comparison to IL-17F, while IL-17AF induced intermediate IL-6 
levels. TNFα induced the highest levels of IL-6. However, when recombinant 
cytokines were added at 50ng/ml, IL-17A elicited higher IL-6 levels than TNFα. 
Similar results were observed when analysing the levels of IL-8 in the fibroblast 
supernatant. All cytokines stimulated IL-8 secretion from fibroblasts in a hierarchical 
fashion. However, in this case TNFα was more potent in driving IL-8 fibroblast 
secretion compared to the IL-17 cytokines. TNFα at a concentration of 0.1ng/ml 
stimulated IL-8 protein levels above the ELISA detection limit.  
 
Next, we sought to investigate whether there were any synergistic or additive effects 
between IL-17A, IL-17F or IL-17AF themselves. To assess this, combinations of the 
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IL-17 cytokines at 10ng/ml were added to synovial fibroblasts for 24 hours and IL-6 
and IL-8 protein levels were assessed by ELISA. As depicted in Figure 4.3, combining 
IL-17A with IL-17F, IL-17AF or both did not lead to increased IL-6 or IL-8 secretion 
levels when compared with IL-17A alone, showing there is no synergistic or additive 






Figure 4.2 IL-17A, IL-17F or IL-17AF addition leads to a dose-dependent 
increase in IL-6 and IL-8 fibroblast secretion. 
RA and PsA synovial fibroblasts (10x103) were cultured with indicated concentrations of human 
recombinant IL-17A, IL-17F, IL-17AF or TNFα for 24 hours. Additionally fibroblasts were cultured 
with vehicle controls for IL-17A, IL-17F and TNFa (0.1% BSA) and IL-17AF (0.1% BSA and 4mM 
HCL). Culture supernatants were collected and IL-6 (RA n=3, PsA n=1) and IL-8 (RA n=2) protein 
levels were measured by ELISA. Dashed red and blue lines indicate lower detection limit and upper 
detection limit, respectively. 
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Figure 4.3 No synergistic or additive effect is observed between IL-17A, IL-17F 
and IL-17AF. 
RA and PsA synovial fibroblasts (10x103) were cultured with combinations of IL-17A, IL-17F or IL-
17AF at 10ng/ml for 24 hours. Additionally, fibroblasts were cultured with vehicle controls for IL-17A, 
IL-17F (0.1% BSA, Vehicle 1) and IL-17AF (0.1% BSA and 4μm HCL, Vehicle 2). Culture 
supernatants were collected and IL-6 (RA n=3, PsA n=1) and IL-8 (PsA n=2) protein levels were 
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4.2.3 IL-17A, IL-17F and IL-17AF synergise with TNFα 
IL-17A, IL-17F and IL-17AF have the ability to exacerbate their inflammatory 
potential by synergising with other cytokines. In these experiments, we focused on the 
synergy between the IL-17 cytokines and TNFα. We investigated to what extent the 
pro-inflammatory ability of IL-17A, IL-17F and IL-17AF increased with TNFα. In 
this experiment a range of concentrations was used to determine the sub-optimal/ 
minimum concentration of cytokine required to see a synergistic effect. 
 
As shown in Figure 4.4A, a synergistic increase in IL-6 secretion by fibroblasts was 
observed with IL-17A and TNFα at concentrations as low as 1 and 0.1ng/ml, 
respectively. A combination of 10ng/ml IL-17A and 1ng/ml TNFα resulted in a 
profound 6.5-fold increase in IL-6 fibroblast secretion when compared with 10ng/ml 
IL-17A alone. Moreover, a 6-fold increase was observed when compared with 1ng/ml 
TNFα alone. Similarly, synergistic responses were observed in the secretion of IL-8 
from concentrations as low as 1ng/ml IL-17A and 0.1ng/ml TNFα. In the case of IL-
17F (Figure 4.4B), the lowest concentrations of recombinant cytokines required to 
drive a synergistic IL-6 response with TNFα were 10ng/ml IL-17F and 0.1ng/ml 
TNFα. The strongest synergistic effect was observed when 1ng/ml of TNFα was added 
to 10ng/ml of IL-17F. This led to a 7.5-fold and 2.8-fold increase in IL-6 levels when 
compared to addition of IL-17F or TNFα, respectively. Similarly, addition of 0.1 or 
1ng/ml of TNFα to 10ng/ml IL-17F led to a synergistic increase in IL-8 protein 
secreted from fibroblasts. Results of the IL-17AF synergy experiments demonstrated 
that the heterodimer can also synergise with TNFα to induce elevated levels of IL-6 
and IL-8 from fibroblasts. Figure 4.4D compares the levels of IL-6 and IL-8 induced 
with 10ng/ml IL-17A, IL-17F and/ or IL-17AF all combined with 1ng/ml TNFα. The 
combination of IL-17A and TNFα elicited the highest production of IL-6 and IL-8 
from target cells, followed by IL-17AF and IL-17F. These data show that the 
inflammatory potential of IL-17A, IL-17F and IL-17AF is significantly enhanced in 
the presence of TNFα. 
 
We next sought to assess whether addition of IL-17F or IL-17AF to IL-17A and 
TNFα further enhances secretion of IL-6 or IL-8. As depicted in Figure 4.5, addition 
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of IL-17F and/ or IL-17AF to IL-17A and TNFα in the fibroblast cultures did not 




Figure 4.4 IL-17A, IL-17F and IL-17AF synergise with TNFα. 
Synovial RA and PsA fibroblasts (10x103) were cultured with combinations of IL-17A, IL-17F, IL-
17AF and TNFα (at indicated concentrations) or with vehicle controls for IL-17A, IL-17F and TNFa 
(0.1% BSA, V1) and IL-17AF (0.1% BSA and 4μm HCL, V2).  Culture supernatants were collected 
and IL-6 and IL-8 protein levels were measured by ELISA. Data show the synergistic effect of TNFα 
and (A) IL-17A, (B) IL-17F and (C) IL-17AF on IL-6 (RA n=1, PsA n=1) and IL-8 (PsA n=1) secretion. 
(D) Displays cumulative IL-6 (RA n=3, PsA n=5) and IL-8 (RA n=2, PsA n=5) data with the IL-17 
cytokines at 10ng/ml and TNFα at 1ng/ml. Dashed red and blue lines indicate lower detection limit and 
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Figure 4.5 Addition of IL-17F or IL-17AF does not further increase the IL-17A 
and TNFα mediated upregulation of synovial fibroblast pro-inflammatory 
cytokine secretion. 
Synovial RA and PsA fibroblasts (10x103) were cultured with combinations of IL-17A, IL-17F, IL-
17AF at 10ng/ml and TNFα at 1ng/ml were for 24 hours. Culture supernatants were collected and IL-6 
(RA n=3, PsA n=5) and IL-8 (RA n=2, PsA n=5) protein levels were measured by ELISA. Dashed red 
and blue lines indicate lower detection limit and upper detection limit, respectively. Statistical analysis 
was performed using Friedman test with comparison to IL-17A and TNFα by Dunn’s Multiple 
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4.2.4 Testing blocking antibodies 
Assessing the role of IL-17F via addition of recombinant cytokines to fibroblast assays 
demonstrated that while the potency of IL-17F in inducing inflammatory cytokine 
production from synovial fibroblasts was enhanced in the presence of TNFα, it was 
not as potent as the combination of IL-17A and TNFα. Furthermore, addition of IL-
17F to IL-17A and TNFα cultures had no further effect on cytokine secretion by 
fibroblasts. This potentially suggests IL-17F is redundant when in the presence of IL-
17A. However, studies have shown dual blockade of IL-17A and IL-17F is more 
efficient in reducing inflammatory cytokine production than blockade of IL-17A alone 
121,363. I therefore sought to examine the role of IL-17F using blocking antibodies.  
 
To perform these experiments, our pharmaceutical collaborator, UCB, provided IL-
17A and IL-17F blocking antibodies. This included a UCB in-house IL-17A blocking 
antibody which neutralizes both the IL-17A homodimer and IL-17AF heterodimer and 
a UCB in-house IL-17F blocking antibody which neutralizes IL-17F with no cross 
reactivity to the other IL-17 cytokines. These experiments also included bimekizumab, 
which is a novel, humanized monoclonal IgG1 antibody that selectively neutralizes 
IL-17A, IL-17F and IL-17AF. The affinities of these blocking antibodies have recently 
been published 121. In summary, biomolecular interaction analysis performed using a 
Biacore 3000 demonstrated that bimekizumab shares a similar affinity to the anti-IL-
17A antibody. However, bimekizumab has a higher affinity for IL-17F than the anti-
IL-17F antibody. Therefore, it was important to determine efficient blocking antibody 
concentrations which completely block IL-17 cytokine function. 
 
A series of preliminary experiments were performed to ensure efficient blockade of 
IL-17 and TNFα cytokines and to ensure minimal cross-reactivity. To begin the 
experiments, a cocktail of IL-17A, IL-17F, IL-17AF and TNFα, all at 10ng/ml in 
DMEM media were added to fibroblast cultures alongside increasing doses of 
blocking antibodies. Following a 24 hour incubation, supernatants were collected and 
IL-17A, IL-17F, IL-17AF and TNFα protein levels were analysed by ELISA. While 
IL-17A protein was detected in the positive control condition, no IL-17A protein was 
detected with the addition of 0.5μg/ml or more of IL-17A blocking antibody, 
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indicating efficient blockade of IL-17A (Figure 4.6A). Similar results were observed 
for IL-17AF. As expected, IL-17F protein was still detectable following the addition 
of IL-17A blocking antibody. As depicted in Figure 4.6B, protein levels of IL-17A 
and IL-17AF were all detectable following the addition of IL-17F blocking antibody. 
Unexpectedly, while blockade of IL-17F at the highest dose (10μg/ml) reduced IL-
17F protein levels to some extent, IL-17F was still clearly detectable. This suggested 
that either the blocking antibody was inefficient at blocking IL-17F, a higher 
concentration of anti-IL-17F was required or the blocking antibody is working and 
inhibits the function of IL-17F but the protein-antibody complex is still recognized by 
the IL-17F ELISA. Bimekizumab completely blocked IL-17A, IL-17F and IL-17AF 
from a concentration of 1μg/ml onwards (Figure 4C). Finally, anti-TNFα effectively 
blocked TNFα protein (Figure 4D).  
 
To investigate why IL-17F protein might still be detectable following addition of 
10μg/ml of anti-IL-17F, fibroblasts were cultured with human recombinant IL-17F 
(10ng/ml) and titrated doses of anti-IL-17F mAb for 24 hours. Although titration of 
anti-IL-17F led to a dose-dependent decrease in IL-17F protein, IL-17F was not 
completely blocked even with a high concentration of 100μg/ml anti-IL-17F blocking 
antibody (Figure 4.7A). To investigate the possibility that the protein-blocking 
antibody complex is recognized by the IL-17F ELISA but the blocking antibody is 
still affecting the function of IL-17F, we measured the same supernatant used in Figure 
4.7A, for IL-6 and IL-8 protein levels. Supernatant from fibroblasts cultured with 
recombinant IL-17F displayed an increase in IL-6 protein levels in comparison to 
medium-only controls. However, an increase in IL-6 protein levels was not observed 
in supernatants from fibroblasts cultured with recombinant IL-17F and anti-IL-17F 
blocking antibody. This indicates that although IL-17F protein is detectable following 
the addition of anti-IL-17F blocking antibody, the IL-17F protein function is 
neutralised. In this set of experiments IL-8 was below the ELISA detection limit in all 
conditions (data not shown). IL-17F alone is a weak inducer of IL-6 and IL-8 by 
fibroblasts. To further validate the efficiency of the IL-17F blocking antibody in a 
system with higher IL-6 levels and detectable IL-8 levels, I performed the same 
experiment, this time adding anti-IL-17F to a combination of IL-17F and TNFα 
recombinant cytokines. As depicted in Figure 4.7C, the combination of IL-17F and 
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TNFα resulted in a synergistic increase in IL-6 and IL-8 secretion. Addition of IL-17F 
blocking antibodies reduced IL-6 and IL-8 levels back to levels similar to that of TNFα 
alone. This further validates that the anti-IL-17F antibody is functional. 
 
The aim of the final experiment in this section was to validate the blocking specificity 
of anti-IL-17A, anti-IL-17F, bimekizumab and anti-TNFα.  It was previously 
demonstrated in Figure 4.6 that anti-IL-17A does not recognize the IL-17F protein; 
similarly, anti-IL-17F does not recognize IL-17A and IL-17AF protein. I sought to 
extend this analysis to demonstrate that the blocking antibodies do not non-specifically 
reduce IL-6 secretion by fibroblasts. IL-17A, IL-17F, IL-17AF and TNFα were 
individually added to fibroblast cultures in the absence or presence of blocking 
antibodies at 10μg/ml. Cultures were incubated for 24 hours and IL-6 protein levels 
were measured by ELISA. As depicted in Figure 4.8, IL-17A-induced IL-6 secretion 
was abrogated by the addition of anti-IL-17A and bimekizumab only. Similar results 
were observed for the IL-17AF heterodimer. Anti-IL-17F and bimekizumab inhibited 
IL-17F-induced IL-6 secretion. Anti-IL-17A and anti-TNFα blocking antibodies 
showed no effect on IL-17F induced cytokine secretion. TNFα induced IL-6 levels 
were inhibited with the addition of anti-TNFα only. Similar results were observed for 






Figure 4.6 Testing blocking antibody concentrations. 
Synovial RA and PsA fibroblasts (10x103) were cultured with a cocktail of human recombinant IL-17A, 
IL-17F, IL-17AF and TNFα (all at 10ng/ml) (+) and indicated neutralising antibodies at the indicated 
concentrations for 24 hours (n=1-3). Cell supernatants were collected and protein levels of the indicated 
cytokines were determined by ELISA. Dashed red and blue lines indicate lower detection limit and 



































































































































































































































































































































Figure 4.7 IL-17F blocking antibody inhibits IL-17F function. 
Synovial PsA fibroblasts (10x103) were cultured with human recombinant IL-17F (10ng/ml) and 
indicated concentrations of anti-IL-17F blocking antibody for 24 hours. Cell supernatants were 
collected and protein levels of (A) IL-17F (n=1) and (B) IL-6 (n=1) were determined by ELISA. (C) 
Synovial PsA fibroblasts (10x103) were cultured with IL-17A and TNFα with titrated doses of anti-IL-
17F blocking antibody for 24 hours. Fibroblast culture supernatants were measured for IL-6 and IL-8 
by ELISA (n=1). Dashed red lines indicate the lower detection limit. The solid green line highlights the 
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Figure 4.8 Testing blocking antibody specificity. 
Synovial RA and/or PsA fibroblasts (10x103) were cultured with 10ng/ml of (A) IL-17A, (B) IL-17F, 
(C) IL-17AF and (D) TNFαin the presence of blocking antibodies at a concentration of 10μg/ml. 
Following 24 hours incubation, cell supernatants were collected and IL-6 protein levels were 
determined by ELISA (n=1-2). Dashed red and blue lines indicate lower detection limit and upper 
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4.2.5 Dual IL-17A and IL-17F blockade in a fibroblast:recombinant 
cytokine system 
Moving forward from successful validation of the IL-17 blocking antibodies, the next 
aim was to assess the effect of dual IL-17A and IL-17F blockade in a reductionist 
system. To achieve this, a cocktail of recombinant cytokine IL-17A, IL-17F, IL-17AF 
and TNFα were added to synovial fibroblast cultures in the presence of ‘low’ or ‘high’ 
(1 vs.10μg/ml) concentrations of IL-17 blocking antibody and anti-TNFα. These 
experiments included a human IgG1 isotype control. As illustrated in Figure 4.9, 
addition of the cytokine cocktail led to an increase in IL-6 fibroblast cytokine 
production in comparison to the medium alone condition. Addition of isotype control 
or anti-IL-17F blocking antibody had no effect on IL-6 production. However, IL-6 
secretion was reduced upon addition of IL-17A blocking antibody. Interestingly, IL-6 
production was further reduced with a combined blockade of IL-17A and IL-17F by 
bimekizumab. Blockade of TNFα reduced IL-6 levels similar to that of bimekizumab. 
Similar results were observed for IL-8. Moreover, similar results were observed when 
using blocking antibodies at both 1 and 10μg/ml. Collectively, these data suggest that 
a combined blockade of IL-17A, IL-17F and IL-17AF is more effective at reducing 
inflammation than blockade of IL-17A alone. In this experiment, the role of IL-17AF 
cannot be assessed as both bimekizumab and the anti-IL-17A blocking antibody both 
inhibit IL-17AF. 
 
Next, we sought to demonstrate that the greater effect of bimekizumab was a result of 
a dual IL-17A and IL-17F blockade and not a result of a potent blockade of IL-17A. 
To achieve this, a cocktail of IL-17A, IL-17F, IL-17AF and TNFα was added to 
fibroblast assays and the effect of bimekizumab and a combination of both anti-IL-
17A and anti-IL-17F single blocking antibodies was compared. As depicted in Figure 
4.10 bimekizumab and a combination of single IL-17A and IL-17F blocking 
antibodies reduced fibroblast IL-6 and IL-8 secretion to comparable levels. This 
suggests that the superior result of bimekizumab can be attributed to dual IL-17A and 





Figure 4.9 A combined blockade of IL-17A and IL-17F reduces pro-
inflammatory secretion by fibroblasts to a greater extent than blockade of IL-
17A alone. 
RA and PsA synovial fibroblasts (10x103) were cultured with a cocktail of human recombinant IL-17A, 
IL-17F, IL-17AF and TNFα (+) in the absence or presence of blocking antibodies (at the indicated 
concentrations) for 24 hours. Cell supernatants were collected and IL-6 and IL-8 protein levels were 
determined by ELISA. (A) displays the results of all blocking antibodies at 1μg/ml while (B) displays 
the data for anti-IL-17A and bimekizumab in a different format. (C-D) shows the results of the blocking 
antibodies at 10μg/ml. Dashed red and blue lines indicate lower detection limit and upper detection 
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Figure 4.10 Similar to bimekizumab, combining single IL-17A and IL-17F 
blocking antibodies reduced IL-6 and IL-8 fibroblast secretion levels to a 
greater extent than IL-17A blockade alone. 
RA and PsA synovial fibroblasts (10x103) were cultured with a cocktail of human recombinant IL-17A, 
IL-17F, IL-17AF and TNFα (+) in the absence or presence of blocking antibodies for 24 hours. Cell 
supernatants were collected and IL-6 and IL-8 protein levels were determined by ELISA. (A) displays 
the results of isotype control at 2μg/ml and the remaining blocking antibodies at 1μg/ml. Anti-IL-17A 
and anti-IL-17F blocking antibodies were added in combination at 1μg/ml each. (B) displays the results 
of isotype control at 20μg/ml and the remaining blocking antibodies at 10μg/ml. Anti-IL-17A and anti-



































































































































































A All blocking antibodies at 1μg/ml
B All blocking antibodies at 10μg/ml
RA n=2, PsA n=4 RA n=1, PsA n=1
RA n=1, PsA n=2 RA n=1, PsA n=1
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4.2.6 Dual IL-17A and IL-17F blockade in bulk CD4+ T cell supernatant 
cell cultures  
Our next aim was to investigate in a physiological system whether dual IL-17A and 
IL-17F blockade is more effective at reducing secretion of pro-inflammatory 
mediators from synovial fibroblasts than blockade of IL-17A alone. 
 
To generate a physiological system, we sought to block IL-17A and IL-17F in 
supernatants from bulk CD4+ T cell cultures. I previously demonstrated in Chapter 3 
that culturing CD4+ T cells with IL-1β, IL-23, αCD28 and αCD3 induced IL-17A, IL-
17F and IL-17AF protein secretion. My initial approach was to add this supernatant to 
the fibroblasts. However, results revealed that the IL-1β and/or IL-23 recombinant 
cytokines used to stimulate the CD4+ T cells elicited a strong IL-6 and IL-8 fibroblast 
response alone and thus was not suitable for the blocking experiments (data not 
shown). The next approach involved generating supernatants from CD4+ T cells 
cultured with αCD28 and αCD3 only. However, this method did not induce sufficient 
levels of the IL-17 cytokines (data not shown).  
 
Next, CD4+ T cells were cultured for 3 days with IL-1β, IL-23, αCD28 and αCD3 
followed by re-stimulating cells with PMA and ionomycin for either 0, 1.5 or 3 hours. 
Cells were then washed to ensure removal of any residual IL-1β, IL-23 or PMA and 
ionomycin and replated (40x103 cells in 200μl) for 24 hours incubation. Cell 
supernatants were then collected and first analysed for IL-17A and IL-17F protein 
expression via ELISA. No IL-17 protein was detected in CD4+ T cell cultures which 
were not stimulated with PMA and ionomycin (data not shown). Moreover, levels of 
IL-17A and IL-17F were low in CD4+ T cell cultures re-stimulated for 1.5 or 3 hours 
with PMA and ionomycin. Therefore, blocking experiments were not performed using 
this supernatant (data not shown). 
 
Cell to cell interactions are described to be important in the RA and PsA synovium. 
My next approach was to explore the effect of culturing in vitro stimulated CD4+ T 
cells (i.e not their supernatant) with synovial fibroblasts in the absence or presence of 
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blocking antibodies. To achieve this, CD4+ T cells were cultured for 3 days with IL-
1β, IL-23, αCD28 and αCD3 followed by re-stimulation with PMA and ionomycin for 
3 hours. Following a wash step, stimulated CD4+ T cells were cultured with synovial 
fibroblasts were then cultured with the at a 2.5:1 ratio in the absence or presence of 
blocking antibodies for 24 hours. Supernatants were then collected and levels of IL-6 
were measured by ELISA. As shown in Figure 4.11, addition of stimulated bulk CD4+ 
T cells to fibroblasts led to an increase in IL-6 secretion. Levels of IL-6 were reduced 
upon addition of anti-IL-17A blocking antibody, bimekizumab and TNFα inhibitor, 
while blockade of IL-17F had little effect. In all three experiments levels of IL-6 were 
lower with the addition of bimekizumab vs. anti-IL-17A blocking antibody, however, 
the differences were minimal. It was considered that the bimekizumab vs. anti-IL-17A 
blockade results were not striking because the IL-17 protein levels present in the bulk 
CD4+ T cell supernatant were too low. Indeed, as shown in Figure 4.11B levels of IL-
17F present in the supernatant of fibroblasts cultured with CD4+ T cells were below 
the detection limit and levels of IL-17A were also low. Therefore, the next aim was to 






Figure 4.11 Assessing the effect of dual IL-17A and IL-17F blockade in bulk 
CD4+ T cell supernatants and synovial fibroblast cultures. 
Bulk CD4+ T cells were cultured with αCD3, αCD28, IL-1β and IL-23. Following 3 days incubation, 
cells were stimulated with PMA and ionomycin for 3 hours. 10x103 RA and PsA synovial fibroblasts 
were cultured with 25x103 activated CD4+ T cells and in the presence of neutralising antibodies (all at 
1μg/ml) for 24 hours. (A) Cell supernatants were collected and IL-6 (n=3) protein levels were 
determined by ELISA. (B) displays the anti-IL-17A vs. bimekizumab in a different format. Individual 
donors (n=2) were incubated with RA and/or PsA fibroblasts. (C) displays the levels of IL-17A and IL-
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4.2.7 Blockade of IL-17A and IL-17F in cultures of synovial fibroblasts 
and sorted CCR6+ CD161+ CD4+ T cells 
Our next aim was to block IL-17A and IL-17F in CD4+ T cell supernatants enriched 
for the IL-17 cytokines. An ideal method would involve generating supernatant from 
sorted IL-17A and IL-17F CD4+ T cells. However, as previously mentioned, while an 
IL-17A secretion assay is commercially available, there are no secretion kits available 
for IL-17F.  
 
To enrich for the IL-17 cytokines, one approach involved sorting CD45RO+ CD25- 
CCR6+ CD161+ CD3+ CD4+ T cells. As previously discussed in chapter 3, section 
3.2.2.1, CCR6 and CD161 have been described as markers of Th17 cells. However, 
the expression of CCR6 and CD161 on CD4+ T cells is down-regulated following a 3 
day in vitro culture and re-stimulation with PMA and ionomycin. To overcome this, 
CCR6+ and CD161+ cells were sorted (using FACS Aria sorter) from freshly isolated 
CD4+ T cells. Cells were sorted into four populations CCR6- CD161-, CCR6+ 
CD161-, CCR6+ CD161+ or CCR6- CD161+. This gating strategy is shown in figure 
4.12. Sorted cells were cultured for three days with IL-1β, IL-23, anti-CD28 mAb and 
anti-CD3 mAb and re-stimulated for 3 hours with PMA and ionomycin. Cells were 
then washed and cultured with synovial fibroblasts at a 2.5:1 ratio in the absence or 
presence of blocking antibodies. As a control, stimulated bulk CD4+ T cells were also 
cultured with synovial fibroblasts. After 24 hours, cell culture supernatants were 
collected.  
 
ELISA analysis showed that in comparison to bulk CD4+ T cells and sorted CCR6+ 
CD161+ CD4+ T cells, sorted CCR6- CD161-, CCR6+ CD161- and CCR6- CD161+ 
elicited low levels of IL-6 secretion by fibroblasts (Figure 4.13). Sorted CCR6+ 
CD161+ CD4+ T cells elicited a slightly higher level of IL-6 secretion when compared 
with bulk CD4+ T cells, suggesting a modest enrichment of the IL-17 cytokines. 
Unfortunately, there was not enough culture supernatant present to examine the 
presence of IL-17A and IL-17F. In the CCR6+ CD161+ CD4+ T cell/fibroblast culture 
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system, while IL-17A blockade reduced levels of IL-6, no superior effect was 
observed with bimekizumab. A limitation to this experiment is that not all total CCR6+ 
and/or CD161+ CD4+ T cells express IL-17A and IL-17F. Furthermore, not all IL-
17A+ and IL-17F+ CD4+ T cells express CCR6 and/or CD161. Therefore we sought 






Figure 4.12 Gating strategy for sorting for CCR6+ CD161+ T cells. 
 Based on forward scatter/side scatter (FSC/SSC) properties, viable lymphocytes were gated. A FSC-
W/FSC-A gate was applied allowing the exclusion of doublet cells. Dead cells were excluded based on 
their uptake of eFluor 780. Within live, single cells CD3+ CD4+ T cells were gated followed by 
selection of CD45RO+ memory T cells. Next, CD127+ CD25- cells were gated allowing the exclusion 
of Tregs. Finally, populations of CCR6- CD161-, CCR6+ CD161-, CCR6+ CD161+ and CD161+ 
















































Figure 4.13 Dual IL-17A and IL-17F blockade in cultures of synovial fibroblasts 
and sorted CCR6+ and CD161+ CD4+ T cells. 
From fresh CD4+ T cells CD45RO+ CD127+ CD25- CD4+ T cells were sorted into CCR6- CD161-, 
CCR6+ CD161-, CCR6+ CD161+ and CCR6- CD161+ populations. Alongside bulk CD4+ T cells, 
sorted cell populations were cultured with αCD3, αCD28, IL-1β and IL-23 for 3 days. Following a three 
hour PMA and ionomycin re-stimulation, cells were washed and cultured with PsA synovial fibroblasts 
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4.2.8 Sorting IL-17A+ CD4+ T cells for functional analysis 
As demonstrated in chapter 3, section 3.2.1.3, CD4+ T cells that co-express IL-17A 
and IL-17F are present in CD4+ T cell cultures stimulated for 3 days with IL-1β, IL-
23, anti-CD28 mAb and anti-CD3 mAb. Therefore, I decided to sort IL-17A+ CD4+ 
T cells and assess the effect of dual IL-17A and IL-17F blockade in this supernatant. 
It is important to note that in this method IL-17F+ IL-17A- CD4+ T cells are not 
captured.  
 
 To sort IL-17A+ CD4+ T cells, bulk CD4+ T cells were first cultured with IL-1β, IL-
23, αCD28 and αCD3 for 3 days. Cells were then re-stimulated with PMA and 
ionomycin for 1.5 hours and a IL-17A secretion assay was performed. Using a FACS 
Aria sorter both IL-17A+ and IL-17A- CD4+ T cells were sorted. A gating strategy of 
the sort is illustrated in Figure 4.14. Sorted IL-17A+ and IL-17A- CD4+ T cells were 
cultured in media for 24 hours. The supernatant was then collected for further analysis 
and functional fibroblast assays. To validate the IL-17A secretion assay method, the 
IL-17A- and IL-17A+ CD4+ T cell supernatant generated was analysed for the 
presence of IL-17A, IL-17F and IL-17AF protein. Detectable levels of IL-17A, IL-
17F and IL-17AF in the IL-17A+ CD4+ T cells were observed, while no IL-17 
cytokines were detectable from the IL-17A- CD4+ T cell supernatants (Figure 4.15A). 
This confirms the successful enrichment of IL-17A+ CD4+ T cells. Next, the effect of 
IL-17A- and IL-17A+ CD4+ T cell supernatant on the IL-6 and IL-8 production from 
synovial fibroblasts was compared. Addition of IL-17A+ CD4+ T cell supernatant led 
to a strong dose-dependent induction of IL-6 and IL-8 fibroblast secretion. These data 
also indicated that addition of 20% IL-17A+ CD4+ T cell supernatant elicits robust 
IL-6 and IL-8 detection levels, suitable to progress to blocking experiments (Figure 
4.14B).  In contrast, addition of the IL-17A- CD4+ T cell supernatants did not induce 
any IL-8 secretion from the synovial fibroblasts and only a limited amount of IL-6 
protein was observed upon addition of the maximum 20% concentration. It is 
important to note that from these data we cannot conclude definitively that IL-17A- 
CD4+ T cell supernatants do not elicit an IL-6 or IL-8 fibroblast response. This is 
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because there may have been a proportion of IL-17A- CD4+ T cells, which were not 
within the IL-17A- CD4+ T cell-sorting gate, shown in Figure 4.14. 
 
Synovial fibroblasts were cultured with 20% of IL-17A+ CD4+ T cell supernatants 
and the effect of IL-17A and IL-17F dual blockade was assessed. As depicted in Figure 
4.15, addition of IL-17A+ CD4+ T cell supernatants to fibroblasts led to an increase 
in IL-6 secretion. Blocking IL-17A reduced IL-6 secretion, whereby IL-17F blockade 
had no effect. Addition of bimekizumab did not show significantly reduced IL-6 
protein when compared to anti-IL-17A. Figure 4.16B examines the anti-IL-17A vs. 
bimekizumab data in more detail. In four out of five experiments bimekizumab 
reduced IL-6 secretion by fibroblasts to a greater extent that IL-17A blockade alone. 
However, in two of these experiments the decrease was minimal. In one out of five 
experiments, IL-6 was slightly increased upon culture with bimekizumab. Therefore 
no consistent results were observed. I sought to determine whether the experiments 
which exhibited a significant decrease in IL-6 levels in bimekizumab vs. anti-IL-17A 
correlated with high IL-17F protein levels present in the matched neat IL-17A+ CD4+ 
T cell supernatants. Indeed, the sorted IL-17A+ CD4+ T cell supernatant which 
displayed the highest levels of IL-17F protein matched with the greatest decrease in 
IL-6 levels in bimekizumab vs. anti-IL-17A (Figure 4.16C). In general a positive 
correlation was observed across the cumulative data. While IL-8 secretion by 
fibroblasts was increased upon addition of IL-17A+ CD4+ T cell supernatant, addition 






Figure 4.14 Gating strategy for sorting IL-17A+ CD4+ T cells. 
After performing an IL-17A secretion assay (described in the materials and methods), viable 
lymphocytes were gated based on their SSC-W/FSC-A properties. Using a SSC-A vs. SSC-W plot 
doublet cells were excluded and dead cells were excluded based on their uptake of the viability dye, 
eFluor 780. Within CD3+ CD4+ CD8- T cells, expression of IL-17A was analysed. IL-17A+ and IL-
17A- gates were set and cells were sorted and collected. (B) To assess non-specific binding, a negative 
control was acquired. The negative control consisted of stimulated cells which had been stained with 
viability dye, CD3, CD4, CD8 and the secondary IL-17A detection antibodies but had not been 



































Figure 4.15 Comparison of sorted IL-17A- vs. IL-17A+ sorted CD4+ T cell 
supernatants on the induction of IL-6 and IL-8 from synovial fibroblasts. 
Bulk CD4+ T cells were cultured with αCD3, αCD28, IL-1β and IL-23 for 3 days. Following a 1.5 hour 
PMA and ionomycin re-stimulation an IL-17A secretion assay was performed. A FACS Aria sorter was 
used to sort IL-17A+ and IL-17A- CD4+ T cells.  Sorted IL-17A+ and IL-17A- CD4+ T cells were 
cultured in RMPI media for 24 hours. (A) Cell supernatants were collected and IL-17A, IL-17F and IL-
17AF protein levels were analysed  by ELISA. Dashed red lines indicate lower detection limit. Results 
show analysis from three individual donors. (B) Supernatants were collected and added to 10x103 PsA 
and RA synovial fibroblasts diluted in different ratios of DMEM media (CD4+ T cell donor n=1 added 
to fibroblasts RA n=1, PsA n=1). 
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Figure 4.16 Assessing the effect of dual IL-17A and IL-17F blockade in Th17 
supernatant. 
Bulk CD4+ T cells were cultured with αCD3, αCD28, IL-1β and IL-23 for 3 days. Following a 1.5 hour 
PMA and ionomycin re-stimulation an IL-17A secretion assay was performed. A FACS Aria sorter was 
used to sort IL-17A+ CD4+ T cells.  Sorted IL-17A+ CD4+ T cells were cultured in RMPI media for 
24 hours. Supernatants were collected, diluted at a ratio of 1:5 in media and added to 10x103 PsA and 
RA synovial in the absence or presence of blocking antibodies (10μg/ml). Supernatants were collected 
and analysed for IL-6 and IL-8 protein levels via ELISA. (A) displays the results of all blocking 
antibodies while (B) displays the data for anti-IL-17A and bimekizumab in a different format. Circle 
symbols represent RA synovial fibroblasts and triangle symbols represent PsA synovial fibroblasts. 
Each colour represents sorted IL-17A+ CD4+ T cell supernatant from an individual healthy donor. (C) 
displays IL-8 ELISA results. (D) The fold change decrease in IL-6 secretion in bimekizumab vs. anti-
IL-17A conditions was correlated to IL-17F protein levels present in the matching neat sorted IL-17A+ 
CD4+ T cell supernatant. (n=5: IL-17A+ CD4+ supernatant individual donors n=3 cultured with RA 
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4.2.9 Examining the interaction of synovial fibroblasts and sorted IL-
17A+ and IL-17A- CD4+ T cells  
Next, synovial fibroblasts were cultured with sorted IL-17A- and IL-17A+ CD4+ T 
cells at a 1:2.5 ratio for 24 hours. Supernatants were then collected and IL-6 and IL-8 
protein levels were measured by ELISA. Similar to our results observed with IL-17A 
sorted cell supernatant, IL-17A+ CD4+ T cells elicited an IL-6 and IL-8 fibroblast 
response, whereas only low levels of IL-6 were observed with IL-17A- CD4+ T cells 
(data not shown). As previously mentioned, it is important to note that from these data 
we cannot conclude that IL-17A- CD4+ T cells do not elicit an IL-6 or IL-8 fibroblast 
response. This is because there may have been a proportion of IL-17A- CD4+ T cells, 
which were not within the IL-17A- CD4+ T cell-sorting gate 
 
The effect of IL-17 and TNFα blockade was assessed in cultures of synovial 
fibroblasts and sorted IL-17A+ CD4+ T cells. As depicted in Figure 4.16, in 
comparison to the isotype control, addition of anti-IL-17A blocking antibody 
decreased IL-6 secretion by fibroblasts, while IL-17F blockade had no effect. In 3 out 
of 5 experiments bimekizumab reduced IL-6 levels to a greater extent than IL-17A 
blockade alone, however in the remaining two experiments elevated levels of IL-6 was 
observed in bimekizumab conditions vs anti-IL-17A. Therefore, no consistent result 






Figure 4.17 Assessing the effect of dual IL-17A and IL-17F blockade in 
fibroblast and IL-17A+ CD4+ T cell cultures. 
Bulk CD4+ T cells were cultured with αCD3, αCD28, IL-1β and IL-23 for 3 days. Following a 1.5 hour 
PMA and ionomycin re-stimulation an IL-17A secretion assay was performed. A FACS Aria sorter was 
used to sort IL-17A+ CD4+ T cells. IL-17A+ CD4+ T cells were cultured with RA and PsA synovial 
fibroblasts at a 2.5:1 ratio in the absence or presence of blocking antibodies (all at 1μg/ml). (A) displays 
the results of all blocking antibodies while (B) displays the data for anti-IL-17A and bimekizumab in a 
different format. Circle symbols represent RA synovial fibroblasts and triangle symbols represent PsA 
synovial fibroblasts. Each colour represents sorted IL-17A+ CD4+ T cell supernatant from an individual 
healthy donor. (C-D) displays IL-8 ELISA results. (n=5: IL-17A+ CD4+ T cell individual donors n=3 






















































































































































































































































4.2.10 Development of an IL-17A and IL-17F CD4+ T cell capture assay 
The focus of the work described in this chapter was to investigate whether IL-17F has 
the functional potential to contribute to the immunopathology of inflammatory 
arthritis. Currently we have shown that IL-17F synergises with TNFα, enhancing its 
inflammatory potential. Moreover, we have demonstrated using recombinant 
cytokines that dual blockade of IL-17A and IL-17F is more effective than blockade of 
IL-17A alone. The superior effect of dual IL-17A and IL-17F blockade was 
demonstrated in fibroblast cultures with IL-17A+ CD4+ T cells and IL-17A+ CD4+ 
T cell supernatant, however, the effect was not as significant as observed with the 
recombinant cytokine cultures. This could be due to the limitations of using IL-17A+ 
CD4+ T cells. With no IL-17F secretion assay commercially available, only IL-17A+ 
CD4+ T cells could be sorted. While this method captured IL-17A+ IL-17F- and IL-
17A+ IL-17F+ CD4+ T cells, IL-17F+ IL-17A- CD4+ T cells were not captured.  
 
Figure 4.18 illustrates the extent to which IL-17F+ IL-17A- CD4+ T cells may be lost 
during an IL-17A secretion assay. Here, bulk CD4+ T cells were cultured for 3 days 
with IL-1β, IL-23, αCD28 mAb and αCD3 mAb. Cells were pooled and while the 
majority were stimulated for 1.5 hours with PMA and ionomycin and followed by an 
IL-17A secretion assay, a small number of cells were stimulated for 1.5 hours with 
PMA, ionomycin and golgistop. This was followed by an intracellular cytokine stain. 
Figure 4.18 shows the flow cytometric results of two individual donors. The results 
demonstrate that a significant number of IL-17F+ IL-17A- CD4+ T cells were present 
in the pre-IL-17A sorted samples which would not be captured by the IL-17A+ CD4+ 
T cell cytokine secretion assay. This suggests that performing the blocking experiment 
using sorted IL-17A+ CD4+ T cells may not reveal the superior extent of dual IL-17A 
and IL-17F blockade. 
 
These data highlighted the need for an IL-17F secretion assay. Moreover, having the 
tools to separate IL-17A and IL-17F expressing CD4+ T cells would allow for further 
extensive characterisation and comparison of the cells, following on from data shown 




As illustrated in Figure 4.19, the aim of this series of experiments was to develop an 
assay which successfully separated IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ 
IL-17A- CD4+ T cells. UCB developed a bespoke anti-CD45 Fab Y fragment as well 
as Fab X fragments which recognize IL-17A (both the IL-17A homodimer and the IL-
17AF heterodimer) and IL-17F (IL-17F homodimer only). These Fab fragments were 
combined to form an anti-IL-17A - anti-CD45 complex and anti-IL-17F - anti-CD45 
complex. While an extensive series of optimisation experiments were performed to set 
up the capture assay protocol, here I present a selection of key experiments. To begin, 
we wanted to test the ability of the Fab complexes to recognize CD45, IL-17A and IL-
17F. To achieve this, fresh PBMC were cultured simultaneously with the anti-IL-17A 
– anti-CD45 and anti- IL-17F – anti-CD45 Fab complex. During this culture the Fab 
complexes should recognize and bind to CD45 expressed on all PBMC. Next, cells 
were cultured in the absence or presence of high concentrations of either human 
recombinant cytokine IL-17A or IL-17F.  Cells were then extracellularly stained for 
IL-17A and IL-17F and analysed by flow cytometry. As expected, no IL-17A or IL-
17F cells were observed in the absence of recombinant cytokines (Figure 4.20). 
However, in the presence of recombinant cytokines, over 90% of total cells were IL-
17A or IL-17F positive. This indicated that the PBMC CD45 marker and the IL-17A 
and IL-17F human recombinant cytokines were all successfully recognized by the Fab 
complexes. 
 
Next, we tested the ability of the Fab complexes to recognize and distinguish IL-17A+ 
IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells from stimulated 
PBMC. In this experiment, PBMC were stimulated for 4 days with IL-1β, IL-23, 
αCD28 and αCD3 and re-stimulated  for 3 hours with PMA and ionomycin. A detailed 
summary of the final optimized IL-17A and IL-17F secretion assay protocol is 
provided in section 2.5.5. In this case, cells were incubated in the absence or presence 
of either anti-IL-17A – anti-CD45 Fab Complex or anti-IL-17F – anti-CD45 Fab 
complex or both simultaneously. An extracellular cytokine stain was then performed 
on the cells assessing the expression of IL-17A and IL-17F.  No IL-17A or IL-17F 
expressing cells were observed in the condition with no Fab complexes (Figure 4.21). 
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However, IL-17A+ CD4+ T cells were detectable in cultures incubated with the IL-
17A Fab complex. Moreover, this condition detected IL-17F+ CD4+ T cells. As the 
IL-17F detection antibody recognizes both the IL-17F homodimer and the IL-17AF 
heterodimer, we predict the IL-17F detection antibody is recognizing IL-17AF 
heterodimer cytokine which has been captured to IL-17A Fab complexes bound to the 
CD4+ T cell. Flow cytometric analysis of PBMC cultures incubated with the IL-17F 
Fab complex revealed IL-17F+ CD4+ T cells. In concordance with the IL-17F Fab 
complex specificity, no IL-17A+ CD4+ T cells were observed. Finally, combining the 
IL-17A and IL-17F Fab complexes allowed for the IL-17A+ IL-17F-, IL-17A+ IL-
17F+ and IL-17F+ IL-17A- CD4+ T cells to be distinguished. These data confirmed 






Figure 4.18 In vitro cultures induce IL-17F+ IL-17A- CD4+ T cells which are 
not captured by IL-17A secretion assays. 
Bulk CD4+ T cells were cultured with αCD3, αCD28, IL-1β and IL-23 for 3 days. While an IL-17A 
secretion assay protocol was performed on the majority of cells, a small number of cells were stimulated 
for 1.5 hours with PMA, ionomycin and golgi stop. These cells were stained intracellularly to analyse 
the expression of IL-17A and IL-17F. Results show the flow cytometric plots from two individual 




















Figure 4.19 Schematic of UCB IL-17A/IL-17F capture assay. 
As shown in (A), the aim of the IL-17A/IL-17F capture assay is to separate the three different IL-17A/ 
IL-17F CD4+ T cell populations – IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- for 
functional and molecular characterisation. (B) The capture assay consisted of 2 Fab complexes, Fab Y 
CD45 – Fab X IL-17A and Fab Y CD45 – Fab X IL-17A. Stimulated CD4+ T cells were incubated 
with both Fab complexes, simultaneously. Bound to CD45 expressed on CD4+ T cells, the Fab 
complexes captured any IL-17A/IL-17F/IL-17AF cytokines secreted from a CD4+ T cell. To detect IL-
17A/ IL-17F CD4+ T cells, secondary detection antibodies were used, which recognised different 
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Figure 4.20 UCB in-house anti-IL-17A and anti- IL-17F Fab fragments 
successfully recognise human recombinant IL-17A and IL-17F. 
Fresh PBMC were incubated with either UCB in-house anti-IL-17A – anti-CD45 Fab complex or anti-
IL-17F – anti-CD45 Fab complex. Cells were then incubated in the absence or presence of IL-17A or 
IL-17F human recombinant cytokine (10μg/ml). An extracellular cytokine stain was then performed 
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Figure 4.21 Testing the IL-17A and IL-17F capture assay. 
PBMCs were cultured with αCD3, αCD28, IL-1β and IL-23 for 4 days and re-stimulated with PMA 
and ionomycin for 3 hours. Cells were incubated in the absence or presence of either anti-IL-17A – 
anti-CD45 Fab Complex, anti-IL-17F – anti-CD45 Fab complex or both simultaneously. To allow for 
cytokine capture, cells were cultured for 45 minutes in X-vivo media, rotating. Intracellular cytokine 
expression of IL-17A and IL-17F was then assessed. Flow cytometric data shows the cytokine 
expression within live CD3+ CD4+ T cells (n=1). 
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4.2.11 Sorting IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- 
CD4+ T cells 
Having established an IL-17A and IL-17F CD4+ T cell capture assay protocol, we 
proceeded to sorting the captured IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ 
IL-17A- CD4+ T cell population and verifying successful isolation via qPCR. Bulk 
CD4+ T cells were cultured with αCD3, αCD28, IL-1β and IL-23 for 3 days and re-
stimulated for 3 hours with PMA and ionomycin. Cells were then incubated 
simultaneously with the IL-17A and IL-17F Fab complexes. As a negative control, to 
assess non-specific binding, a small number of cells were not incubated with the Fab 
complexes. To allow for cytokine capture, cells were then incubated for 45 mins, 
rotating. Cells were stained with DAPI viability dye, extracellular markers and IL-
17A and IL-17F detection antibody. Using a FACS Aria sorter, the different IL-17-
expressing CD4+ T cell populations were sorted. Figure 4.22 illustrates the gating 
strategy used. This experiment was performed on two individual donors. 
 
The total RNA from sorted IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- 
CD4+ T cell populations was isolated using a micro-RNA kit. Reverse transcription 
was then performed, converting the RNA into cDNA. qPCR reactions were performed 
using primers for CD4 and human IL-17A and IL-17F. The ACTB gene was used as 
an endogenous control. Figure 4.23 displays the qPCR results from two individual 
donors. In all sorted populations from the two healthy donors, CD4 mRNA was 
detected. IL-17A mRNA was detected in sorted IL-17A+ IL-17F- and IL-17A+ IL-
17F+ CD4+ T cell populations, whereas, the relative mRNA IL-17A expression was 
low/ not detectable in the sorted IL-17A- IL-17F- and IL-17F+ IL-17A- CD4+ T cell 
populations. This result was observed in both sorts. Similarly, IL-17F mRNA was only 
at high expression levels observed in the sorted IL-17F+ IL-17A- and IL-17A+ IL-
17F+ CD4+ T cell populations.  
 
These data suggest that the IL-17A and IL-17F capture assay protocol has successfully 
isolated and separated three different IL-17 populations – IL-17A+ IL-17F-, IL-17A+ 
IL-17F+ and IL-17F+ IL-17A- CD4+ T cells. However, it is important to note that the 
raw Ct qPCR values indicate that the sorted populations may not be 100% pure. For 
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example, IL-17A+ IL-17F- CD4+ T cells captured in the first sort shown a Ct value 
of 24 for IL-17F expression. Generally, a Ct value of 30 or higher indicates the absence 
of the mRNA of interest. Therefore, IL-17F mRNA may be present within the IL-
17A+ IL-17F- CD4+ T cell population. Further validation of the IL-17A and IL-17F 
capture assay is currently being carried out by UCB. Once validation is complete, the 






Figure 4.22 Gating strategy for IL-17A and IL-17F capture assay. 
Following the IL-17A/IL-17F capture assay protocol (described in the materials and methods), viable 
lymphocytes were gated based on their FSC-W/FSC-A properties. Dead cells were excluded based on 
their uptake of the viability dye, DAPI. Within CD3+ CD4+ T cells, expression of IL-17A and IL-17F 
was analysed. Gates were applied to separate and sort IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-
17F+ IL-17A- CD4+ T cells. (B) To assess non-specific binding, a negative control was acquired. The 
negative control consisted of stimulated cells which had been stained with CD3, CD4 and the secondary 




































Figure 4.23 Validation of the IL-17A and IL-17F capture assay. 
Bulk CD4+ T cells were cultured with αCD3, αCD28, IL-1β and IL-23 for 3 days and re-stimulated 
with PMA and ionomycin for 3 hours. Cells were incubated simultaneously with UCB in-house anti-
IL-17A – anti-CD45 Fab Complex, anti-IL-17F – anti-CD45 Fab complex or both simultaneously. To 
allow for cytokine capture, cells were cultured for 45 minutes in X-vivo media, rotating. Cells were 
stained with DAPI viability dye, extracellular markers and IL-17A and IL-17F detection antibodies. 
Using a FACS Aria sorter, IL-17A- IL-17F-, IL-17A+ IL-17F-. IL-17A+ IL-17F+ and IL-17F+ IL-
17A- CD4+ T cells were sorted. Total RNA was isolated from all sorted populations and converted into 
cDNA via reverse transcription. QPCR was then performed to assess the mRNA expression levels of 
IL17A, IL17F and CD4 (n=2 independent experiments). 






















































































































































































































































































































































4.2.12 Examining the function of the remaining IL-17 cytokines 
The function of the remaining IL-17 cytokines - IL-17B, IL-17C, IL-17D and IL-17E 
is less well studied. In this final section we explored the effect of the remaining IL-17 
family members on PsA and RA synovial fibroblasts. Similar to the experiments 
described in the beginning of this chapter, human recombinant IL-17B, IL-17C, IL-
17D and IL-17E were added to PsA and RA synovial fibroblasts at the indicated 
concentrations. As a positive control, IL-17A, IL-17F, IL-17AF and TNFα were 
included in the assays. Following 24 hours incubation, the supernatant was collected 
and stored at -80 before being tested by ELISA for IL-6 and IL-8 protein levels. IL-
17A, IL-17F, IL-17AF and TNFα elicited an IL-6 and IL-8 fibroblast response, as 
previously demonstrated (Figure 4.24). However, IL-17B, IL-17C, IL-17D and IL-
17E did not induce IL-6 and IL-8 fibroblast secretion. 
 
Next, I examined whether there was any synergistic effect between IL-17B, IL-17C, 
IL-17D or IL-17E and TNFα. Unexpectedly, a strong synergistic effect was observed 





Figure 4.24 IL-17B, IL-17C, IL-17D and IL-17E alone do not elicit an IL-6 or 
IL-8 response from synovial fibroblasts. 
RA and PsA synovial fibroblasts (10x103) were cultured with indicated concentrations of human 
recombinant IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, IL-17AF and TNFα for 24 hours. 
Culture supernatants were collected and IL-6 and IL-8 (PsA n=1, RA n=1) protein levels were measured 
by ELISA. Dashed red and blue lines indicate lower detection limit and upper detection limit, 
respectively. 
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Figure 4.25 IL-17E synergises with TNFα, augmenting IL-6 and IL-8 synovial 
fibroblast secretion. 
Synovial RA and PsA fibroblasts (10x103) were cultured with human recombinant IL-17A, IL-17B, IL-
17C, IL-17D, IL-17E and IL-17AF (10ng/ml) in the absence or presence of TNFα (1ng/ml) with for 24 
hours. Culture supernatants were collected and IL-6 and IL-8 protein levels were measured by ELISA. 
Dashed red and blue lines indicate lower detection limit and upper detection limit, respectively (RA 





































































































































Data presented in this chapter show that the inflammatory potential of IL-17A and IL-
17F is synergistically enhanced with TNFα. However, in the presence of IL-17A, the 
effect of IL-17F on inflammation is limited. Nevertheless, this chapter suggests that 
in an environment whereby IL-17A and IL-17F are present, dual blockade of these 
cytokines is more effective at reducing inflammation. Using a reductionist system, 
whereby synovial fibroblasts are cultured with a cocktail of recombinant cytokines, 
results show dual blockade of IL-17A and IL-17F is more effective at reducing IL-6 
and IL-8 secretion by fibroblasts than blockade of IL-17A alone. This chapter explores 
the effect of dual IL-17A and IL-17F blockade in a variety of different physiological 
systems. The superior effect of dual IL-17A and IL-17F blockade was not always 
consistent across the physiological systems. This is likely due to the levels of IL-17F 
protein present. These data highlight the need for an IL-17F secretion assay. In 
collaboration with UCB, an IL-17A and IL-17F secretion assay was developed, which 
following further validation will be a useful tool to further characterise IL-17A and 
IL-17F producing cells.  Finally, data presented in this chapter demonstrate that IL-
17E also synergises with TNFα enhancing IL-6 and IL-8 secretion by fibroblasts. 
 
Experimental evidence has implicated IL-17A in the immunopathology of 
inflammatory arthritis. Seminal research blocked IL-17A in the CIA mouse model 
with a soluble IL-17 receptor fusion protein; this resulted in suppressed arthritis 
development and joint damage. Moreover, overexpression of IL-17A in CIA led to 
accelerated development and enhanced severity of synovial inflammation and joint 
damage 358. In contrast, the role of IL-17F in inflammation remains questioned. 
Reports often describe IL-17F to be redundant to IL-17A. In the EAE mouse model, 
IL17F knock-out did not lead to a reduction in disease severity 106.  
 
IL-17A, IL-17F and IL-17AF all signal through the same IL-17RA and IL-17RC 
receptor complex. Literature has previously shown that IL-17A, IL-17F and IL-17AF 
elicit an inflammatory response in a hierarchical fashion, with IL-17A the most potent 
cytokine followed by IL-17AF and then IL-17F 78. This is supported by data in this 
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chapter, whereby human recombinant IL-17A induced the highest levels of IL-6 and 
IL-8 secretion by synovial fibroblasts, IL-17AF induced intermediary levels and IL-
17F induced the lowest levels. Reports attribute the difference in potency to the 
cytokine binding affinities to the IL-17RA receptor. IL-17A and IL-17F bind with 
equally high affinity to IL-17RC, however, in comparison to IL-17A, IL-17F binds 
with at least 100-fold lower affinity to IL-17RA 85. 
 
Data presented in this chapter show that IL-17A, IL-17F and IL-17AF all synergise 
with TNFα leading to an enhancement in IL-6 and IL-8 secretion by fibroblasts. Once 
again, a hierarchical result is observed with the combination of TNFα and IL-17A 
eliciting the highest levels of IL-6 and IL-8, followed by TNFα/IL-17AF and 
TNFα/IL-17F. This is supported by studies present in the current literature 106. 
Nevertheless, these data importantly show that the low potency of IL-17F alone is 
significantly enhanced in the presence of TNFα. Therefore, it is important to consider 
the roles of IL-17F in concert with other molecules. Expanding upon data in the 
literature, the results presented show there is no synergistic or additive effect between 
the IL-17 cytokines themselves. Moreover, it is shown that addition of IL-17F and/ or 
IL-17AF does not further enhance IL-6 or IL-8 levels secreted by fibroblasts which 
are cultured with IL-17A and TNFα. This indicates that in the presence of IL-17A, IL-
17F may be redundant. 
 
However, blocking experiments performed in cultures of synovial fibroblasts and 
recombinant cytokines (a cocktail of IL-17A, IL-17F, IL-17AF and TNFα) revealed 
that dual IL-17A and IL-17F blockade by bimekizumab is more effective at reducing 
IL-6 and IL-8 secretion by fibroblasts vs. blockade of IL-17A alone. Blockade of IL-
17F alone had no effect on fibroblast secretion. Blockade of TNFα reduced IL-6 and 
IL-8 secretion levels similar to that of dual IL-17A and IL-17F blockade. These data 
show that in the presence of IL-17A, IL-17F has a limited effect on fibroblasts. 
However, in the absence of IL-17A, IL-17F can synergise with TNFα and elicit a 
significant inflammatory response. Therefore in an environment where IL-17A and 





The superior effect of dual IL-17A and IL-17F has recently been reported by Glatt et 
al. In this study, target cells were stimulated with Th17 supernatant in the absence or 
presence of IL-17 specific blocking antibodies 121. To generate the Th17 supernatant 
blood CD4+ CD45RO+ CCR6+ CXCR3- Th17 cells were sorted from healthy donors 
and stimulated with anti-CD3 mAb and anti-CD28 mAb for 96 hours. In PsA 
synoviocyte cultures, dual IL-17A and IL-17F neutralization by bimekizumab resulted 
in a greater downregulation of IL-8. Moreover, transcriptional analysis in Th17 
stimulated normal synoviocytes confirmed that dual IL-17A and IL-17F led to further 
decrease in the inflammatory profile vs. blockade of IL-17A alone.  
 
Prior and following the Glatt et al. publication, experiments performed in this chapter 
aimed to show in a physiological in vitro system (i.e blockade of IL-17 cytokines in 
CD4+ T cell supernatant) that dual IL-17A and IL-17F blockade is more effective in 
reducing inflammation than IL-17A alone. No superior effect of a combined IL-17A 
and IL-17F blockade was observed in synovial fibroblast cultures stimulated with in 
vitro bulk CD4+ T cell supernatants. This is likely due to the low IL-17 protein levels 
observed in the generated supernatant. To generate CD4+ T cell supernatant enriched 
for IL-17 protein levels two approaches were used, sorting CCR6+ CD161+ CD4+ T 
cells or sorting IL-17A+ CD4+ T cells. Although culturing sorted CCR6+ CD161+ 
CD4+ T cells with synovial fibroblasts elicited a higher level of IL-6 secretion when 
compared with cultures of bulk CD4+ T cells and fibroblasts, addition of bimekizumab 
did not lead to a greater reduction of IL-6 secretion than blockade of IL-17A alone. 
However, this experiment has only been performed once and it may be worthwhile to 
repeat. A limitation to this experiment is that not all total CCR6+ and/or CD161+ 
CD4+ T cells express IL-17A and IL-17F. Furthermore, not all IL-17A+ and IL-17F+ 
CD4+ T cells express CCR6 and/or CD161. 
 
As previously discussed, while an IL-17A secretion assay is commercially available, 
there is not one for IL-17F. Therefore, it is not possible to enrich for both IL-17A+ 
and IL-17F+ CD4+ T cells. However, there is a population of CD4+ T cells that co-
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express IL-17A and IL-17F present in CD4+ T cell cultures stimulated for 3 days with 
IL-1β, IL-23, anti-CD28 mAb and anti-CD3 mAb. Therefore, it was decided to sort 
IL-17A+ CD4+ T cells and assess the effect of dual IL-17A and IL-17F blockade in 
this supernatant. Synovial fibroblasts cultured with sorted IL-17A+ CD4+ T cells or 
sorted IL-17A+ CD4+ T cell supernatants in the absence or presence of IL-17 specific 
blocking antibodies led to varying results. Correlation analysis demonstrated that in 
general, the greatest effect of dual IL-17A and IL-17F blockade was observed when 
higher levels of IL-17F protein was present, which varied from donor to donor. 
Certainly, as this experiment was performed in 3 donors, performing additional 
experiments may provide stronger evidence for the role of dual IL-17A and IL-17F 
blockade in reducing inflammation using more physiological supernatants. A 
limitation to using sorted IL-17A+ CD4+ T cell supernatant for dual IL-17A and IL-
17F blockade was the fact that IL-17F+ IL-17A- CD4+ T cells are not captured. 
Therefore, the full effect of dual blockade is not observed. An ideal experiment would 
involve capturing IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T 
cells, pooling these together and incubating for 24 hours. The generated supernatant 
could then be added to synovial fibroblast cultures in the absence or presence of IL-
17 specific blocking antibodies. 
 
There was thus an increasing need for a combined IL-17A and IL-17F secretion assay. 
Such an assay would be a great tool for sorting of IL-17A+ IL-17F-, IL-17A+ IL-17F+ 
and IL-17F+ IL-17A- CD4+ T cell populations. This would allow for the functional 
potential and characterisation of IL-17F expressing CD4+ T cells (discussed in chapter 
3) to be elucidated. Fab fragments directed against IL-17A, IL-17F and CD45 were 
designed by UCB. In collaboration with UCB, a protocol was developed to effectively 
sort IL-17A and IL-17F producing cells using the Fab fragments. Data in this chapter 
show the effective sorting of IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-
17A- CD4+ T cells, as evidenced by RNA analysis. However, RNA analysis did 
indicate the sorted IL-17 populations may not be 100% pure. Therefore, further 
validation work is required to confirm successful sorting of the different IL-17 
populations. Another validation approach could involve culturing the sorted IL-17 
populations for 24 hours and then measuring the supernatant for IL-17A, IL-17F and 
IL-17AF protein levels via ELISA. It could then be confirmed that IL-17A+ IL-17F- 
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CD4+ T cells only produce IL-17A protein, IL-17A+ IL-17F+ CD4+ T cells secrete 
IL-17A, IL-17F and IL-17AF and so on. It is unknown whether the different IL-17 
populations arise from one another. For example, under specific stimulatory 
conditions do IL-17A+ IL-17F- CD4+ T cell populations skew to IL-17A+ IL-17F+ 
and then IL-17F+ IL-17A- CD4+ T cells? If so, it may be possible sorted IL-17F+ IL-
17A- CD4+ T cells over time revert back to IL-17A+ IL-17F+ or IL-17A+ IL-17F- 
CD4+ T cells and alter the IL-17 cytokines secreted. Therefore, it would be of great 
interest to analyse the supernatant of the sorted IL-17 expressing CD4+ T cell 
populations across multiple time-points.  
 
Blockade of IL-17 cytokines in in vivo would be the best way to determine 
demonstrate whether IL-17A and IL-17F blockade can further help alleviate 
inflammatory arthritis. It was shown in the CIA mouse model that combined IL-17A 
and IL-17F blockade was not significantly different when compared to blockade of 
IL-17A alone. However, the study did demonstrate that in this model levels of IL-17F 
were low 362. In contrast, an investigation which involved treating colitic mice with 
IL-17A and IL-17F neutralising antibodies demonstrated that neutralisation of both 
IL-17A and IL-17F significantly reduced T cell-mediated colitis development, 
whereas neutralisation of IL-17A or IL-17F alone was inefficient at reducing disease 
severity 363. In humans, brodalumab which blocks the IL-17RA receptor thereby 
preventing the function of IL-17A and IL-17F has been shown alleviate inflammation 
in psoriasis and PsA 403,404. However, with no head-to-head comparisons between the 
effectiveness of brodalumab and therapies which target IL-17A alone, it is difficult to 
understand the contribution of IL-17F to disease pathology. A recent report from 
Sawyer et al. performed a systematic literature review and network meta-analysis to 
examine the relative efficacy of brodalumab compared with other approved biologics 
in moderate-to-severe psoriasis 412. The primary analysis assessed the proportion of 
patients achieving psoriasis area severity index (PASI) 50, 75, 90 or 100. This refers 
to the percentage of disease reduction compared to base-line. For example, a PASI 50 
score represents a 50% improvement from base-line and is acknowledged as a 
clinically significant end-point 413. In this study it was suggested that consistent with 
PASI 50, 75 and 90, brodalumab displayed superior efficacy to the anti-IL-17A 
antibody secukinumab, however, its efficacy was similar to the other IL-17A inhibitor, 
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ixekizumab. While this meta-analysis study may provide insights into whether dual 
IL-17A and IL-17F blockade may be beneficial in reducing inflammation in psoriasis, 
it is difficult to interpret without a head-to-head study. Additionally, it is difficult to 
delineate whether possible superior effects of brodalumab are attributed to IL-17F or 
other mechanisms by IL-17RA blockade. As previously discussed, bimekizumab is 
currently in clinical trial and demonstrated efficacy in PsA and psoriasis 121,414. 
However, at this point it is difficult to assess whether it has a superior effect than 
blockade of IL-17A alone. 
 
Of course, the success of dual IL-17A and IL-17F in inflammatory arthritis depends 
on the presence of these cytokines. While extensive literature has confirmed the 
presence of IL-17A in RA and PsA, there is a lack of robust evidence confirming the 
presence of IL-17F. This is further explored in the final chapter of this thesis. It is also 
important to note that as IL-17A and IL-17F play an important role in providing 
protection against extracellular pathogens and fungal infections, dual blockade of IL-
17A and IL-17F in inflammatory disease patients may lead to increased risk of 
infections. One of these adverse reactions could include chronic mucocutaneous 
candidiasis (CMC), which is characterised by recurrent or persistent infection of nails, 
skin and mucosae predominantly by candida albicans. This is evidenced by the fact 
that autosomal recessive IL-17RA and autosomal dominant IL-17F deficiencies are 
associated with CMC 415. 
 
The final section in this chapter explores the effect of the remaining IL-17 cytokines 
(IL-17B, IL-17C, IL-17D and IL-17E) on synovial fibroblasts. None of these 
cytokines induced an IL-6 or IL-8 response from synovial fibroblasts. However, IL-
17E combined with TNFα elicited a potent IL-6 and IL-8 response. To the best of my 
knowledge synergy between IL-17E and TNFα has not been previously reported. 
Studies have described IL-17E to have anti-inflammatory 125 and inflammatory 
properties 384. The anti-inflammatory effect of IL-17E has been attributed to the ability 
of IL-17E to suppress IL-17A expressing cells 125. In contrast, IL-17E has been shown 
to activate macrophages leading to an inflammatory response 384. It would be of 
interest to investigate whether synergy between IL-17E and TNFα could be observed 
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in a physiological system (i.e. blockade of IL-17E in a supernatant whereby IL-17E 
and TNFα are present at significant levels). One challenge to this experiment is that 
IL-17E producing cells, for example Th2 cells do not reportedly co-express TNFα. For 
this reason, in the next chapter we were interested to determine the presence of IL-17E 
protein in RA and PsA synovial fluid.  
 
Although microarray analysis revealed the presence of all IL-17 receptors on RA and 
PsA synovial fibroblasts, IL-17B, IL-17C or IL-17D did not elicit an inflammatory 
response from synovial fibroblasts. The receptor expression on the cell lines used was 
not analysed, therefore it could be that the receptor expression on these cell lines were 
low. Future experiments could assess the effect of these cytokines on other target cells. 
 
While the function of the IL-17 cytokines is covered in this chapter, the final chapter 











In this final results chapter, I explored the presence of IL-17A and IL-17F in 
inflammatory arthritis. Inflammatory arthritis encompasses rheumatoid arthritis (RA), 
psoriatic arthritis (PsA), ankylosing spondylitis and juvenile idopathic arthritis among 
others. In this project we focus on RA and PsA. 
 
The link between IL-17A and  RA  pathology was established in 1999 when 
rheumatoid synovial explants were shown to produce functional IL-17A and IL-17A 
producing cells were identified in T cell-rich areas of the synovium 83. Seminal 
research blocked IL-17A in the collagen-induced arthritis (CIA) mouse model with a 
soluble IL-17 receptor fusion protein; this resulted in suppressed arthritis development 
and joint damage 358. Studies have revealed levels of IL-17A are elevated in the serum 
and synovial fluid of RA patients and correlate with the disease activity and severity 
366,367. Moreover, it has been shown that there is a significant increase in the 
frequencies of IL-17A+ CD4+ and IL-17A+ CD8+ T cells in the synovial fluid of PsA 
patients when compared to the peripheral blood of the same patient 374. 
 
While the literature provides strong evidence for the presence and 
immunopathological role of IL-17A in RA and PsA, robust evidence is lacking for IL-
17F. The limited available studies both support and refute the presence of IL-17F in 
RA and PsA. One study which stimulated RA SFMC for 24 hours with PMA and 
ionomycin detected IL-17A and IL-17AF protein in the culture supernatant, whereas 
IL-17F was undetectable 7. However, immunohistochemistry staining has revealed 
significantly increased IL-17F expression in PsA synovial tissue compared to OA 112. 
Moreover, a recent study has observed IL17F mRNA expression in 6 out of 14 PsA 
synovial tissue samples 121. The main aim of this final chapter was to investigate 




Specific aims for this chapter were as follows: 
• Investigate the presence of IL-17A, IL-17F, IL-17AF, IL-17E and other pro-
inflammatory cytokines in matched serum and SF samples from RA and PsA 
patients.  
• Assess the effect of RA and PsA serum and SF on synovial fibroblasts. 
• Investigate the presence of IL-17A and/or IL-17F producing CD4+ T cells and 
other immune cell subsets in RA and PsA PB and SF.  
• Examine the mRNA levels of IL17A and IL17F and the remaining IL-17 
cytokine members in cells from RA and PsA PB and SF. 





5.2.1 Investigating the presence of IL-17A, IL-17F and IL-17AF in 
matched serum and SF from RA and PsA patients 
To begin, I investigated the presence of IL-17A, IL-17F and IL-17AF in healthy 
control cell-free serum and RA and PsA matched cell-free serum and synovial fluid 
by Luminex. Information on this patient cohort is displayed in Table 5.1 (patient 
cohort 1). At the time of sample collection, patients were receiving no treatment, 
methotrexate or anti-TNF. Due to the limited numbers of patient samples, comparisons 
were not drawn between different treatment groups. Figure 5.1 illustrates the Luminex 
results of IL-17A and IL-17F. In 7 out of 8 RA donors, IL-17A protein was detected 
at higher levels in the RA SF vs. serum. Statistical significance was not achieved, 
presumably due to one donor displaying high levels of IL-17A in the serum vs. SF. 
Similar results were observed for IL-17F. IL-17F protein was detectable and present 
at higher levels in RA SF vs. serum, approximately 74 vs. 15 pg/ml, respectively. We 
also observed higher levels of IL-17A and IL-17F in PsA SF vs. serum, although 
statistical significance was not achieved. 
 
Since data in the current literature both support and refute the presence of IL-17F 
protein in the synovial fluid, my next aim was to validate these findings. Serum from 
healthy controls and paired serum and SF from RA and PsA were analysed for IL-17A 
and IL-17F protein levels via ELISA (eBioscience, Platinum ELISA). For this analysis 
matched serum and SF from OA patients was also included. This provided an 
additional negative control. Information on this patient cohort is displayed in Table 
5.2 (patient cohort 2).  Moreover, samples were analysed with an IL-17AF heterodimer 
ELISA (eBioscience, Platinum ELISA). In this instance, the IL-17A homodimer, IL-
17F homodimer and IL-17AF heterodimer ELISA had no or limited cross-reactivity 
with one another. In line with the previous findings, IL-17A protein was detectable in 
both RA and PsA synovial fluid (Figure 5.2). No IL-17A was detectable in the 
matched RA or PsA serum, healthy control serum or paired OA serum and SF. In 
contrast with the Luminex results, little IL-17F protein was detected. No clear increase 
of IL-17F protein in RA or PsA SF vs. serum was observed. Finally, IL-17AF protein 
was not detectable in any samples. The same result was observed with samples diluted 
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at different ratios including neat and 1:5 (data show IL-17A samples diluted 1:5 and 
IL-17F and IL-17AF samples analysed neat). 
 
While Luminex analysis detected IL-17F in RA and PsA SF, our ELISA results did 
not. It is important to note the lower detection limit for IL-17F varied between the 
Luminex and ELISA (2 vs. 15.6pg/ml, respectively). However, I still expected to 
detect IL-17F if it was present in SF with the ELISA. With these contradicting results, 
we sought to address whether the SF composition prevents detection of IL-17F using 
this particular ELISA kit. To achieve this, assay diluent or OA/RA/PsA serum or SF 
were spiked with either human recombinant IL-17A, IL-17F or IL-17AF. Samples 
were then analysed with the corresponding IL-17 ELISA. As displayed in Figure 5.3, 
IL-17F protein was detected in assay diluent and paired serum and SF samples spiked 
with human recombinant IL-17F. Similar results were observed for IL-17A and IL-
17AF. These data suggest that the SF composition does not block the recognition of 
IL-17F or IL-17AF protein via ELISA. These results indicate that the serum and SF 
ELISA analysis were reliable and IL-17F and IL-17AF were not present in the patient 
samples.  
 
With these data, the presence of IL-17F protein in RA and PsA serum and SF remains 
inconclusive. Why the luminex analysis generated clear positive IL-17F results and 
the ELISA analysis did not remains unknown. One speculation is that the positive IL-
17F luminex result was due to non-specific binding. These results highlight the 
variability in detecting IL-17F in patient samples using different methods. This, in 
part, could explain the contradicting studies present in the current literature. To move 
forward it was decided to investigate the presence of IL-17F using different methods 
including IL-17F blockade in serum and SF and flow cytometry analysis of IL-17F+ 




Table 5.1 Demographic and clinical parameters of patients included in luminex 




(n = 9) 
PsA 
Paired PB/SF 





















Age, mean ± SEM years 61.0  ± 3.8 44.2  ± 4.8 
 
39.50  ± 8.0 
 
 
Disease duration ± SEM years 





   
No treatment 3 3 - 
MTX 3 3 - 
Anti-TNF 3 - - 
 
DAS28 
   
Mean ± SEM 4.8  ± 0.46 4.6  ± 0.64 - 






Figure 5.1 Analysing the presence of IL-17A and IL-17F in RA and PsA 
matched serum and SF samples via Luminex. 
IL-17A and IL-17F protein levels in paired cell-free serum and synovial fluid from RA (n=7) and PsA 
(n=6) patients were analysed by luminex. Dashed blue lines represent the lower detection limit. 
Statistical significance was calculated using a Wilcoxon matched pairs test. Patient cohort information 























































































































Table 5.2 Demographic and clinical parameters of patients included in 
ELISA assays (patient cohort 2) 
 
 

























Age, mean ± SEM 
years


















Mean ± SEM 4.6  ± 0.3 4.6  ± 0.5 - -






Figure 5.2 Analysing the presence of IL-17A and IL-17F in RA and PsA 
matched serum and SF samples via ELISA. 
Serum from healthy controls (n=3) and paired serum and synovial fluid from OA patients (n=3), RA 
patients (n=7) and PsA patients (n=6) were analysed by ELISA for protein levels of IL-17A, IL-17F 
and IL-17AF. Dashed red and blue lines represent the lower and upper detection limit respectively. 
Statistical significance was calculated using a Wilcoxon matched pairs test. Patient cohort information 
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Figure 5.3 Human recombinant IL-17A, IL-17F and IL-17AF spiked in serum 
and SF samples are easily detectable via ELISA. 
Human recombinant IL-17A (100pg/ml), IL-17F (500pg/ml) and IL-17AF (500pg/ml) were 
individually spiked in either assay diluent (AD), or matched serum or SF from OA, RA or PsA patients. 
Samples were then analysed by the corresponding IL-17 cytokine ELISA (n=1). Dashed red and blue 
lines represent the lower and upper detection limit respectively. 






































































5.2.2 The cytokine profile of RA and PsA serum and SF and their effect 
on synovial fibroblasts 
In addition to IL-17A and IL-17F, the luminex assay also analysed the presence of 
other cytokines – including IL-23, IL-1β, IL-6, IFNγ, TNFα, IL-10, IL-4, IL-21, IL-
22 and IL-17E. These results are shown in Figure 5.4 and Figure 5.5. Focusing on the 
Th17 polarising cytokines - IL-1β and IL-23, luminex analysis revealed elevated levels 
of IL-1β in RA and PsA SF vs. matched serum, although levels of IL-1β in SF are low. 
IL-23 was present in RA and PsA SF. IL-23 was also detected in 4 out of 9 RA serum 
samples and at higher levels than the matched SF. No IL-23 was detected in the healthy 
control serum samples. Levels of the pro-inflammatory cytokines – IL-6, IFNγ and 
TNFα were detected at higher levels in RA and PsA SF vs serum samples. IL-21 and 
IL-22 were detectable in RA SF, however levels were very low in PsA SF. 
Interestingly, the anti-inflammatory cytokine, IL-10, was detected at elevated levels 
in both RA and PsA SF. Similar results were observed for the Th2 polarising cytokine, 
IL-4. Overall, these data show the cytokine profile of SF is different to matching serum 
in both RA and PsA samples. Finally, following our results in chapter 4, whereby IL-
17E synergised with TNFα to induce elevated levels of IL-6 and IL-8 from synovial 
fibroblasts, we were interested to investigate whether IL-17E was present in 
inflammatory arthritis. As shown in Figure 5.5, IL-17E protein was detected in one 
out of four HC serum samples and some RA and PsA serum and SF samples, however 
levels were low. 
 
Next, we assessed the effect of RA and PsA serum and SF on synovial fibroblasts. 
PsA synovial fibroblasts were cultured with increasing percentage concentration of 
matched PsA serum and SF. Following a 24 hour culture, supernatants were collected 
and IL-6 and IL-8 protein levels were analysed by ELISA. As shown in Figure 5.6A, 
addition of 0.5% PsA serum led to an increased IL-6 secretion. Similar IL-6 protein 
levels were observed upon addition of 1 and 2% serum, however levels significantly 
dropped with 5% serum. In contrast, addition of 0.5% PsA SF to PsA fibroblasts led 
to a slight increase in IL-6 secretion, however levels were low. Moreover, IL-6 was 
undetectable following addition of 1, 2 or 5% SF. The lack of IL-6 induction by SF 
may be attributed to the toxicity of the sample. For example, SF contains hyaluronic 




As IL-17A and TNFα have been shown to be present in RA and PsA SF, blocking 
experiments were performed to assess their role in SF-mediated IL-6 and IL-8 
fibroblast secretion. Moreover, as the presence of IL-17F in RA and PsA remained 
inconclusive, it was of interest to examine the effect of IL-17F blockade. As 0.5% 
serum or SF elicited the highest levels of IL-6 secretion, this concentration was added 
to fibroblasts in the absence or presence of blocking antibodies. As illustrated in figure 
5.6B, in this experiment addition of 0.5% serum or SF did not result in an increase in 






Figure 5.4 RA and PsA SF display increased cytokine levels vs. matched serum. 
Paired cell-free serum and synovial fluid from RA (n=7) and PsA (n=6) patients were analysed by 
luminex. Dashed blue lines represent the lower detection limit. Statistical significance was calculated 

















5 0 0 0











































H C R A P s A





























H C R A P s A






















































































































H C R A P s A

















1 0 0 0










H C R A P s A





























H C R A P s A





Figure 5.5 Low levels of IL-17E are detectable in RA PB and  SF. 
IL-17E protein levels in paired cell-free serum and synovial fluid from RA (n=7) and PsA (n=6) patients 
were analysed by luminex. Dashed red lines represent the lower detection limit. Statistical significance 
was calculated using a Wilcoxon matched pairs test. Patient cohort information displayed in Table 5.1 


































Figure 5.6 Addition of RA or PsA serum or SF to synovial fibroblasts. 
(A) 10x103 PsA fibroblasts were cultured with increasing doses of PsA serum or SF (n=1). (B) 10x103 
PsA fibroblasts were 0.5% of PsA serum or SF in the absence or presence of blocking antibodies (n=1).  
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5.2.3 Examining the presence of IL-17A and IL-17F CD4+ T cells in RA 
and PsA PBMC and SFMC 
While the presence of IL-17A+ CD4+ T cells in the inflamed arthritic knee has been 
widely reported 10, little is known regarding the presence of IL-17F+ CD4+ T cells. 
With this is mind and the inconclusive IL-17F protein detection results in RA and PsA 
SF, it was of interest to explore the presence of IL-17 expressing CD4+ T cells in RA 
and PsA PBMC and SFMC.  
 
Paired PBMC and SFMC from RA or PsA patients were stimulated for 3 hours with 
PMA, ionomycin and Golgistop. Patient cohort information is provided in Table 5.3 
(Patient cohort 3). Cells were stained to assess intracellular cytokine expression and 
analysed by flow cytometry. Figure 5.7 shows a representative plot of the gating 
strategy applied to PBMC and SFMC samples. Within CD3+ CD4+ T cells, IL-17A 
expressing cells were increased in the SF compared to the PB of patients with RA (2.7 
vs. 0.9%, respectively) and PsA (2.5 vs. 1%, respectively) (Figure 5.8). However, 
statistical significance was only achieved with the PsA cohort. Flow cytometry 
analysis revealed very few IL-17F expressing CD4+ T cells in matched PBMC and 
SFMC from RA and PsA samples. Similarly, the frequency of IL-17AF+ CD4+ T cells 
detected in inflammatory arthritis PB and SF was low. 
 
We next examined whether different ex vivo stimulation conditions would reveal the 
presence of IL-17F+ CD4+ T cells. First we compared the 3 hour PMA and ionomycin 
stimulation with Golgistop (monensin), GolgiPlug (Brefeldin) or a combination of 
both Golgistop and Golgiplug. Our results revealed no difference in the percentage of 
IL-17F+ CD4+ T cells detected with the different protein transport inhibitors (data not 
shown).  Our next approach involved stimulating PBMC and SFMC with either PMA 
and ionomycin, αCD3 and αCD28 or Golgistop alone for 3, 5 or 8 hours. This was 
performed with one RA and one PsA donor. As shown in Figure 5.9, IL-17A 
expressing CD4+ T cells were increased in the SF compared to the PB only in the RA 
sample following 3 hours PMA and ionomycin stimulation. However, IL-17A+ CD4+ 
T cells were detected at higher frequencies in the SF vs. PB in both donors following 
a 3 hour stimulation with αCD3 and αCD28. Very few IL-17A+ CD4+ T cells were 
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observed following incubation with Golgistop only. Only a small increase in the 
percentage of IL-17A+ CD4+ T cells was observed in the RA SFMC with 8 hours 
incubation with Golgistop. None of these conditions revealed the presence of IL-17F+ 
CD4+ T cells in the RA and PsA paired PB and SF sample. The IL-17AF heterodimer 
stain was not included in this experiment. 
 
IL-17A protein and IL-17A+ CD4+ T cells were robustly detected in RA and PsA SF. 
To conclude this section, correlation analyses were performed. Firstly, correlation 
analysis was performed on matched ICCS and ELISA patient samples. As shown in 
Figure 5.10 A, the frequency of IL-17A+ CD4+ T cells detected in RA/PsA PB or SF 
demonstrated a positive correlation to the levels of IL-17A protein detected in the 
serum or SF counterpart. Next, we correlated the frequency of IL-17A+ CD4+ T cells 
present in RA or PsA SF to the patient’s disease activity score in 28 joints (DAS28). 
This score is calculated at the time of sample collection using a number of assessment 
criteria including the number of tender and swollen joints, the erythrocyte 
sedimentation rate (ESR) and the C-reactive protein (CRP) level. No correlation was 
observed in either RA or PsA samples (Figure 5.10 B). Moreover, no correlation was 
observed between the concentration of IL-17A present in RA or PsA SF and the patient 
DAS28 score (Figure 5.10C). 
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Table 5.3 Demographic and clinical parameters of patients included in ex vivo 
















Age, mean ± SEM years 54.9  ± 7.0 41.7  ± 4.2
Treatment, no.










Mean ± SEM 5.2  ± 0.4 4.5  ± 0.5






Figure 5.7 Gating Strategy for matched RA and PsA PBMC and SFMC 
samples. 
RA or PsA PBMC and SFMC were stimulated for 3 hours with PMA, ionomycin and GolgiStop. Cells 
were then stained with fluorescently-conjugated antibodies against extracellular markers and 
intracellular cytokines. In this representative SFMC gating, cells were first gated for lymphocytes (SSC-
A vs. FSC-A). The lymphocyte gate was further analysed for uptake of the Live/Dead eFlour 780 stain 
to determine live vs. dead cells. Within live cells, a FSC-W/FSC-A gate was applied allowing exclusion 
of doublet cells. Next, within CD3+ cells, CD4+ CD8- and CD8+ CD4- T cells were selected for 

































Figure 5.8 Examining the presence of IL-17A, IL-17F and IL-17AF expressing 
CD4+ T cells in inflammatory arthritis. 
Matched PBMC and SFMC from RA and PsA donors were stimulated for 3 hours with PMA, 
ionomycin and Golgistop and then assessed for intracellular IL-17A, IL-17F and IL-17AF cytokine 
expression. (A) Representative dot plot whereby fluorescence minus (FM) controls were used to set 
gates to depict positive cytokine expression. (B) Cumulative data show frequencies of IL-17A and IL-
17F expressing cells within the total CD4+ T cell population of matched PBMC and SFMC from RA 
(n=8) and PsA (n=7) samples. Similarly, the frequencies of IL-17AF expressing CD4+ T cells were 
analysed in RA (n=3) and PsA (n=1) samples. Statistical significance was calculated using a Wilcoxon 
matched pairs test. 
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Figure 5.9 Stimulating RA and PsA paired PBMC and SFMC with different ex 
vivo conditions. 
Matched PBMC and SFMC from one RA and one PsA donor were stimulated with PMA, ionomycin 
and Golgistop, αCD3, αCD28 and Golgistop or Golgistop alone for 3, 5 or 8 hours. Cells were then 
stained for analysis of IL-17A and IL-17F cytokine expression by flow cytometry. Gated within live 
CD3+ CD4+ T cells (A) displays representative dot plots of IL-17A cytokine expression observed in 
RA PBMC and SFMC. (B) Cumulative flow cytometric data show frequencies of IL-17A and IL-17F 



































































































































































































































































































































































Figure 5.10 Correlation analysis on the presence of IL-17A+ CD4+ T cells vs. 
IL-17A protein present in inflammatory arthritis samples and assessing 
correlation with DAS28 scores. 
 (A) The frequency of IL-17A CD4+ T cells detected in RA (n=3) and PsA (n=2) PB and SF following 
an ex vivo stimulation were correlated with the levels of IL-17A detected in the matched serum or SF 
via ELISA. (B) The frequency of SF IL-17A+ CD4+ T cells detected in RA (n=7) (red symbols) or PsA 
(n=4) (black symbols) were compared against the corresponding patient DAS28 score. (C) The levels 
of IL-17A protein present in RA (n=7) or PsA (n=6) were correlated with patient DAS28 scores. 
Symbols represent individual donors. Data was analysed using Spearman non-parametric correlation 
analysis. 






%  o f  IL -1 7 A +  c e lls







p = 0 .6




p = 0 .0 6






































p = 0 .2
B ICCS vs. DAS28 C ELISA vs. DAS28









5.2.4 In vitro stimulation induces IL-17A, IL-17F and IL-17AF expressing 
CD4+ T cells from inflammatory arthritis matched PBMC and 
SFMC 
We hypothesised that culturing inflammatory arthritis PBMC and SFMC in vitro with 
IL-1β, IL-23, αCD3 and αCD28 would induce IL-17A, IL-17F and IL-17AF 
expressing CD4+ T cells. Moreover, we speculated that due to the inflammatory origin 
of SFMC, this stimulation would induce a higher frequency of IL-17A+, IL-17F+ and 
IL-17AF+ CD4+ T cells in SFMC vs. PBMC. 
 
As shown in Figure 5.11, culturing inflammatory arthritis PBMC and SFMC in vitro 
induced IL-17A and IL-17F expressing CD4+ T cells. However, there was no 
consistent enhancement of IL-17 expressing CD4+ T cells in the SF vs. PB. It is 
important to note the viability of the SFMC samples following in vitro culture varied, 
with some samples displaying a significant percentage of cell death. It may be SFMCs 
are fragile and more prone to cell death following a culture period. Similarly, while 
ELISA analysis revealed the presence of IL-17A and IL-17F in inflammatory arthritis 
PBMC and SFMC in vitro cultures, no consistent differences were observed between 




Figure 5.11 IL-17A, IL-17F and IL-17AF expressing CD4+ T cells can be 
induced from inflammatory arthritis PBMC and SFMC upon in vitro 
stimulation. 
RA or PsA matched PBMC and SFMC (1x106) were cultured with platebound anti-CD3 mAb, anti-
CD28 mAb, IL-1β (10ng/ml) and IL-23 (20ng/ml). After 3 days incubation, cells were re-stimulated 
for 3 hours with PMA, ionomycin and Golgistop. Cells were then stained with fluorescently-conjugated  
antibodies against extracelluar markers (CD3, CD4 and CD8) and intracellular IL-17 cytokines. (A) 
Representative dot plots and (B) cumulative data show frequencies of IL-17A and IL-17F expressing 
cells within the total CD4+ T cells of paired PBMC and SFMC from RA (n=3) (red symbols) and PsA 
(n=3) (black symbols) patients, respectively. (C) Prior to re-stimulation, cell supernatant was analysed 
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5.2.5 Investigating the presence of CD8+ IL-17 producing cells in 
inflammatory arthritis 
Although this project focused on IL-17 producing CD4+ T cells, we were keen to 
explore whether other immune cells producing IL-17F are present in inflammatory 
arthritis. Our lab has previously reported the increased presence of IL-17A+ CD8+ T 
cells in the inflamed joint of PsA patients 6. Currently, IL-17F+ CD8+ T cells have 
not been described in PsA. This provided me with the rationale to examine the 
presence of IL-17F+ CD8+ T cells in inflammatory arthritis. The cytokine expression 
of CD8+ T cells present in RA and PsA was analysed  using the same PMA and 
ionomycin ex vivo stimulated RA/PsA PBMC and SFMC data set generated to analyse 
CD4+ T cells (patient cohort 3).  Using the gating strategy shown in Figure 5.5, we 
gated within CD8+ CD4- T cells and analysed the cytokine expression of IL-17A and 
IL-17F. In line with the lab’s previous findings, we observed a significant enrichment 
of IL-17A+ CD8+ T cells in PsA SF vs. matched PB (approximately 3.5 vs. 0.2 % of 
IL-17A+ cells within CD8+ T cells) (Figure 5.12). While one out of seven PsA 
samples showed an enhanced frequency of IL-17F+ CD8+ T cells in the SF vs. PB 
(0.66 vs. 0.03%, respectively), the remaining six PsA samples displayed low 
percentages (0.08 vs. 0.03%, respectively).  Therefore, although this data set generated 
statistical significance, IL-17F expressing CD8+ T cells were only robustly detected 
in one sample. A small percentage of IL-17A+ CD8+ T cells was observed in RA 
SFMC, however this did not reach significance. Very few IL-17F+ CD8+ T cells were 
observed in RA PBMC or SFMC.  
 
Next, we sought to investigate whether any CD4- CD8- immune cell subsets present 
in RA or PsA PB or SF expressed IL-17A or IL-17F. In the majority of patient ex vivo 
experiments, the live/dead and CD14 stain were combined to generate a ‘dump’ gate. 
However, in some experiments, the cytokine profile of CD14+ monocytes could be 
analysed. In these experiments, IL-17A or IL-17F expressing CD14+ monocytes were 
not observed in RA or PsA PB or SF (data not shown). To finalise the analysis of the 
ex vivo patient data set, backgating analysis was performed on all live CD14- IL-17 
expressing cells. This was to potentially reveal any IL-17A or IL-17F producing cells 
which were CD3+ CD4- CD8- or CD3-. Double negative (DN) T cells (CD3+ CD4- 
CD8-) constitute approximately 1-5% of T cells in humans. Studies have shown they 
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can function similarly Treg cells or produce cytokines including IL-17A, IFNγ and 
TNFα 10. CD14- CD3- cells present in PBMC and SFMC can include CD19+ B cells, 
CD56+ NK cells and innate lymphoid cells (ILC), of which NK cells and ILC3 have 
been identified as an IL-17A producing population 11. 
 
As demonstrated in Figure 5.13, live CD14- IL-17+ cells were gated and then surface 
marker expression was used to determine the cytokine producing cell. Back gating was 
only performed on samples with 300 or more IL-17A or IL-17F expressing cell events. 
The majority of IL-17A producing cells in both RA and PsA PBMC and SFMC were 
CD3+ cells (approximately 94%) (Figure 5.14). In the RA PBMC samples, the 
majority of CD3+ IL-17A+ cells were CD4+ CD8- T cells (approximately 93%). In 5 
out of 8 RA SFMC samples approximately 95% of CD3+ IL-17A+ cells were CD4+ 
CD8- T cells. However, in three RA donors 53%, 64% and 61% respectively of SF 
CD3+ IL-17A+ cells were CD4+ CD8- T cells. Moreover, in these three donors 31%, 
29% and 29% respectively of CD3+ IL-17A+ cells were CD8+ CD4- T cells. This is 
in contrast to the low frequencies of IL-17A+ CD8+ CD4- T cells present in the 
remaining RA SF samples (approximately 0.9%). Two of the RA patients with 
enhanced frequencies of IL-17A+ CD8+ CD4- T cells in the SF was seronegative, 
whilst the other was seropositive. In 7 PsA PB donors approximately 85% of IL-17A+ 
cells were CD4+ CD8- T cells and 7% were CD8+ CD4- T cells. In contrast, the PsA 
SF was enriched with IL-17A+ CD8+ CD4- T cells. Approximately 36% of IL-17A+ 
cells were CD8+ CD4- T cells, whereas 45% were CD4+ CD8- T cells. Across all RA 
and PsA samples, only one PsA SF sample had over 300 events of detectable IL-17F 
expressing cells. Back-gating analysis revealed all IL-17F expressing cells were CD3+ 





Figure 5.12 Assessing the presence of IL-17A and IL-17F expressing CD8+ T cells 
in inflammatory arthritis. 
Matched PBMC and SFMC from RA and PsA donors were stimulated for 3 hours with PMA, 
ionomycin and Golgistop and then assessed for intracellular IL-17A, IL-17F and IL-17AF cytokine 
expression via flow cytometry. Gating within live CD8+ CD4- T cells (A) displays representative dot 
plots of a patient with PsA and (B) shows cumulative data of IL-17A and IL-17F frequencies within 
the total CD8+ T cell population of matched PBMC and SFMC from RA (n=8) and PsA (n=7) samples. 
Statistical significance was calculated using a Wilcoxon matched pairs test. 
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Figure 5.13 Back- gating on RA or PsA PBMC and SFMC IL-17 expressing live 
CD14- cells. 
Matched PBMC and SFMC from RA and PsA donors were stimulated for 3 hours with PMA, 
ionomycin and Golgistop and then assessed for intracellular IL-17A and IL-17F cytokine expression 




































Figure 5.14 Back- gating on RA or PsA PBMC and SFMC IL-17 expressing live 
CD14- cells. 
Matched PBMC and SFMC from RA and PsA donors were stimulated for 3 hours with PMA, 
ionomycin and Golgistop and then assessed for intracellular IL-17A and IL-17F cytokine expression 
via flow cytometry. Live CD14- IL-17A+ or IL-17F+ cells were gated upon. Back gating analysis was 
performed on samples with 300 or more IL-17+ events to determine the cytokine producing cells. 
Cumulative data showing cell surface marker expression on IL-17A+ cells present in (A) RA PB and 
SF (n=8) and (B) PsA PB and SF (n=7). (C) Marker expression on IL-17F+ cells present in PsA SF 
(n=1). 
A RA PB and SF IL-17A+ cells
B PsA PB and SF IL-17A+ cells C PsA SF IL-17F+ cells
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5.2.6 Investigating the RNA expression of IL-17 family members in RA 
and PsA PBMC and SFMC 
My next aim was to investigate whether IL17A and IL17F mRNA could be detected 
in cells from inflammatory arthritis serum or SF. It is important to note that IL-17AF 
is formed post-transcriptionally and cannot be analysed at an RNA level. Bulk cells 
were isolated from fresh RA or PsA serum or SF samples and approximately 1-2x106 
cells were lysed in trizol. Cells were not stimulated with PMA or ionomycin. Using 
the chloroform immunoprecipitation method, RNA was extracted and reverse 
transcription was performed. QPCR reactions were performed using primers for 
human IL-17A and IL-17F; moreover, the ACTB gene was used as an endogenous 
control. In all RA and PsA PBMC and SFMC samples, IL17A and IL17F mRNA 
expression levels were not reliably detected (Figure 5.15) with a CT value of 30 or 
above and similar to no reverse transcription control samples. Unfortunately, in this 
experiment a positive control (i.e RNA isolated from stimulated PBMC known to 
contain IL17A and IL17F mRNA) was not used. ELISA and ICCS results have clearly 
demonstrated the presence of IL-17A in the SF. Therefore, it was proposed the IL17A 
mRNA was not detected in bulk SFMC because the IL-17 producing cells are only a 
small proportion of the total cells in the SF. 
 
To investigate this hypothesis, the presence of IL17A and IL17F mRNA in sorted 
immune subsets from RA PB and SF was examined. Unfortunately, due to limited 
patient sample availability this experiment was only performed in RA samples (n=3). 
Fresh PBMC or SFMC were stained, without stimulation for extracellular markers 
(CD3, CD4, CD8, CD19 and CD14). Immune cell subsets were then sorted on a BD 
FACS ARIA. This gating strategy is shown in Figure 5.16. Sorted cell subsets were 
lysed in trizol and total RNA was extracted. Following this, reverse transcription was 
performed. As a positive control, RNA isolated from healthy PBMC stimulated for 3 
days with IL-1β, IL-23, anti-CD3 and anti-CD28 was also included in the reverse 
transcription stage, adding in the same total of RNA as the sorted T cell samples. 
QPCR reactions were then performed using primers for IL-17A and IL-17F and the 
ACTB gene was used as an endogenous control. As displayed in Figure 5.17, IL17A 
and IL17F mRNA was detectable in the positive control sample, indicating the reverse 
transcription step and qPCR reactions were successful. In contrast, no IL17A and 
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IL17F mRNA was detectable in CD4+ or CD8+ T cell subsets sorted from HC PB or 
RA PB and SF. All CT values were above 30 and similar to no reverse transcription 
controls. 
 
Next, I investigated whether similar results were observed in data previously generated 
in our lab which analysed the gene expression profile of sorted CD25- CD4+ T cells 
from RA PB and SF using an affymetrix microarray. Affymetrix data analysis uses 
robust multi-array average (RMA) values, whereby the raw intensity values are 
background corrected, log2 transformed and quantile normalised. I analysed this data-
set to assess the gene expression levels of all IL-17 cytokines members in RA CD25- 
CD4+ T cells. As a positive control the expression of CD4 was analysed. Additionally, 
as a significant proportion of CD4+ T cells express TNFα and IFNγ, the expression 
levels of these genes were analysed. To achieve this, RMA values were transformed 
(2^Y) and plotted as the probe intensities. In general, a gene with a probe intensity of 
below 100 is considered not detectably expressed. As shown in Figure 5.18, CD4 gene 
expression was detected at moderate levels and with minimal differences between the 
PB and SF subset. Gene expression of TNFA was detectable at various levels across 
the samples, with no consistent difference between PB and SF. Where IFNG gene 
expression levels were moderate and in 4 out of 5 samples, the gene expression level 
was enhanced in the SF CD25- CD4+ subsets. In contrast, all IL-17 family members 
exhibited low probe intensity values. In fact, IL17A displayed the lowest probe 
intensity values compared with IL17B and IL17C which are cytokines that have not 
been reported to be produced by CD4+ T cells. Therefore, it can be concluded that 
there are no detectable gene expression levels of the IL-17 cytokines in CD25- CD4+ 





Figure 5.15 Low levels of IL17A and IL17F mRNA are detected from bulk RA 
and PsA PBMC and SFMC. 
Approximately 1-2x106 RA (n=2) (red symbol) or PsA (n=2) (black symbol) PBMC and SFMC were 
lysed in trizol. Following RNA extraction, reverse transcription was performed. QPCR was performed 
using primers for IL17A and IL17F and ACTB was used as an endogenous control. Each data point is 
an individual donor. 


























































Figure 5.16 Sorting strategies for immune cell subsets from PB and SF. 
 Based on forward scatter/side scatter (FSC/SSC) properties, viable lymphocytes were gated. A FSC-
W/FSC-A gate was applied allowing the exclusion of doublet cells. Dead cells were excluded based on 
their uptake of the viability dye, eFluor506. Within live, single cells CD19+ CD3- B cells were gated 
and collected. CD3+ cells were further analysed for their expression of CD4+ and CD8+ and 
CD4+CD8- and CD8+CD4- cells were gated and collected. Gating within CD3- cells. Red boxes 





























Figure 5.17 IL17A and IL17F mRNA is undetectable in sorted CD4+ and CD8+ 
T cells from RA PB and SF. 
Mononuclear cells were isolated from the blood of a healthy donor (HC) (n=1) and the PB and SF from 
RA patients (n=3). Cells were stained with extracellular surface markers and using a FACS Aria sorter 
CD3+ CD4+ CD8- and CD3+ CD8+ CD4- T cells were sorted. Total RNA was isolated from all sorted 
populations and converted into cDNA via reverse transcription. QPCR was then performed to assess 



















































































































Figure 5.18 IL-17 gene expression profile of CD4+ CD25- T cells from RA PB 
and SF. 
Cell sorting, RNA isolation and microarray analysis was performed by a previous member of the lab, 
Veerle Fleskens. Data mining for the indicated genes was performed by myself. CD25- CD4+ T cells 
from RA matched PB and SF were sorted on a BD FACS Aria (n=5). Total RNA was isolated from 
all sorted populations and analysed by an affymetrix microarray. The RMA values of CD4, TNFA, 
IFNG and IL-17 family members were transformed (2^Y) and plotted as probe intensity. Each line is 
an individual donor. 
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5.2.7 Examining the presence of IL-17A and IL-17F expressing cells in 
RA or PsA tissue 
The synovium of patients with active RA and PsA is infiltrated with a variety of 
mononuclear cells, including T cells. While T cells can be detected in the SF of RA or 
PsA, some T cells remain embedded in the synovial tissue. To conclude the 
investigation of IL-17F present in inflammatory arthritis, we examined the presence 
of IL-17F and IL-17A cells present in RA synovial tissue. 
 
The following protocol was optimised by another member of our lab, Lucy Durham. 
Moreover, these experiments were performed in collaboration with Lucy Durham, 
with Lucy acquiring all samples. Synovial tissue samples were collected from two RA 
patients at the time of elective knee replacement surgery. Synovial tissue was cut into 
1-2 mm pieces and digested by incubating with an enzyme mastermix (Miltenyi) on a 
gentleMACS dissociator. Isolated cells were stimulated for 3 hours with PMA and 
ionomycin. Cells were then stained for extracellular markers and intracellular 
cytokines and analysed by flow cytometry. Figure 5.19 illustrates the gating strategies 
applied to cells isolated from both RA synovial tissue samples. In donor one, only a 
small proportion of these cells were lymphocytes, with the remaining being either 
debris or synovial fibroblasts, whereas donor two displayed a higher frequency of 
lymphocytes. 
 
In the RA synovial tissue from donor 1, flow cytometry results shown that 2.7% of 
total CD4+ T cells expressed IL-17A. However only three events were captured within 
the IL-17A+ gate, therefore this result cannot be interpreted accurately (Figure 5.20). 
However, in donor two, 2.3% of total CD4+ T cells expressed IL-17A and a substantial 
number of events were captured within the IL-17A+ gate. No IL-17F+ CD4+ T cells 
were detected in donor one and although 0.3% IL-17F+ CD4+ T cells were detected 
in donor two, the event number is too low for accurate interpretation. Donor one and 
donor two displayed 53% and 55% of IFNγ+ CD4+ T cells, respectively. With regards 
to CD8+ T cells, donor one displayed 21.4% of IL-17A+ CD8+ T cells, whereas no 
IL-17A+ CD8+ T cells were detectable in donor 2. In both donors, event numbers 
were too low to draw conclusions on IL-17F+ CD8+ T cells. In donor one, 41% of 
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total CD8+ T cells were IFNγ+, whereas donor two displayed 93% IFNγ+ CD8+ T 
cells. In summary, IL-17A+ CD4+ T cells were present in one donor and IL-17A+ 
CD8+ T cells were present in the other. Due to low event numbers, no IL-17F+ CD4+ 
or CD8+ T cells were definitively detected. 
 
Our next aim was investigate the presence of any IL-17 expressing CD4- or CD8- 
immune cell subsets present in RA synovial tissue. To achieve this, back-gating 
analysis was performed on IL-17A and IL-17F expressing live CD14- cells (Figure 
5.21). In both donors the majority of IL-17A+ cells were CD45+ and CD3+, although 
a CD45+ CD3- population was observed in donor one. The majority of IL-17A+ CD3+ 
cells in donor one were CD4-CD8- and CD8+CD4- T cells, however for donor two 
the predominant subsets were CD4+CD8- and CD4-CD8- T cells. Caution must be 
taken when interpreting the CD4+CD8- and CD4-CD8- T cell populations as results 
may be due to poor staining of the CD4 marker. Too few IL-17F+ cells are present in 
the donor one tissue sample to accurately interpret. However back-gating analysis 
performed on the donor 2 sample revealed that approximately 70% of IL-17F+ cells 
are CD45-. Within CD45+ cells approximately 57% and 43% are CD3+ cells and 
CD3- cells, respectively. Finally, the CD45+ CD3+ cells appear to be both CD4+CD8- 
and CD4-CD8- subsets. 
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Table 5.4 Demographic and clinical parameters of RA synovial tissue sample 









































Figure 5.19 Gating strategy for CD4+ and CD8+ T cells from RA synovial 
tissue. 
Synovial tissue was digested by incubation with a Miltenyi enzyme mastermix on a gentleMACS 
dissociator. Isolated cells were stimulated ex vivo for 3 hours with PMA and ionomycin. Cells were 
then stained with fluorescently-conjugated antibodies against extracellular markers and intracellular 
cytokines. Flow cytometric plots show the gating strategy for (A) donor 1 and (B) donor 2. Cells were 
first gated for lymphocytes (SSC-A vs. FSC-A), excluding any synovial tissue debris or fibroblasts. 
The lymphocyte gate was further analysed for uptake of the Live/Dead eFlour 780 stain to determine 
live vs. dead cells. Within live cells, a FSC-W/FSC-A gate was applied allowing exclusion of doublet 










































































Figure 5.20 Examining the presence of IL-17A and IL-17F expressing CD4+ 
and CD8+ T cells from RA synovial tissue. 
Cells isolated from RA synovial tissue were stimulated for 3 hours with PMA, ionomycin and Golgistop 
and then assessed for intracellular IL-17A, IL-17F and IFNγ cytokine expression via flow cytometry. 
Gating within live CD4+ T cells or CD8+ T cells the frequency of IL-17A, IL-17F and IFNγ expressing 
















































Figure 5.21 Back-gating on IL-17A and IL-17F producing cells. 
Cells isolated from RA synovial tissue were stimulated for 3 hours with PMA, ionomycin and Golgistop 
and then assessed for intracellular IL-17A, IL-17F cytokine expression via flow cytometry. Live CD14- 
IL-17A+ or IL-17F+ cells were gated upon. Flow cytometric plots show the results of (A) donor 1 and 
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The data presented in this chapter clearly demonstrate that the presence of IL-17A 
protein and IL-17A+ T cells is increased in the SF vs. PB of RA and PsA patients. In 
contrast, the data suggests IL-17F and IL-17F+ CD4+ T cells is not consistently 
present in inflammatory arthritis.  The presence of IL-17F in RA and PsA SF remained 
inconclusive with inconsistent Luminex and ELISA and results and ex vivo analysis 
showed that IL-17F+ CD4+ T cells were either undetectable or present at very low 
frequencies. In one out of seven PsA patients, IL-17F+ CD8+ T cells frequencies were 
observed in the SF but this was not seen in the other six patients.  Analysis of IL17F 
gene expression in RA T cells provided no further clarification on the presence of IL-
17F. Similarly, few IL-17F+ expressing CD4+ T cells were present in RA synovial 
tissue. Collectively, this chapter suggests that while IL-17A+ T cells are consistently 
present in RA and PsA SF, only a small percentage of RA or PsA patients may exhibit 
low frequencies of IL-17F+ T cells. 
 
In concordance with previous studies 103,251, Luminex and ELISA analysis confirmed 
the presence of IL-17A protein at elevated levels in RA and PsA synovial fluid vs. 
serum. This shows IL-17A protein is elevated in the inflamed joints rather than 
systemically. While Luminex analysis revealed the presence of IL-17F in the SF of 
RA and PsA patients, these results were not confirmed by ELISA. ELISA results 
showed IL-17F to be undetectable or present at very low levels in both serum and SF 
samples. Moreover, IL-17AF protein was undetectable in RA and PsA serum and SF 
samples. Recombinant IL-17F spiked-in serum and SF samples was detected by 
ELISA, demonstrating the composition of the samples was not preventing the 
detection of IL-17F. These data highlight the difficulties in generating reliable results 
for detecting IL-17F in SF samples. Moreover, they highlight how investigating a 
hypothesis using different methods may lead to different results. In concordance with 
these results, there are inconsistencies across the literature of the levels of IL-17A 
detected in SF. For example, a publication by Ziolkowska et al. detected high IL-17A 
protein levels (approximately 1000pg/ml) in RA SF using ELISA 416. In contrast, a 
different report analysed the SF from RA and healthy control donors using a highly 
sensitive Erenna immunoassay system and observed very low levels of IL-17A with 
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no difference between RA and healthy control SF (0.07 vs. 0.07pg/ml) 370. Moreover, 
this report identified IL-17F protein at higher levels in RA vs. healthy control samples 
(130 vs. 1.6pg/ml).  
 
These inconsistencies in IL-17 protein levels present in SF may arise from true 
variation in patient groups, differences in sampling handling or differences in the 
specific assay method used. Moreover, it is important to take into consideration the 
possibility of interference from heterophilic antibodies. Heterophilic antibodies can 
include autoantibodies such as rheumatic factor or polyspecific antibodies that consist 
of poorly defined antibodies with multiple binding specificities 417. They can cause 
false negative results but more frequently, they cause false positive results. Moreover, 
the extent of heterophilic antibody interference may vary across assays as it is often 
unclear what measures, if any, manufacturers have taken to prevent interference. In 
our experiments, no steps were taken to prevent heterophilic intereference. Therefore, 
it may be possible the IL-17F luminex results are false-positive due to heterophilic 
interference. Future repeat experiments should include measures to prevent 
heterophilic antibody interference. This can include diluting serum or SF samples in 
buffer containing IgG from the same species as the capture antibody. Moreover, 
samples could be preadsorbed on human γ-globulin-coated polystyrene beads. To 
conclude this section it is important to also highlight a study by Soderstrom et al., 
which raises the issue that outside of cultured cell environments, cytokines (in 
particular IL-17A) are often difficult to study. This is because cytokines act locally 
and often in low abundance. Their report suggests that analysis of IL-17 cytokines in 
serum or SF samples should be carried out using a highly sensitive single molecule 
(SMC) immunoassay 418. Although having an assay that can effectively detect low 
levels of cytokine is beneficial, it is important to consider whether the cytokine can 
elicit much of a functional effect at the detected concentration. For example, as shown 
in chapter 4, IL-17F has a low inflammatory potency and requires substantial levels to 
elicit an IL-6 fibroblast response. 
 
The composition of SF is complex and strongly influences the microenvironment of 
the joint. Both the literature and our data have shown that RA and PsA SF contains 
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pro-inflammatory cytokines including IL-17A and TNFα. As SF and synovial 
fibroblasts play pivotal roles in both the initiation and perpetuation of inflammatory 
arthritis. Preliminary experiments sought to assess the effect of SF derived from the 
inflamed arthritic joint on in vitro synovial fibroblasts. This would recreate a 
physiopathological microenvironment, typical of RA or PsA.  However, unfortunately 
these preliminary experiments were unsuccessful. Addition of 0.5% PsA SF led to a 
small increase in IL-6 secretion, however, undetectable levels of IL-6 were observed 
with higher concentrations of SF. Higher concentrations of  SF are likely to be 
required to assess the effect of blockade of IL-17 cytokines and TNFα.  As an early 
study has reported that 30% of RA SF elicited an increase in IL-6 levels from base-
line 419, further work should be continued. This should also involve assessing the 
viability of fibroblasts upon culture with SF, as there may be components which are 
toxic to the cell. 
 
In concordance with previous studies 367,368 and the Luminex and ELISA data 
generated in this thesis, flow cytometry analysis demonstrated the presence of IL-
17A+ CD4+ T cells at elevated frequencies in the synovial fluid vs. blood in both RA 
and PsA patients. Moreover, we observed a positive correlation between the levels of 
IL-17A protein present in the SF vs. the frequency of IL-17A+ CD4+ T cells detected. 
The levels of IL-17A protein or frequencies of IL-17A+ CD4+ T cells did not correlate 
with the patient DAS28 scores. However, further n numbers are required to confirm 
this. Elevated frequencies of IL-17A+ CD4+ T cells were also detected in the SF vs. 
PB of an RA and PsA patient upon a three hour stimulation with αCD3 and αCD28. 
This demonstrates that PMA and ionomycin is not required to detect these cells. 
However, no IL-17A+ CD4+ T cells were observed in SFMC samples which were not 
re-stimulated and cultured with Golgi-Stop alone. It is possible that as soon as the cells 
are removed from the inflamed joint or the inflammatory microenvironment of the SF, 
their ability to produce IL-17A is limited. Therefore, SF CD4+ T cells require a small 
stimulation to re-elicit IL-17A expression and demonstrate their enhanced potential to 
produce IL-17A vs. CD4+ T cells from the PB. To investigate the importance of SF 
in maintaining IL-17A expression from CD4+ T cells, a future experiment could 
involve adding Golgi-Stop directly to SF samples. In doing so, the CD4+ T cells 
present would still be in the inflammatory environment, whilst the Golgi-Stop is 
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retaining any IL-17A protein being expressed in the cell. Following an incubation 
period, cells can then be washed and stained for flow cytometry.  
 
In contrast to IL-17A, few IL-17F+ CD4+ T cells were detected. Moreover, different 
ex vivo stimulation conditions did not reveal the presence of IL-17F expressing CD4+ 
T cells. Similarly, low frequencies of IL-17AF+ CD4+ T cells were observed. In light 
of these data it can be concluded IL-17F+ CD4+ T cells are either undetectable or 
present at very low frequencies following ex vivo stimulation. In vitro stimulation of 
RA and PsA PB and SF was performed to assess whether CD4+ T cells from the SF 
demonstrated an enhanced ability to express IL-17F vs. PB CD4+ T cells. However, 
no consistent difference was observed in IL-17F or IL-17A expression or secretion 
between PB and SF CD4+ T cells. 
 
As discussed in the introduction, literature describes numerous other immune cells as 
IL-17A and IL-17F producers, including CD8+ T cells. In line with a previous report 
from the lab 374, analysis of CD8+ T cells revealed the presence of IL-17A+ CD8+ T 
cells present at higher levels in SF vs. PB in PsA patients.  In one out of seven PsA 
patients, IL-17F+ CD8+ T cells frequencies were observed. This suggests that IL-
17F+ CD8+ T cells may be present in the SF of a small percentage of inflammatory 
arthritis patients. To address this hypothesis a significantly larger cohort should be 
analysed. It is important to acknowledge that back-gating on ex vivo stimulated RA 
PBMC and SMFC revealed the enrichment of IL-17A+ CD8+ T cells in the SF of 
three out of eight RA patients. Currently, the literature implicates that IL-17A+ CD8+ 
T cells are enriched in the SF of PsA and not RA patients 244,374. As two out of the 
three RA patients with SF IL-17A+ CD8+ T cells were seronegative, this suggests 
there may be a link between the presence of IL-17A+ CD8+ T cells in the inflamed 
joint and seronegative RA.  
 
IL17A or IL17F mRNA was not detectable in PB or SF sorted CD4+ or CD8+ T cells 
from RA patients. Additionally, microarray analysis revealed undetectable IL17A or 
IL17F gene expression levels in CD25- CD4+ T cells from RA PB or SF. These IL17A 
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gene expression results are in contrast to our robust flow cytometry data which 
detected elevated levels of IL-17A+ CD4+ T cells in the SF of RA patients. The lack 
of IL17A gene expression may be attributed to the fact that only a small percentage of 
bulk CD4+ T cells express IL-17A, therefore IL17A gene expression is masked by the 
majority of IL-17A- CD4+ T cells present in the RA SF. Another possibility for the 
lack of IL17A mRNA expression may be due to the absence of a PMA and ionomycin 
re-stimulation. Flow cytometry revealed the presence of IL-17A+ CD4+ T cells in SF 
samples following a 3 hour re-stimulation with PMA/ionomycin or αCD3 and αCD28. 
However, IL-17A+ CD4+ T cells were undetectable with the addition of Golgi-Stop 
alone. Future experiments could involve re-stimulating CD4+ T cells from the RA 
and/or PsA with either PMA/ionomycin or αCD3/αCD28 and then extracting RNA for 
analysis of IL17A and IL17F mRNA expression. 
 
Investigating the presence of IL-17 cytokines in RA or PsA synovial tissue may reveal 
results not observed in the SF. This is because there are cells such as TRMS which 
remain embedded in the tissue and do not re-circulate in the SF. TRM cells have been 
shown to produce IL-17A 420. To the best of my knowledge, these cells have not yet 
been shown to produce IL-17F. Studies in the literature have demonstrated the 
presence of IL-17A and IL-17F mRNA or IL-17A and IL-17F producing cells in the 
synovial tissue of RA and PsA patients. A recent study showed that out of 14 PsA 
synovial tissue samples, IL17A mRNA was detectable in 9 samples and IL17F mRNA 
was detectable in 6 samples 121. However, the cellular source of IL-17A and IL-17F in 
this study remains unknown. Moreover, immunohistochemical analysis demonstrated 
the presence of IL-17A and IL-17F producing cells in the RA but not OA synovial 
tissue 112. Similar to the Glatt et al., study the IL-17 producing cells were unidentified. 
In this chapter, flow cytometry results of cells isolated from RA synovial tissue 
revealed the presence of IL-17A+ CD4+ T cells, however with low cell events, further 
experiments are required to confirm this. The number of events in all IL-17F+ gates 
was very low; therefore an accurate conclusion on the presence of IL-17F+ cells in 
RA tissue cannot be reached with this data. To progress this work further additional 
RA and PsA tissues could be analysed. Moreover, it would be of interest to include 
TRM markers such as CD103 in the staining panel, to investigate whether any IL-17 




Limited experiments in this thesis were performed to investigate the presence of IL-
17B, IL-17C, IL-17D and IL-17E in inflammatory arthritis. Data in chapter 4 
demonstrated a synergistic effect between IL-17E and TNFα in eliciting IL-6 and IL-
6 secretion by fibroblasts. Therefore, we were keen to examine the presence of IL-17E 
in the SF. Luminex results show low levels of IL-17E present in some serum and SF 
samples from RA and PsA patients. Furthermore, undetectable IL-17E gene 
expression levels were observed in CD25- CD4+ T cells from RA PB and SF samples. 
Following on from the discussion regarding protein analysis of human samples, it 
would be worthwhile to repeat analysis of IL-17E protein with an ELISA and/or 
luminex including steps to prevent heterophilic interference. Moreover, flow 
cytometry could be used to analyse the presence of IL-17E+ CD4+ T cells in ex vivo 
stimulated RA and PsA PBMC and SFMC. IL-17D has been shown to be produced by 
resting CD4+ T cells, however IL17D gene expression levels were undetectable in 
CD25- CD4+ T cells from RA PB and SF. Additionally, IL17B and IL17C gene 
expression was undetectable in RA PB and SF CD25- CD4+ T cells. However, this is 
expected as CD4+ T cells have not been reported to be their cellular source. During 
this study one of the limitations to studying the remaining human IL-17 family 
members has been the lack of reagents available, for example ELISA kits and flow 
cytometry antibodies. However, more reagents are now becoming available. In the 
final discussion I discuss how future experiments can investigate the presence of the 
remaining cytokines in inflammatory arthritis. 
 
To summarise, this section demonstrates that while IL-17A and IL-17A+ T cells are 
robustly and consistently detected in the RA and PsA inflamed joint, IL-17F, IL-17AF 
and IL-17F+ and IL-17AF+ CD4+ T cells are not and therefore may not play a 




6 Final discussion 
To conclude this thesis, this final chapter summarises key findings, highlights 
outstanding questions and discusses potential areas of future research. 
 
6.1 Summary of Chapter 3 results 
Data presented in this chapter show that in the presence of IL-1β and IL-23, a higher 
concentration of anti-CD28 mAb in CD4+ T cell cultures leads to an increase in IL-
17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells, while frequencies of IL-17A+ IL-
17F- CD4+ T cells are decreased. This anti-CD28 mAb was shown to be mediated by 
IL-2 and in part IFNγ. Similarly, frequencies of IL-17F+ CD4+ T cells were 
preferentially induced with a higher concentration of anti-CD3 mAb. These data led 
us to hypothesise that a strong T cell stimulation drives IL-17F expression. Moreover, 
we hypothesise IL-17A and IL-17F are differentially regulated. Finally, I show IL-
17A+ and IL-17F+ CD4+ T cells display different cytokine profiles. Notably, IL-
17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells display significantly lower 
frequencies IL-10 and higher frequencies of IFNγ when compared with IL-17A+ IL-
17F- CD4+ T cells. 
 
6.2 Summary of Chapter 4 results 
Fibroblast assays demonstrated that the inflammatory potential of IL-17F is enhanced 
in the presence of TNFα leading to synergistically increased levels of IL-6 and IL-8 
secretion by fibroblasts. However, in the presence of IL-17A, IL-17F is redundant. 
Nevertheless, in line with other reports I show that in an environment whereby IL-17A 
and IL-17F are present, dual blockade of these cytokines is more effective at reducing 
inflammation. This chapter described the development of an IL-17A and IL-17F 
secretion assay. Following further validation this will be a useful tool to further 
characterise IL-17A and IL-17F producing cells. Finally, data presented in this chapter 





6.3 Summary of Chapter 5 results 
This chapter provides robust evidence that IL-17A protein and IL-17A+ CD4+ T cells 
are increased in the SF vs. PB of RA and PsA patients. Moreover, elevated frequencies 
of IL-17A+ CD8+ T cells were observed in PsA SF vs. PB. IL-17A+ CD4+ and CD8+ 
T cells were also identified in RA synovial tissue. Across all approaches IL-17F 
protein or IL-17F+ T cells were not consistently or reliably detected. Contradicting 
luminex and ELISA results meant the presence of IL-17F protein in inflammatory 
arthritis remained inconclusive. Ex vivo flow cytometry analysis showed that IL-17F+ 
CD4+ T cells were either undetectable or present at very low frequencies. In one out 
of seven PsA patients, IL-17F+ CD8+ T cells were observed but this was not seen in 
the other six patients. No IL-17F+ T cells were reliably detected in RA synovial tissue. 
In vitro cultures demonstrated that in a particular environment these RA and PsA PB 
and SF CD4+ T have the potential to express IL-17F. 
 
6.4 Outstanding questions and future research 
6.4.1 Are IL-17A and IL-17F differentially regulated in CD4+ T cells? 
Studies have shown that high-strength T cell activation suppresses the induction of IL-
17A+ CD4+ T cells 221,225. In some reports this suppressive effect has been attributed 
to IL-2 221.  In this study, titration of anti-CD28 mAb did not affect the frequency of 
total IL-17A+ CD4+ T cells. Moreover, blockade of IL-2 in CD4+ T cell cultures led 
to no consistent differences in total IL-17A+ CD4+ T cells percentages. In contrast, 
our data clearly demonstrated that higher concentrations of anti-CD28 mAb induced 
IL-17F expression and this effect was shown to be mediated by IL-2. Collectively, 
data from chapter 3 led us to hypothesise that high-strength T cell activation promotes 
IL-17F+ CD4+ T cells and that IL-17A and IL-17F expression in CD4+ T cells are 
differentially regulated. As previously mentioned, IL-2 has been shown to mediate its 
effects via STAT5 223. Reports have also suggested IL-2 down-regulates IL-17A 
expression in CD4+ T cells via the ability of STAT5 to directly compete with STAT3 
to enhancers within the IL17A gene locus 222. In contrast, data in this thesis suggest 
STAT5 is important for driving IL-17F expression in CD4+ T cells. We hypothesise 




To investigate this hypothesis future research could firstly involve examining whether 
other cytokines which act via STAT5, including IL-15 421 induce IL-17F+ CD4+ T 
cell expression similar to IL-2. The IL-17A and IL-17F capture assay described in this 
thesis can be utilised to sort IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-
17A- CD4+ T cells following a 3 day in vitro CD4+ T cell culture and examining 
STAT3 and STAT5 phosphorylation. Phosphorylation of STATs can be examined by 
lysing the sorted cells and performing a western blot with pSTAT3 and pSTAT5 
antibodies. If our hypothesis is correct, we may observe a strong signal for pSTAT3 
in IL-17A+ IL-17F- CD4+ T cells and conversely a strong pSTAT5 signal in sorted 
IL-17F+ IL-17A- CD4+ T cells. For a more sophisticated approach, direct 
STAT3/STAT5 binding to the IL17A or IL17F promoter could be assessed in the 
different IL-17 populations via chromatin immunoprecipitation interrogated with 
next-generation sequencing (ChIP-seq). ChIP is a method used to study protein-DNA 
interactions. It involves cross-linking proteins to their bound DNA via formaldehyde 
treatment. An antibody specific to the protein of interest (in this case STAT3 and 
STAT5) is then used to selectively co-immunoprecipitate the protein-bound DNA 
fragments that were covalently cross-linked. Finally, the immunoprecipitated protein-
DNA links are reversed and the recovered DNA is analysed to determine the sequences 
bound by that protein. Although multiple approaches are available to analyse the 
released DNA fragments such as microarray hybridisation (ChIP-chip), next-
generation sequencing technology (ChIP-seq) offers distinct advantages 422. 
Therefore, IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells 
could be sorted by the described IL-17A and IL-17F capture assay following a three 
day in vitro culture. Sorted cells could then undergo the ChIP-seq protocol and STAT3 
and STAT5 binding on the IL17A and IL17F locus can be assessed in the different IL-
17 expressing subsets.  
 
Another approach to investigate the hypothesis that IL-17A and IL-17F are 
differentially regulated could include mouse model studies especially as the 
importance of STAT3 in the generation of IL-17A+ CD4+ T cells was demonstrated 
in mouse studies 203. Laurence et al. demonstrated that STAT5 deficient mouse T cells 
produced significantly increased amounts of IL-17A and elevated levels of IL-17A 
were detectable in the serum of STAT5a/b vs. wild type mice 218. To date, no studies 
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have investigated the effect of IL-17F in STAT5 or IL-2 deficient mice. It would be of 
interest to investigate whether, in contrast to IL-17A, IL-17F is significantly decreased 
in these mouse models. In line with this, a study by Lin and colleagues generated 
transgenic mice that express hyper-active STAT5 in haematopoietic stem cells and 
derived lineages in a temporally and spatially controlled manner. They demonstrated 
that hyper-active STAT5 resulted in abnormally high numbers of circulating 
granulocytes that led to severe airway destruction. Granulocyte accumulation was 
reduced and the air-way was restored upon down-regulation of excessive STAT5 423.  
The mechanism of the granulocyte accumulation was unknown, however, it is line 
with studies reporting the role of IL-17F in inducing neutrophilia, especially in 
asthmatic patients 108,109. Therefore, it could be speculated that hyper-active STAT5 
led to excessive production of IL-17F and subsequently increased granulocyte 
accumulation. I believe investigating the hypothesis that IL-17A and IL-17F are 
differentially regulated is interesting to pursue as currently no studies prove this. It 
may also help us understand when IL-17F can be present in disease, for example where 
there is an increase in STAT5-signalling proteins. 
 
6.4.2 Is there a functional difference between IL-17A+ and IL-17F+ CD4+ 
T cells? 
We have shown that by increasing anti-CD28 mAb concentration in CD4+ T cell 
cultures, the frequency of IL-17A+ IL-17F- CD4+ T cells are decreased, whilst IL-
17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cell frequencies are increased. One of 
the key remaining questions is what is the functional impact of skewing Th17 cells 
into different IL-17A/ IL-17F expressing populations? As IL-17F is considered a 
weaker inducer of inflammation, one plausible explanation could be IL-17A+ IL-17F- 
CD4+ T cells are skewed to IL17F+ IL-17A- CD4+ T cells to dampen the 
inflammatory effect of IL-17A. In the event of high T cell stimulation, driving a Th17 
population from predominantly IL-17A+ IL-17F- CD4+ T cells to IL-17F+ IL-17A- 
CD4+ T cells will limit the potent inflammatory effect of IL-17A, whilst carrying out 
similar roles. However, it is important to note that in this culture system, as IL-17A+ 
IL-17F+ CD4+ T cell frequencies were also increased with a higher concentration of 





Interestingly, data in this thesis demonstrated that IL-17A+ IL-17F+ and IL-17F+ IL-
17A- CD4+ T cells have a lower frequency of IL-10+ cells and higher frequencies of 
IFNγ+ cells when compared to IL-17A+ IL-17F- CD4+ T cells. It would be of interest 
to examine whether the differences in cytokine profiles lead to different functional 
properties. Future studies could firstly expand upon the characterisation and 
comparison of IL-17A+ and IL-17F+ CD4+ T cells. Following a 3-day CD4+ T cell 
culture with IL-1β, IL-23, anti-CD28 mAb and anti-CD3 mAb, IL-17A+ IL-17F-, IL-
17A+ IL-17F+, IL-17F+ IL-17A- and IL-17A- IL-17F- CD4+ T cell populations could 
be sorted (using the method and regents described in this thesis). Next, the gene 
expression profile of the sorted IL-17 populations could be analysed by RNA-seq. 
Briefly, a typical RNA-seq experiment would involve converting RNA from cells of 
interest into a library of cDNA fragments. Sequencing adaptors are added to each 
cDNA fragment and a short sequence is obtained from each cDNA using high-
throughput sequencing technology. The resulting sequence reads are aligned with a 
reference genome or transcriptome 424. Performing RNA-seq would allow a wide-
range of genes encoding cytokines, markers and transcription factors to be analysed 
and compared between the different IL-17 subsets. Firstly, differences in IL-10 and 
IFNγ expression can be validated at the RNA level. Next, it would be of interest to 
compare the gene expression of homing markers e.g. CLA, CCR4, α4β7, and CCR5 to 
investigate whether the different IL-17 subsets might have different migratory 
properties. T-cell subsets that bear cutaneous lymphocyte antigen (CLA) 425 are 
specialised for skin homing and CCR4 is a skin homing marker 426. The integrin α4β7 
is responsible for homing into gut-associated lymphoid tissues 427 and CCR5 directs 
cells to sites of inflammation 428. The rationale for looking at the expression of homing 
markers is that studies have reported the presence of IL-17F in psoriasis 108,382 and gut 
inflammation 429. Therefore, it may be that IL-17F+ CD4+ T cells may play a more 
predominant role at specific sites of inflammation.  
 
The next important experiment would be to assess whether IL-17A+ IL-17F-, IL-17A+ 
IL-17F+ and IL-17F+ IL-17A- CD4+ T cells elicit different responses from target 
cells. To investigate this, following a 3-day in vitro culture, an IL-17A and IL-17F 
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secretion assay can be performed, sorting the different IL-17 populations. Sorted IL-
17 populations can then be cultured for 24 hours in RPMI media and collected. Firstly, 
a Luminex assay can be performed on the supernatants to assess any differences in 
cytokines secreted by IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- 
CD4+ T cells. Next, similar to previous experiments, the supernatants from IL-17A+ 
IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells can be added to 
fibroblast cultures and the levels of IL-6 and IL-8 secretion can be assessed. However, 
as IL-17F+ CD4+ T cells displayed significantly lower co-expression levels of IL-10, 
it would be of interest to assess how the supernatant from the different sorted IL-17 
subsets affects other immune cells including monocytes and/or macrophages. IL-10 is 
a potent anti-inflammatory cytokine, which plays an important role in regulating the 
immune response. The importance of IL-10 in regulating the immune response is 
evidenced by the IL-10 knock-out mouse phenotype, which displays dysregulated 
inflammatory responses 28. One of the mechanisms by which IL-10 exerts anti-
inflammatory effects is by potently inhibiting monocyte/macrophage activation. 
Addition of IL-10 to J744 mouse macrophage cells in the presence of LPS, inhibited 
macrophage activated by LPS 29. IL-10 potently inhibits monocyte and macrophage 
production of TNFα and CC and CXC chemokines, therefore reducing chemokine-
driven recruitment of neutrophils and other immune cells to sites of inflammation 30. 
To examine whether the different IL-10 co-expression levels observed in the IL-17A+ 
IL-17F+ CD4+ T cells and IL-17F+ IL-17A- vs. IL-17A+ IL-17F- CD4+ T cells have 
a functional effect, the supernatants of the sorted IL-17 populations can be added to 
cultures of CD14+ monocytes in the absence or presence of LPS. It can then be 
assessed whether addition of IL-17A+ IL-17F- CD4+ T cell supernatants reduces the 
secretion of TNFα or chemokines from monocytes, whereas IL-17F+ CD4+ T cell 
supernatant has no effect due to the absence/ low levels of IL-10 present. These results 
would indicate whether skewing a Th17 population towards predominantly IL-17F 





6.4.3 Is IL-17F present in inflammatory arthritis? 
In this thesis, I phenotypically characterised healthy IL-17F+ CD4+ T cells and 
showed the potential benefit of IL-17A and IL-17F dual blockade in reducing 
inflammation. Moreover, I describe the development of an IL-17F secretion assay 
which will allow for further characterisation IL-17F+ cells. We sought to apply this 
knowledge into understanding the role of IL-17F in inflammatory arthritis. However, 
the presence of IL-17F in the serum or SF of RA and PsA patients remained 
inconclusive. Furthermore, out of eight RA and seven PsA patients, only one PsA 
patients revealed observable frequencies of IL-17F+ CD8+ T cells in the SF. Overall, 
the data in this thesis suggest that while IL-17A+ T cells are consistently present in 
RA and PsA SF, only a small percentage of RA or PsA patients may exhibit low 
frequencies of IL-17F+ T cells. In this thesis, the predominant focus is IL-17F+ T 
cells, however, other cells such as mast cells and macrophages have been reported to 
secrete IL-17F. In our RA and PsA ex vivo dataset, flow cytometry analysis was 
performed to identify any non-T cell IL-17F+ producing cells, however, none were 
found. To conclude work on the presence of IL-17F in inflammatory arthritis future 
experiments could involve performing an ICCS on all the cells (no Lymphoprep step) 
present in RA PB and SF. In the case of PB samples, red blood cells would need to be 
lysed. Performing this experiment would allow for the presence of IL-17F+ 
neutrophils or mast cells present in RA/PsA SF to be examined. To analyse a wide-
array of cell surface markers, CyTOF staining and acquisition could be performed. 
 
6.4.4 Does IL-17F contribute to the pathology of other diseases? 
Future research could explore the role of IL-17F in other diseases and investigate 
whether dual blockade of IL-17A and IL-17F may alleviate disease symptoms. 
Evidence has linked IL-17F to the immunopathology of other disease including 
psoriasis, asthma, inflammatory bowel disease and periodontitis. Here, I review the 
presence of IL-17F in other diseases and discuss future experiments in different 





As previously discussed in the introduction, psoriasis is a chronic inflammatory skin 
disorder. While the pathology of psoriasis is complex, studies have suggested the 
initiation and perpetuation of psoriasis is driven by interactions between T cells, 
dendritic cells, neutrophils and cytokines secreted by immune cells 430. IL-17A+ T 
cells have been implicated as a key contributor to the pro-inflammatory state of 
psoriasis 378,379 and as previously mentioned in the introduction, studies have identified 
the presence of IL17F mRNA and protein in psoriasis 108,382. Targeting IL-17A in 
psoriasis by secukinumab and ixekizumab has led to dramatic success in the clearance 
of psoriatic lesions 398,431. Moreover, similar success has been observed with 
brodalumab, whereby IL-17RA is blocking thereby inhibiting the function of IL-17A, 
IL-17F, IL-17C and IL-17E 432.  Glatt et al. shown that psoriatic patients receiving 
bimekizumab demonstrated significant disease improvement 121. However, head-to-
head trials are necessary to demonstrate that a combined blockade of IL-17A and IL-
17F is more effective at clearing psoriasis than blockade of IL-17A alone. 
 
6.4.4.2 Asthma 
Asthma is characterized by chronic deregulated airway inflammation and bronchial 
hyper-responsiveness. Patients suffer with recurrent chest wheezing, coughing and 
shortness of breath. Immunohistochemistry staining for IL-17A and IL-17F in 
bronchial epithelium samples revealed elevated frequencies of IL-17A+ and IL-17F+ 
cells in severe asthma patients vs. healthy control. While IL-17A was predominantly 
expressed in both mononuclear cells, IL-17F+ cells were both mononuclear and 
epithelial cells. In concordance, IL17A and IL17F mRNA was detectable in bronchial 
biopsies from severe asthmatic patients 433. Moreover, another study detected elevated 
levels of IL-17F protein in the serum of asthma patients vs. non-asthmatic controls 434. 
 
Although the pathology of asthma remains to be fully elucidated, eosinophilic and 
neutrophilic inflammation in the airways are characteristic features. Research has 
demonstrated that neutrophils are present at a two-fold higher concentration in 
bronchoalveolar lavage fluid (BALF) when compared to mild/moderate asthmatics or 
normal controls 435. Linking IL-17 cytokines to the pathology of asthma, studies have 
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shown overexpression of IL-17A or IL-17F in mouse airways leads to increased 
numbers of neutrophils in BALF 436,437. This is likely due to the ability of IL-17A and 
IL-17F to induce the secretion of chemokines such as IL-8. Additionally, reports have 
demonstrated the ability of IL-17F to induce pro-fibrotic cytokines including IL-11 
and insulin-like growth factor-1 (IGF-1) in bronchial epithelial cells 438,439. These 
cytokines can contribute to airway remodelling in asthma. Airway structural changes 
include sub-epithelial fibrosis and increased smooth muscle mass which contribute to 
the thickening of airway walls, which can lead to airway narrowing and bronchial 
hyper-responsiveness 440. In the airways of asthma patients, a positive correlation 
between the number of CD4+ T cells and neutrophil infiltration has been observed 441. 
Moreover, in the asthma rat model, depletion of CD4+ T cells significantly inhibited 
neutrophil infiltration 442. Collectively, these reports suggest that CD4+ T cells in 
asthma regulate neutrophilic inflammation. It may be possible that IL-17F+ and IL-
17A+ T cells are encompassed in this CD4+ T cell population. 
 
The use of biologics as a treatment for severe asthma is being explored, including 
inhibition of IL-17. Kirsten et al. studied the effect of secukinumab in ozone-induced 
airway neutrophilia in healthy volunteers. They reported no difference in secukinumab 
vs. placebo group in the number of neutrophils in induced sputum 443. In a double-
blind placebo-controlled phase II study, 302 patients with inadequately controlled 
moderate to severe asthma were randomized to brodalumab or placebo. Across all 
patients, no clinical differences in lung function or asthma symptoms were observed. 
However, when assessing asthma sub-groups, patients with high bronchodilator 
reversibility demonstrated a clinical response 444. Since this clinical trial study, studies 
investigating the therapeutic potential of IL-17 cytokines in asthma have been limited. 
As asthma is a heterogeneous disease with many other factors such as Th2 cytokines 
and IgE levels playing a key role, the benefit of dual IL-17A and IL-17F blockade in 





6.4.4.3 Inflammatory bowel disease 
Inflammatory bowel disease encompasses ulcerative colitis and crohn’s disease, which 
are both long-term conditions that involve gut inflammation. Ulcerative colitis affects 
the colon, whereas crohn’s disease can affect any part of the digestive system. A report 
by Seiderer et al. showed that IL17F gene expression is up-regulated in active crohn’s 
disease but not ulcerative colitis when compared to uninflamed lesion samples from 
the same patients 429. Although, animal models suggested dual IL-17A and IL-17F 
blockade may reduce intestinal inflammation 363, a clinical trial which investigated the 
effect of brodalumab in patients with active crohn’s disease yielded negative results 
445. Finally, a double-blind, randomised, placebo-controlled proof-of-concept study in 




Studies have implicated IL-17A to the immunopathology of periodontitis 198,447. 
Periodontitis is a chronic inflammatory disease characterised by the destruction of the 
supporting structures of teeth (alveolar bone and periodontal ligament). Although 
evidence is not strong, IL-17F has been linked to periodontitis. A study by Luo et al. 
suggested that IL-17A+ IL-17F- and IL-17F+ IL-17A- CD4+ T cells are elevated in 
the PB of chronic periodontitis patients vs. healthy controls 448. However, care must 
be taken when interpreting these data as the representative flow cytometric plot is not 
convincing for an IL-17F positive stain. To the best of my knowledge, blockade of IL-
17A or IL-17RA has not been tested as a therapy for periodontitis. 
 
6.4.4.5 The role of IL-17F in non-inflammatory arthritis diseases: Future work 
After reviewing the current literature of IL-17F in other diseases, in my view it would 
be of interest to expand upon the role of IL-17F in psoriasis. This is because initial 
studies have detected IL-17F in psoriatic lesions and brodalumab and secukinumab 
have demonstrated significant success in clearing psoriatic lesions. In contrast, 
although evidence has implicated IL-17A and IL-17F in asthma and inflammatory 
bowel disease, clinical trials have shown blockade of IL-17A or IL-17RA is not 
effective at ameliorating disease. Although psoriasis is associated with PsA, in this 
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thesis psoriatic lesions were not studied. Future experiments could involve isolating 
cells from psoriatic lesions and examining the presence of IL-17F and IL-17A 
expressing cells by flow cytometry. If indeed IL-17A+ and IL-17F+ CD4+ T cells are 
present, flow cytometry analysis could be performed to investigate whether they 
display different cytokine profiles as demonstrated in this thesis. Furthermore, sorting 
IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells from 
psoriatic lesions for gene expression profiling would be of interest, although a 
significant limitation would be the low cell numbers. However, this limitation could 
be overcome by performing single-cell RNA-seq 449. 
 
6.4.5 Investigating the presence of IL-17B, IL-17C, IL-17D and IL-17E in 
inflammatory arthritis 
A lot remains unexplored regarding the presence and role of IL-17B, IL-17C, IL-17D 
and IL-17E in human inflammatory arthritis and this may be interesting for future 
work to pursue. Future work could involve performing CyTOF to analyse the 
expression of all IL-17 family members in all immune cell subsets present in 
inflammatory arthritis PBMC and SFMC. Additionally, new technology (Hyperion 
Imaging System) has combined CyTOF with imaging capability which allows for 
visualisation of protein markers in the context of a tissue micro-environment. Using 
this approach, the presence of all IL-17 cytokines could be analysed in human tissue 
samples from inflamed arthritic joints. 
 
6.5 Concluding remarks 
The main findings of this thesis are summarized in Figure 6.1. Data in this thesis 
suggest that high-strength T cell stimulation drives IL-17F expressing CD4+ T cells. 
It is demonstrated that addition of anti-CD28 drives IL-17F+ CD4+ T cells via an IL-
2 dependent mechanism. We hypothesise that STAT5 plays a role in IL-17F induction. 
Results also show that IL-17A+ and IL-17F+ CD4+ T cells display different cytokine 
profiles and may be functionally distinct. These data suggest there is more to IL-17F 
in addition to being co-expressed with IL-17A. Finally, the pro-inflammatory 
functions of IL-17F are enhanced in the presence of TNFα and the induced 
inflammation will persist during blockade of IL-17A alone. We show that in an 
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environment whereby IL-17A, IL-17F and TNFα are present at sufficient levels, dual 
IL-17A and IL-17F blockade is more effective at reducing inflammation than blockade 




Figure 6.1 Insights into the expression and function of IL-17F 
Data presented in this thesis demonstrate that in the presence of IL-1β and IL-23, anti-CD28 mAb 
enhances the frequency of IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells in an IL-2 dependent 
mechanism. In contrast, the frequency of IL-17A+ IL-17F- CD4+ T cells is reduced. We hypothesise 
IL-17A and IL-17F are differentially regulated and a strong T cell stimulation drives IL-17F expressing 
cells, of which STAT5 plays an important role. Results also demonstrate IL-17A+ and IL-17F+ CD4+ 
T cell populations display different cytokine profiles. Regarding the function of IL-17F, we show the 
ability of IL-17F to induce the pro-inflammatory mediators IL-6 and IL-8 from target fibroblast cells is 
enhanced in the presence of TNFα, however, when IL-17A is present the effect of IL-17F is limited. 
Nevertheless, in an environment where IL-17A, IL-17F, IL-17AF and TNFα are all present combined 
blockade of IL-17A (which also blocks IL-17AF) is more effective at reducing inflammation than 
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7.1 Analysis of IL-17A/IL-17F CD4+ T cells via CyTOF 
 
Mass cytometry (CyTOF) analysis was performed to provide a broad overview of the 
co-expression of cytokines in IL-17A and IL-17F CD4+ T cell populations. Following 
a three day culture, cells were re-stimulated with PMA and ionomycin for 3 hours, 
stained with metal-conjugated antibodies as described in the materials and methods 
and then acquired on CyTOF Helios. Data were analysed using Cytobank. This 
experiment was performed with one individual donor. 
 
The gating strategy applied is illustrated in Figure 7.1A. Unlike flow cytometry, cell 
FSC-A and FSC-W characteristics are unavailable as cells are vaporized during 
CyTOF acquisition. Therefore, to begin gating CD45 and DNA intercalator expressing 
cells were selected. Within this population, live cells were selected and CyTOF 
calibration beads were excluded. Dead cells were excluded based on the presence of 
cisplatin and CD3+ CD4+ T cells were selected. Next, a t-distributed stochastic 
neighbour embedding (t-SNE) was performed to visually (viSNE) map individual 
CD4+ T cells based on their phenotypic relationship. To perform this, all cytokines 
analysed (IL-17A, IL-17F, IL-17AF, TNFα, IFNγ, GM-CSF, IL-21, IL-22, IL-13, IL-
4 and IL-10) were selected for viSNE mapping. Cells which have high variability of 
cytokines will be polarized apart, whereas cells with low cytokine variance will be 
closer on the viSNE map. The viSNE map generated is illustrated in Figure 7.1B and 
depicts the CD4+ T cells which express IL-17A and IL-17F. To compare the cytokine 
co-expression of IL-17A and IL-17F expressing CD4+ T cells, IL-17A and IL-17F 
CD4+ T cells were selected on the viSNE map and a spanning-tree progression 
analysis of density-normalized events (SPADE) algorithm was applied. The SPADE 
analysis applied clusters of cells into populations or ‘nodes’ based on their cytokine 
expression. Colouring can then demonstrate the relative cytokine staining intensity in 
each cluster of cells. Based on IL-17A and IL-17F expression SPADE nodes were 
grouped into IL-17A+ IL-17F-, IL-17A+ IL-17F+ or IL-17F+ IL-17A- CD4+ T cells 




Next, as displayed in Figure 7.2, SPADE maps were used to compare the co-
expression of cytokines in IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- 
CD4+ T cells. It is important to note, the SPADE map for each cytokine has an 
individual scale range which indicates the range of mean staining intensity. This varies 
from cytokine to cytokine depending on the signal of cytokine present. Broadly 
analysing the SPADE CyTOF results, it is clear IL-17AF is highly co-expressed by 
IL-17A+ IL-17F+ and not IL-17A+ IL-17F- and IL-17F+ IL-17A- CD4+ T cell 
populations. This is in concordance with previous data demonstrated in Figure 3.8. All 
IL-17 populations co-expressed TNFα, IFNγ, GM-CSF and IL-8. Although co-
expressed by the IL-17 populations the total staining intensity of IL-21, IL-22 and IL-
6 was low. The Th2 cytokine, IL-13 was undetectable and total levels of IL-4 was low. 
The anti-inflammatory cytokine, IL-10 appeared to be predominantly co-expressed by 
IL-17A+ IL-17F- and IL-17A+ IL-17F+ CD4+ T cells. 
 
For validation purposes and to analyse the data in more depth, the dataset acquired by 
CyTOF was analysed by FlowJo. Here I focus on the co-expression of the cytokines 
TNFα, IFNγ, GM-CSF and IL-10. Using the same gating strategy applied in the 
Cytobank analysis, the cytokine co-expression of live CD3+ CD4+ T cells was 
analysed. To assist with depicting a positive cytokine expression gate for the sample, 
flow cytometry plots were compared with a no PMA and ionomycin control sample 
(Figure 7.3A). Small ‘bleb’ like populations resting on the negative control were 
observed in the IL-17A and IL-10 sample FACS plots. While it may be a true cytokine 
population, it is also possible the population could be a result of antibodies sticking 
together, therefore they were excluded from the positive gate. To compare cytokine 
expression, TNFα, IFNγ, GM-CSF and IL-10 gates were then applied to IL-17A+ IL-
17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cell populations. All IL-17 
populations highly expressed TNFα (>90% of IL-17 producing cells). Interestingly, 
higher IFNγ co-expression levels were observed in IL-17A+ IL-17F+ and IL-17F+ IL-
17A- CD4+ T cells when compared with IL-17A+ IL-17F- CD4+ T cells. IL-17A+ 
IL-17F+ CD4+ T cells displayed the highest co-expression levels of GM-CSF and IL-




While this CyTOF data provides a good indication IL-17A+ IL-17F-, IL-17A+ IL-
17F+ and IL-17F+ IL-17A- CD4+ T cells may display a different cytokine profile, it 
was only an initial analysis showing the results of one individual donor. Moreover, the 
analysis of the raw data indicates potential ‘stickiness’ of the antibodies which leads 
to the reliability of the results being questioned. While CyTOF offers the advantage 
of investigating an extensive panel, in this case it was decided to move forward by 
analysing the co-expression of TNFα, IFNγ, GM-CSF and IL-10 by IL-17A and IL-
17F CD4+ T cell populations by flow cytometry, shown in section 3.2.2.2. Differences 
in the CyTOF vs. flow cytometry data were observed. This is likely to be attributed to 
the lack of n numbers for the CyTOF data and possible issues with antibody staining. 
The flow cytometry data presented in section 3.2.2.2 is robust with multiple n numbers 







Figure 7.1 CyTOF gating strategy. 
Bulk CD4+ T cells were cultured with anti-CD3 mAb, αCD28 mAb, IL-23 and IL-1β. After 3 days, 
cells were re-stimulated with PMA and ionomycin, stained with metal-conjugated antibodies and 
acquired on CyTOF Helios. Data was analysed using CytoBank. (A) shows the gating strategy applied. 
CD45+ and DNA intercolator+ events were selected. Within this population, live cells were selected 
and CyTOF calibration beads were excluded. Dead cells were excluded based on the presence of 
cisplatin and CD3+ CD4+ T cells were selected. (B) visNE plots of CD4+ T cells clustering using 
intracellular cytokines, shown are heatmaps for the expression of IL-17A and IL-17F. (C) Gating within 
IL-17A+ and IL-17F+ CD4+ T cell events on the visNE plot, a spanning-tree progression analysis of 
density-normalized events (SPADE) algorithm was applied. Nodes are coloured by IL-17A or IL-17F 
median intensity and size is based on cell number. Grouped together are IL-17A+ IL-17F-, IL-17A+ 






































Figure 7.2 Comparison of IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-
17A- CD4+ T cells by SPADE analysis. 
Bulk CD4+ T cells were cultured with anti-CD3 mAb, αCD28 mAb, IL-23 and IL-1β. After 3 days, 
cells were re-stimulated with PMA and ionomycin, stained with metal-conjugated antibodies and 
acquired on CyTOF Helios. Data was analysed using CytoBank. Grouped together are IL-17A+ IL-
17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells. Nodes are coloured by the individual 










Figure 7.3 Flow Jo analysis on CyTOF acquired data. 
Bulk CD4+ T cells were cultured with anti-CD3 mAb, αCD28 mAb, IL-23 and IL-1β. After 3 days, 
cells were re-stimulated with PMA and ionomycin, stained with metal-conjugated antibodies and 
acquired on CyTOF Helios. Data was analysed using Flow Jo. Gated within live CD45+ CD3+ CD4+ 
T cell events (A) displays the flow cytometric plots of total IL-17A, IL-17F, TNFα, IFNγ, GM-CSF 
and IL-10 cells present within CD4+ T cells in conditions unstimulated and stimulated with PMA and 
ionomycin. (B) Gating within IL-17A+ IL-17F-, IL-17A+ IL-17F+ and IL-17F+ IL-17A- CD4+ T cells 
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